var title_f41_44_42688="Left neck lymphodenopathy";
var content_f41_44_42688=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F68538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F68538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Left neck cervical lymphadenopathy with draining sinuses (patient 12",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Phillips, P, Bonner, S, Gataric, N, et al. Nontuberculous Mycobacterial Immune Reconstitution Syndrome in HIV-infected patients spectrum of disease and long-term follow-up. Clin Infect Dis 2005; 41:1483. Copyright &copy; 2005 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42688=[""].join("\n");
var outline_f41_44_42688=null;
var title_f41_44_42689="Patient information: Groin (inguinal) hernias in children (The Basics)";
var content_f41_44_42689=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/82986\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/62/42976\">",
"         Groin hernias",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?41/62/42977\">",
"         Patient information: Inguinal and femoral (groin) hernias (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Groin (inguinal) hernias in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/groin-inguinal-hernias-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H13447739\">",
"      <span class=\"h1\">",
"       What is a groin (inguinal) hernia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A groin hernia (also called an &ldquo;inguinal hernia&rdquo;) is a bulge in the part of the body where the thigh meets the trunk (",
"      <a class=\"graphic graphic_figure graphicRef64249 \" href=\"mobipreview.htm?41/62/42976\">",
"       figure 1",
"      </a>",
"      ). In boys, the bulge can extend into the scrotum, the sac that holds the testicles. In girls, the bulge can extend into the outer lips of the vagina.",
"     </p>",
"     <p>",
"      Normally, organs in the belly are held in place by a wall of muscle. Groin hernias happen when a piece of intestine or other organ in the belly pushes out through that wall of muscle. Groin hernias are common in babies, because babies have a hole in the muscle wall that normally closes soon after birth. But if the hole does not close, or if the baby is born early, a hernia can happen.",
"     </p>",
"     <p>",
"      Groin hernias can be dangerous if a piece of intestine gets trapped in the hernia and can&rsquo;t slide back into the belly. Doctors call this an &ldquo;incarcerated&rdquo; hernia. When this happens, the intestine does not get enough blood, so it can become swollen and damaged.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13447754\">",
"      <span class=\"h1\">",
"       What are the symptoms of a groin hernia in children?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The main symptom of a groin hernia is a bulge in the groin that comes and goes. It often appears when the child has been crying or straining and then goes away when the child is resting. The child might also be fussy and not eat well.",
"     </p>",
"     <p>",
"      If the intestine gets trapped, the bulge in the groin does not go away. In that case, the hernia might feel firm. Other symptoms of trapped intestines might include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Crying",
"       </li>",
"       <li>",
"        Vomiting",
"       </li>",
"       <li>",
"        Swollen belly",
"       </li>",
"       <li>",
"        The bulging area turns red or blue",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13447769\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If your child has bulge in the groin that comes and goes, see your child&rsquo;s doctor or nurse. Groin hernias in children almost always need to be treated.",
"     </p>",
"     <p>",
"      If your child has a bulge in the groin that does not go away, see your doctor or nurse right away. This is an emergency!",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13447784\">",
"      <span class=\"h1\">",
"       Will my child need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;That depends on whether you have a boy or a girl.",
"     </p>",
"     <p>",
"      In boys, tests are not usually needed. Doctors can usually tell if a boy has a hernia by learning about his symptoms and doing an exam. In some cases, the doctor might also do an ultrasound to see if the bulge is a hernia or if there is another cause for the swelling.",
"     </p>",
"     <p>",
"      In girls, the doctor will usually do an ultrasound to see if the ovary is trapped in the hernia.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13447799\">",
"      <span class=\"h1\">",
"       How are hernias treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Almost all children who have hernias need to have surgery. Doctors usually do surgery soon after the hernia is found to keep the intestines from getting trapped. A special doctor called a &ldquo;surgeon&rdquo; will do the surgery on your child.",
"     </p>",
"     <p>",
"      Surgeons can repair groin hernias with surgery in 1 of 2 ways. Your child&rsquo;s doctor will decide which way is best for your child. The 2 types of surgery are:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Open surgery&nbsp;&ndash; During an open surgery, the surgeon makes a small cut near the hernia. Then he or she gently pushes the bulging tissue back into place. Next, the surgeon sews the muscle layer together so that nothing can bulge through.",
"       </li>",
"       <li>",
"        Laparoscopic surgery&nbsp;&ndash; During laparoscopic surgery, the surgeon makes a few cuts that are much smaller than the ones used in open surgery. Then he or she puts long thin tools into the area near the hernia. One of the tools has a camera on the end, which sends pictures to a TV screen. This tool is called a &ldquo;laparoscope.&rdquo; The surgeon can look at the picture on the screen to guide his or her movements. Then the surgeon uses the long tools to fix the muscle layer with stitches.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If the intestines get trapped, the doctor will first try to &ldquo;reduce&rdquo; the hernia, which means gently pushing it back into the belly. If this works, a surgeon will do surgery to fix the hernia within a few days. If the doctor is not able to reduce the hernia, emergency surgery might be needed.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H13447814\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/62/42977?source=see_link\">",
"       Patient information: Inguinal and femoral (groin) hernias (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?41/44/42689?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 82986 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-23B01FB2C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42689=[""].join("\n");
var outline_f41_44_42689=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13447739\">",
"      What is a groin (inguinal) hernia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13447754\">",
"      What are the symptoms of a groin hernia in children?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13447769\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13447784\">",
"      Will my child need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13447799\">",
"      How are hernias treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13447814\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/82986\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/62/42976\">",
"      Groin hernias",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/62/42977?source=related_link\">",
"      Patient information: Inguinal and femoral (groin) hernias (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_44_42690="Needle aspiration of an auricular hematoma";
var content_f41_44_42690=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51507&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Needle aspiration of an auricular hematoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 297px; height: 618px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    After cleansing and provision of local anesthesia, the most flucutant part of the hematoma is identified and aspirated using an 18 gauge needle while simultaneously milking the hematoma to ensure complete drainage (top figure) OR, for large hematomas or those that are over 24 hours but less than seven days old, incise along the curvature of the auricle at the base of the hematoma and use curved hemostats to completely evacuate the hematoma and any clots (bottom figure).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Martinez NJ, Friedman MJ. External ear procedures. In: Textbook of Pediatric Emergency Procedures, 2nd Edition, King C, Henretig FM (Eds), Lippincott Williams &amp; Wilkins, Philadelphia, 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42690=[""].join("\n");
var outline_f41_44_42690=null;
var title_f41_44_42691="Expected compensation ranges for simple acid-base disorders";
var content_f41_44_42691=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79833&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Expected compensation ranges for simple acid-base disorders",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 588px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Harrington JT, Cohen JJ, Kassirer JP. Mixed acid-base distrurbances. In: Acid/Base, Cohen JJ, Kassirer JP (Eds), Little, Brown, Boston: 1982. Copyright &copy; 1982 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42691=[""].join("\n");
var outline_f41_44_42691=null;
var title_f41_44_42692="Secretin";
var content_f41_44_42692=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secretin",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42692/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42692/contributors\">",
"     Rodger A Liddle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42692/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42692/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42692/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42692/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/44/42692/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The field of endocrinology and the study of \"hormones\" began at the turn of the twentieth century when Bayliss and Starling described a chemical substance in intestinal extracts that, when injected intravenously, stimulated pancreatic secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/1\">",
"     1",
"    </a>",
"    ]. They named this substance",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    because it caused the pancreas to secrete fluid when acid was present in the gut. This discovery led to a search for other chemical substances that when released from one tissue could excite or stimulate organ function in a different location. The Greek word \"hormone,\" meaning \"arise to activity,\" was used to designate these chemical messengers. It is now known that secretin stimulates pancreatic fluid and bicarbonate secretion leading to neutralization of acidic chyme in the intestine. Secretin also inhibits gastric acid release and intestinal motility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MOLECULAR FORMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite knowledge of physiological activity, it took more than 50 years for the chemical nature of the hormone",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    to be identified. The amino acid sequence was not determined until the 1960s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/2\">",
"     2",
"    </a>",
"    ]. Human secretin is a 27 amino-acid peptide, with a molecular weight of 3055 D. Its sequence is conserved across many mammalian species (",
"    <a class=\"graphic graphic_figure graphicRef58228 \" href=\"mobipreview.htm?38/18/39213\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Similar to other gastrointestinal peptides,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    is amidated at the C-terminus. It is the founding member of the",
"    <span class=\"nowrap\">",
"     secretin/glucagon/vasoactive",
"    </span>",
"    intestinal polypeptide family of gastrointestinal hormones. The gene structure of preprosecretin contains an N-terminal signal peptide, a short peptide sequence, secretin, and a C-terminal extension peptide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/3\">",
"     3",
"    </a>",
"    ]. The gene encoding secretin is selectively expressed in specialized enteroendocrine cells of the small intestine, called S cells. The details of secretin gene transcriptional control have been studied in secretin-producing islet cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TISSUE DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunocytochemistry has demonstrated that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    -producing cells are found along the small intestine (",
"    <a class=\"graphic graphic_figure graphicRef76730 \" href=\"mobipreview.htm?9/20/9551\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/5\">",
"     5",
"    </a>",
"    ]. Other sites shown to produce secretin mRNA include the hypothalamus, cortex, cerebellum, and brainstem [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/3,6\">",
"     3,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RECEPTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    receptor is a member of the family of G protein coupled receptors (GPCRs), within which the",
"    <span class=\"nowrap\">",
"     secretin/glucagon",
"    </span>",
"    family is structurally unique. This group consists of receptors for secretin, glucagon, calcitonin, parathyroid hormone, pituitary adenylyl cyclase-activating peptide (PACAP), vasoactive intestinal polypeptide (VIP), and others. These receptors lack structural signature sequences present in the",
"    <span class=\"nowrap\">",
"     rhodopsin/beta-adrenergic",
"    </span>",
"    receptor family (such as a DRY motif &mdash; Asp-Arg-Tyr &mdash; at the end of the third transmembrane spanning domain), which appear to be important in receptor coupling to G proteins. Secretin binds to its specific heptahelical membrane receptor and activates the heterotrimeric G protein, Gs, leading to elevation of cellular cAMP levels. This second messenger begins the signaling cascade that initiates appropriate cell physiological responses. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/49/22293?source=see_link\">",
"     \"Peptide hormone signal transduction and regulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    receptor signal termination involve receptor phosphorylation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/7\">",
"     7",
"    </a>",
"    ], mediated by G protein-coupled receptor kinases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/8\">",
"     8",
"    </a>",
"    ]. The mechanism for secretin receptor internalization is distinct from that used by prototypical Class I GPCRs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/9\">",
"     9",
"    </a>",
"    ]. The specific mechanism for receptor internalization suggests that novel proteins may be involved in its regulation.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     Secretin",
"    </a>",
"    receptors are abundant on duct and acinar cells of the pancreas, where they mediate secretin-stimulated fluid and bicarbonate secretion and may potentiate cholecystokinin and acetylcholine-stimulated enzyme secretion. Secretin receptors are also present in brain cells, sensory neurons in the vagus nerve, and endocrine and other cells of the GI tract. It is possible the secretin and cholecystokinin receptors on vagal sensory neurons synergistically enhance postprandial pancreatic enzyme secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     Secretin",
"    </a>",
"    receptors are also found on some tumors of the gastrointestinal tract. Alternative splicing of secreting receptor pre-mRNA in such tumors may be biologically important for understanding the function of the receptor and in developing potential chemotherapeutic targets [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     SECRETIN RELEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major physiological actions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    are stimulation of pancreatic fluid and bicarbonate secretion. Bicarbonate, upon reaching the duodenum, neutralizes gastric acid and raises the duodenal pH, thereby \"turning off\" secretin release via a negative feedback mechanism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/12\">",
"     12",
"    </a>",
"    ]. It has been suggested that acid-stimulated secretin release is regulated by an endogenous intestinal secretin releasing factor (SRF) (",
"    <a class=\"graphic graphic_figure graphicRef74092 \" href=\"mobipreview.htm?20/9/20625\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/13\">",
"     13",
"    </a>",
"    ]. This peptide stimulates secretin until the flow of pancreatic proteases is sufficient to degrade the releasing factor and terminate secretin release. Confirmation of this negative feedback pathway awaits identification of the putative SRF.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the primary action of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    is to produce pancreatic fluid and bicarbonate secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/14\">",
"     14",
"    </a>",
"    ], it is also an enterogastrone (a substance that is released by ingested fat and inhibits gastric acid secretion). In physiological concentrations, secretin inhibits gastric acid release, gastric motility, and gastrin release [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/15\">",
"     15",
"    </a>",
"    ]. When studied using pharmacological doses, secretin also increases bile flow [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/16\">",
"     16",
"    </a>",
"    ], gastrointestinal motility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/17\">",
"     17",
"    </a>",
"    ], and lower esophageal sphincter pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many studies suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    can promote growth of the pancreas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/19\">",
"     19",
"    </a>",
"    ]. This latter finding has raised speculation that secretin may contribute to pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/20\">",
"     20",
"    </a>",
"    ]. However, direct evidence for secretin in the pathogenesis of pancreatic cancer is currently lacking. Interestingly, targeted ablation (knockout) of secretin-producing cells in transgenic mice resulted in an animal devoid of many enteroendocrine cells, suggesting that secretin expression may be necessary at an early step in the development of gut endocrine cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL USES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common clinical application of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    is in the diagnosis of gastrin-secreting tumors. Under normal conditions, secretin administration inhibits gastrin release (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Physiology'",
"    </a>",
"    above). However, in gastrinomas, injection of secretin causes a paradoxical increase in gastrin release. This pathophysiological phenomenon is the basis for the secretin stimulation test. This test is a safe, effective, and reliable method for determining the presence of a gastrin-producing tumor (",
"    <a class=\"graphic graphic_table graphicRef64937 \" href=\"mobipreview.htm?3/8/3212\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14504?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to its effect on pancreatic exocrine secretion,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"     secretin",
"    </a>",
"    has been used clinically to diagnose pancreatic insufficiency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=see_link\">",
"     \"Clinical features and diagnosis of malabsorption\"",
"    </a>",
"    .) Acute administration of secretin causes temporary dilation of pancreatic ducts by increasing pancreatic secretions. This pharmacological effect is the basis for administration of secretin during endoscopic retrograde cholangiopancreatography (ERCP) to aid in ductal cannulation (primarily the minor duct). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3431?source=see_link\">",
"     \"Anatomy and clinical significance of pancreas divisum\"",
"    </a>",
"    .) In addition, secretin has been used in magnetic resonance imaging of the pancreas during functional testing to evaluate pancreatic secretion and ductal obstruction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. Secretin-enhanced MR cholangiopancreatography is particularly useful to detect and diagnose congenital, inflammatory, and neoplastic conditions of the pancreas and may be more useful than standard MR imaging to evaluate subtle changes in chronic pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In addition, secretin administration appears to accentuate regions of pancreatic vascular hypoperfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42692/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"       Secretin",
"      </a>",
"      is a 27 amino-acid peptide produced by cells in the small intestine, hypothalamus, cortex, cerebellum, and brainstem, (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Molecular forms'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"       Secretin",
"      </a>",
"      receptors are abundant on duct and acinar cells of the pancreas, where they mediate secretin-stimulated fluid and bicarbonate secretion leading to neutralization of acidic chyme in the intestine and may potentiate cholecystokinin and acetylcholine-stimulated enzyme secretion (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Tissue distribution'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Receptors'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      The most common clinical application of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/49/28435?source=see_link\">",
"       secretin",
"      </a>",
"      is in the diagnosis of gastrin-secreting tumors. Under normal conditions, secretin administration inhibits gastrin release. However, in gastrinomas, injection of secretin causes a paradoxical increase in gastrin release. This pathophysiological phenomenon is the basis for the secretin stimulation test. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Physiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical uses'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/1\">",
"      Bayliss WM, Starling EH. The mechanism of pancreatic secretion. J Physiol 1902; 28:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/2\">",
"      Mutt V, Jorpes JE, Magnusson S. Structure of porcine secretin. The amino acid sequence. Eur J Biochem 1970; 15:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/3\">",
"      Kopin AS, Wheeler MB, Leiter AB. Secretin: structure of the precursor and tissue distribution of the mRNA. Proc Natl Acad Sci U S A 1990; 87:2299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/4\">",
"      Nishitani J, Rindi G, Lopez MJ, et al. Transcriptional regulation of secretin gene expression. J Clin Gastroenterol 1995; 21 Suppl 1:S50.",
"     </a>",
"    </li>",
"    <li>",
"     Leiter AB, Chey WY, Kopin AS. Secretin, 1st ed, Raven Press, New York 1994.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/6\">",
"      Lee SM, Yung WH, Chen L, Chow BK. Expression and spatial distribution of secretin and secretin receptor in human cerebellum. Neuroreport 2005; 16:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/7\">",
"      Ozcelebi F, Holtmann MH, Rentsch RU, et al. Agonist-stimulated phosphorylation of the carboxyl-terminal tail of the secretin receptor. Mol Pharmacol 1995; 48:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/8\">",
"      Shetzline MA, Premont RT, Walker JK, et al. A role for receptor kinases in the regulation of class II G protein-coupled receptors. Phosphorylation and desensitization of the secretin receptor. J Biol Chem 1998; 273:6756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/9\">",
"      Walker JK, Premont RT, Barak LS, et al. Properties of secretin receptor internalization differ from those of the beta(2)-adrenergic receptor. J Biol Chem 1999; 274:31515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/10\">",
"      Li Y. Sensory signal transduction in the vagal primary afferent neurons. Curr Med Chem 2007; 14:2554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/11\">",
"      K&ouml;rner M, Miller LJ. Alternative splicing of pre-mRNA in cancer: focus on G protein-coupled peptide hormone receptors. Am J Pathol 2009; 175:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/12\">",
"      Schaffalitzky de Muckadell OB, Fahrenkrug J. Secretion pattern of secretin in man: regulation by gastric acid. Gut 1978; 19:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/13\">",
"      Li P, Lee KY, Chang TM, Chey WY. Mechanism of acid-induced release of secretin in rats. Presence of a secretin-releasing peptide. J Clin Invest 1990; 86:1474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/14\">",
"      You CH, Rominger JM, Chey WY. Effects of atropine on the action and release of secretin in humans. Am J Physiol 1982; 242:G608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/15\">",
"      You CH, Chey WY. Secretin is an enterogastrone in humans. Dig Dis Sci 1987; 32:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/16\">",
"      Boyer JL, Bloomer JR. Canalicular bile secretion in man. Studies utilizing the biliary clearance of (14C)mannitol. J Clin Invest 1974; 54:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/17\">",
"      Dinoso VP Jr, Meshkinpour H, Lorber SH, et al. Motor responses of the sigmoid colon and rectum to exogenous cholecystokinin and secretin. Gastroenterology 1973; 65:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/18\">",
"      Cohen S, Lipshutz W. Hormonal regulation of human lower esophageal sphincter competence: interaction of gastrin and secretin. J Clin Invest 1971; 50:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/19\">",
"      Solomon TE, Vanier M, Morisset J. Cell site and time course of DNA synthesis in pancreas after caerulein and secretin. Am J Physiol 1983; 245:G99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/20\">",
"      Talamini G. Duodenal acidity may increase the risk of pancreatic cancer in the course of chronic pancreatitis: an etiopathogenetic hypothesis. JOP 2005; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/21\">",
"      Rindi G, Ratineau C, Ronco A, et al. Targeted ablation of secretin-producing cells in transgenic mice reveals a common differentiation pathway with multiple enteroendocrine cell lineages in the small intestine. Development 1999; 126:4149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/22\">",
"      McGuigan JE, Wolfe MM. Secretin injection test in the diagnosis of gastrinoma. Gastroenterology 1980; 79:1324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/23\">",
"      Brady CE 3rd. Secretin provocation test in the diagnosis of Zollinger-Ellison syndrome. Am J Gastroenterol 1991; 86:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/24\">",
"      Catalano MF, Lahoti S, Geenen JE, Hogan WJ. Prospective evaluation of endoscopic ultrasonography, endoscopic retrograde pancreatography, and secretin test in the diagnosis of chronic pancreatitis. Gastrointest Endosc 1998; 48:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/25\">",
"      Raimondo M, Imoto M, DiMagno EP. Rapid endoscopic secretin stimulation test and discrimination of chronic pancreatitis and pancreatic cancer from disease controls. Clin Gastroenterol Hepatol 2003; 1:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/26\">",
"      Khalid A, Peterson M, Slivka A. Secretin-stimulated magnetic resonance pancreaticogram to assess pancreatic duct outflow obstruction in evaluation of idiopathic acute recurrent pancreatitis: a pilot study. Dig Dis Sci 2003; 48:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/27\">",
"      Monill J, Pernas J, Clavero J, et al. Pancreatic duct after pancreatoduodenectomy: morphologic and functional evaluation with secretin-stimulated MR pancreatography. AJR Am J Roentgenol 2004; 183:1267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/28\">",
"      Akisik MF, Sandrasegaran K, Aisen AA, et al. Dynamic secretin-enhanced MR cholangiopancreatography. Radiographics 2006; 26:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/29\">",
"      Balci NC, Alkaade S, Magas L, et al. Suspected chronic pancreatitis with normal MRCP: findings on MRI in correlation with secretin MRCP. J Magn Reson Imaging 2008; 27:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42692/abstract/30\">",
"      Bali MA, Metens T, Denolin V, et al. Pancreatic perfusion: noninvasive quantitative assessment with dynamic contrast-enhanced MR imaging without and with secretin stimulation in healthy volunteers--initial results. Radiology 2008; 247:115.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2560 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-124.240.187.80-1825C1B6E2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42692=[""].join("\n");
var outline_f41_44_42692=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MOLECULAR FORMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TISSUE DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RECEPTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      SECRETIN RELEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL USES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2560\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2560|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/18/39213\" title=\"figure 1\">",
"      Secretin amino acid sequence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/20/9551\" title=\"figure 2\">",
"      Secretin tissue distribution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/9/20625\" title=\"figure 3\">",
"      Secretin regulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2560|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?3/8/3212\" title=\"table 1\">",
"      Secretin stimulation test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/22/3431?source=related_link\">",
"      Anatomy and clinical significance of pancreas divisum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/21/38232?source=related_link\">",
"      Clinical features and diagnosis of malabsorption",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/10/14504?source=related_link\">",
"      Clinical manifestations and diagnosis of Zollinger-Ellison syndrome (gastrinoma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/49/22293?source=related_link\">",
"      Peptide hormone signal transduction and regulation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_44_42693="Apical 4 chamber color Doppler diastole";
var content_f41_44_42693=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F54278%7ECARD%2F68049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F54278%7ECARD%2F68049&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical four chamber view with color flow Doppler during diastole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 288px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEgAXEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDz2L9pDx9HEifa7M7RjJtwSeO5NXb79pfxnLp1hHZm2guoUYXU7Rq3nsTwQuMLgdhXhXpxSVHs15/ey+d/0kezD9o/4h7gTqFnjpj7IlWrz9pTxxLpthBazW0F1CpFzcmFWNwc8HaRhcDsK8Poo5F/TFzv+kevn9or4j/9BeDp/wA+kX59Ks6n+0d48uDa/Y7yC0EUAjkCwq/mv3kO4cE+g4rxijtSdKO41No9XP7QPxGO3GujgY/49ouff7tbfiz9obxRcxaQPDupXVm0VjHHemWONvOuQMO65BwD6V4ZRT9nHsHtJHq0fx0+IDLKs/imeMqhKbLaI7m7AnbwPepNS/aA+IF2tsINYNoIoFhfyo1PmsM5kOQfmPH5V5LS5o9nHsHtJdz0o/HL4i5H/FT3Jxx/q4//AImrus/Hvx9qN0J7bW3sEWNYxDAowSByxJB5PU15PRR7OPYPaS7npD/Gz4hsNv8AwlN7txjIVAf5Vb1r47+PtSv2uINcmsI9qqsFuAEGBjPPJJ615ZRR7ON72Fzy7noknxm+IDhgfFepAYxkEA/oKtaz8cPHuo3huI/EF1Zgoi+TasVQYGM4OeT1Pua8y9aBR7OPYOeXc9DsvjF45iv7aa58T6tPbxyq8kX2gr5igglc9s4xVrxR8ZvGGq6/f3mla9rOnWM8peG0S8YiFf7uRjOPpXmVKDj1FPkjroP2ku53Ft8V/HUN1FM3izWpAjBtj3blWx2Iz0qfVPiz431LU7m8/wCEn1mzE7tIIba6kWKMEk7UXdwo4A9K8/qRAxG47yq/Lx29v50KC7B7ST6neaf8UfHNpeQXL+KNdmMLrJ5U15K0b45ww3cqe/tV7U/iX421TUrq/k8T6zZCYmUwWt7LHDFnPyoob5Rxj8PevP4I2ckkOVXqxPAHvX1B+z78I43itvFHii1R4CfO02zkJPQ5WVx0PsD6Z70NRiw5mdH8GvB/jSeCHXvGHivxLAWw9ppz3zv8uD80ytkHPUL2780/4l/DvxdDpD3/AIH8ZeK575GLS2U2qyYkTqfLORhvbpXtROTk8k0KcelClboS7t3ufBelfFTxxo2sW96niXV7t4pCfs95dyyxMcYKuhOD16epHSs25+Jfjm4uZJf+Ev19DKxbbHfyqoJ7ABsAe1e8/tHfCWO4tr3xf4eRIpY0DXtnGNof5uZV9+mR369q+WWyVJUnGcMcd/WrcVvESm3oz0Dwl8XfF2h67DfX+vatq1ukcivaXOpS7H3IVBPzdQSG/CsaT4l+NwzAeMfEGCcjGozf/FV3GlfEfwVD8Mdc0ebwbZQapPbw28Rj3P57hSDOzkfIVOGwOpavGGdiCCcg9felpbYbbvqzvtA+MXjvRb83UXiXU7smNo/Kvrl7iPnvtYkZHr1rOPxL8cYb/isvEWc8f8TCXn/x6uQz3ozzx3oSQXZ32ifF7x3pN59ri8UatdSbWTyry5eePkYztYkZHb0rP/4WX44xk+MfEWQf+gjN/wDFVyFB780WQXZ3mnfF3x3Y219CvinVphdxeUzT3TyNGM53RsTlG9xzVEfEvxxgf8Vh4i4/6iUv/wAVXI0CiyC7O+034v8AjvT4L6KPxNqs32uLyma5uXlaLnO6Msfkb3FUF+JXjfofGHiPH/YSm/8Aiq5DFFFkF2el+H/jF4s0zT9Zt7nWtY1B7+38mKafUZt1qwOd6fNwaxf+Fk+NwMf8Jl4i4/6iMv8A8VXHYpKLK1hXO/h+LPjmLSriwTxXq7pO6ymV7pzMhXPCyE5UHuB1wKqL8SPGuPm8ZeI8Z4xqUvX67ulcZRRYd2d/D8VvG40qXTx4r1kxvIJzO13IZgQCNok3ZCn06VRl+JPjYbfL8ZeJMH11Gb/4r61yAY7h83FK77lUZPFFguzsv+FrePf7OFl/wl+t+SJPM3fa38zOMY8zO/H+znHtVY/Enxx/0OPiP/wZTf8AxVclRRYLnazfFXx7Na29u/i/WxHACEKXbo5yc/M4IZ/+BE46Diq//CyvHP8A0OPiL/wZTf8AxVclRQF2dd/wsvxz/wBDj4i/8GM3/wAVRXI0U7k2QtJX6CaZ8MvAw021lfwno7u8aOx+zg54GSP5/nXzJ+1RoWleH/HVla6Hptlp9q9msmy1j2BmJOSaIe+m10V/y/zG9HY8XNJRRSAKKKKACiiigAooooAKKKKAFpKKKAFoFHeigA70vpjNNpaAF/A1YiXKnhvXJPQc8f8A16iH3lAOcdO1evfBD4aTeI9Rt9a1y1mTw5aTLvDof9Kfn5UHdRwWPpR6DOv/AGevhGNblTxD4hhdNIiYPBZzIR9qPUO2QAUzyMda+rMbcKAAAMAYxgD2qjCtnp9hbWltAgtCPLiiiGERQOAB2FJdarZWmGnmRTI2AWcYz2BPasrN6lN30L9BHGOhYHHFZc+tQxXIght7q6yu4SRqNn/fXc1TXWGuL24t0tLyOUL99gGA9tv+c1ai9yTYYM0kaOHf5RuUjGfXPb8M18x/Hn4PvcXV74g8H6ZDGsOFu9PtQ24tnl0Xbjp1xx6V79Lc3rwvIWvVQ5/0UuIZ2OR8ykcqOcbazNcgePRp90drYxsOcPjj/eY9T0IrSkvs33Jne2h8AOrKGV1wV454I6VGe9em/GPwS2garJqFlBEljdYfyI8jyGwMjDHJGQQT0zn2rzGiUeV2BO6HMCrEHGfammlbBOQMD0ptSMWjPFJRQAUtJRQAtHTvSUtAC9qSiigBRSHrxR+VBoAB17ilJyByTSUd6AEoqePbkfKMEYI6mvaP2fLrRkl1u11bwvpetTyxxPbvewRusW0sGHzA4zuB4/uisq1aNGDnPRI1pUZVZckNzxCivt6Hwj4avB5r+F9ADYwVTTYVA49AtTQeCvCpyT4Y0NuDn/QIhgev3a+Ynxbh1NxUHbvodby6a3aufDdFffv/AAgnhT/oVdC/8FMH/wATRWn+tNH/AJ9v8Dn+rvudvpWDpNkcLtMCfKOmNvT6V8hftgsP+Fl2qg/dsI+B25NfXeiuJNF05wwYNbxncO/y9a+Qv2wBj4nW/vp8Xb619Rh7csvT9Uc0/iXr/meFnGaSlOe9FAxKKKKACiiigAooooAKKKKACiiigBaSlpKACl7UVv8AgnQW8SeIINPEgjjIJkcYyF74B6nmmgPR/gL8JW+IF3PqOrStF4ftn2SGIbJLh8Z2ocYAHc19R3tlB4Z0mNLW4uW0yzhEcECEHyVXAC9ORjHv161m+DZ9S8PaRFp81jo8WnRgQwXGlAiIcDmVf4XJ5PrzXFePfEH2tpluruwtdSh+4RdSRbx0XfGDtcHHHpz0q4U5OWom0loJ4g8ex7Lc6TcNbWO/asG0s8v94sSfl+tYl58Qf7Mu7qSawilkkIEZeIyxN8vG7B4xnqOvpXl2o+J7iyuGH2+CWK4QxzBXdSADyODk/jmrXgG0sPFkPjSa/a5lXSdDnvrA+ayFJEGBnB5HOMcg81pOcbWQ0mr3O3tPiGN+mwyRzycFPMneNnU9Pl2kFfxFUdS+Ic+n6vKllqH8J+V/9Zk9t6ngdOOvWuH8HaPFrPhHxnqTC5n1XSltpbPYxBUSOVcleAc8dQcVN8bNLsPDHjaHS9Pt3jt00+3eaEyl3SRkJcEk5H06AHtUxre7YbWtz1Pw38Qb22EsF3MbFLhlKXlmUyeejFy+M5wQe/pW+dV87T41XQpr65uizR3N6gmO7qJMBip9eAMV88WmpGSZp9I09rI+Vt3rKzMRu7Fs4yOvvmvW/h1LqWuvp3kXr2ywIE8wO0SMvou/CkerDNaQiou7RDbZoat4Kj1jUDJqOkTX8ygO88UrfMTxzIRgqOOFwMjPNeT/ABg+Hlp4bvPtHhxLy4sV4mDLvjjbAJKOPvD14+Xpk17/AONr9dKtkgg0+1uUnIXcga9MknOGcghdoI6YODg9sVxEcdrBHBFewvqOoTt5Rswdp5OP3jY2qvsM4zWkkpfERfsfMmOB0/Okr1b4tfCvVPC0EmuGOxj0+aXm3tZC4tweAMnqM4HHrXlNccouLNE7higDNJS5qRhmkoooAKKKKAF+tJRRQAtFFJQAo9utLjnFJS/qKAHjBOchTn6mvSfg9P5WsX27DAQKCoGcgODnNeZ8ZPYe9d78LpjDqt0UwEMGdp9N4Gc/561w5jHmw015HoZX/vUP66H1N4fvPMtIsNuXGcKeRkdhXQRSBlUYGf4QByD615v4a1NEESDcCc8g8Djp+Nd3bTo8Y29SM4zk5x0r8sxVB0qjtsfQYqjZ3R0exf8AnlL/AN8N/jRWVtb/AJ6xf9/BRTt5fgzy/Zf3jo/Ccvm+GNJJXj7HCQccNlAeK+Sf2vz/AMXRhG4n/QIuD0Xr0r6z8GHPg3QTuVs2EHKjAPyDpXyP+142fizj00+D+tfr9B+4/T9UeJP4jxGilPWkpiCiiigAooooAKKKKACiiloASlxxmkpaACkopyqWOFGT1oAltLaW7l8uBdz4zjNb/h9mTUoEsIpc7sJPCv77PBxjOCf/AK9YVjLHBdxvNGZEBGVBwevavWz4e8IWCWmr6Trqtaybf3dwTgNgfLIMZB5PI469OlXGPMF7M9o+G3iaL/hFNSt1lijkO7NypMjMMfM0y4BGPpxXLfFWyjGmre7bKZL6AeXeEiMSsBgEA/dfpwOvNc9K02i2kyX95BqQUCRZEISQx9fllHHHXk9uc1k2Wu/2nYXmiN4juf7LdA8MF/MMRnAIKZBII5HysBycCupWgv6/4JMlqeS3c5luLnz5D1APAJYg9c9BXaeH/i14g0O+hubOPSwYdOGmYNkrK8QbcCwyMsSBknt2rmtUgvRFeSxWZlsbaYRPdpDlVbt+8A79eTk1m29o00bSOzFQwGFZcnP1PXpx9a45NR3/AK/qxrGMpu0TvD8WfE1z4utvEMbaZDqEUBtFhjtQkLoST8yDhjk5Ge+K5W9ubn+2ZpL6dnv7hi80s3JLMD3b+E5x1z7U5bO2gQG72Rn+Dzgxzjr904x/nNbvhvwsda059RtprOFVLZQXxhMCgHlgyN8p4xz61FGpGUtF8zWvhXRinNq/br/wCGS1m02w8xbsQGQHJhmL7ic/wlflBPv3rpfB/j3V7ubS9Fvbu4l06ICCBYoNzxpj7saAHP8AhXnF3P8AvnjvWeWSB/L4k3cBjyCOD6Z+lbXgbW9WsNRjbR5XSeP7rqfnHsCcjH14rrq1VKS5FZI5Yw011PftP0/XtNKy6N4e1IRuwEt5qt4luvP8KxjIUYP4960v7AfXr67GoaheQvKuyUxTKMoOy4GAvGfWsqW08R3MM663C9xfRKJ2hupWmIGcxlvL+Q5z97nGM4rX8MSeJNQsPsBi+yxuu6SS5jEscG45Hljqx9CxbnsK3afLzX+ZOt7Mx73QtLlWGLRrKS8S3JQrezNLG7nswbAJ6cjpmvC/HXgTUdCjfUisclnI+W8lTiEnkA9gPSvpHxBoVlaRWmlW9zOZ45sldgDXTHBb7nOPXPHP413PhXwjo9hC9xdWs8/2wCNo9QImaUY+7sOVA7/nUVJQ9mrglK90fn9iivbvjv8ACmPQtSudW8H6denQY133m4qUtJM/dU5yR+ePWvEz90dK42rblpjKWkopDCiiigAopc0lAC9qSiigBaXFNpaADJ611nw9crqko5IMJHtncMZNcnmug8GSLHqb7s7WiKk9uoPP5Vhio81KSOzL5qGJhJ9z23Rr9lwSxIXuCMj69sV32iaqxBLSMpBPXA7fyrxywvlBi3sSvBwRyeO57Cuo07Ul8xcyDefmxs647Y/Ovj8RgHV6H2FWrSktz1H7Uv8Asf8AfxaK83/4SOL1b/v2P8aK5f7Jl5fieben3R9CfDubzvAPh2QsDnToMt2z5Y5r5M/a5YH4uNyDiwgHH0NfUPwqvN3w08MucE/YYicH/ZH/ANavlT9qqZZvi9dsiIpFtCDtxydvU+9foFG6i/T9T5afxHj1FFFMQUUUUAFFFFABRRRQAUUUUAFFFbPhTw3qninWINN0a3aaeVgpYghI8/xO3RR7mgDJjjeQkIpbAycDoPU+1SSQvCF85Sm5dyk9xXpGr+GtW8DIudIFzESEuJ/MJEhGdy4U/KvUHOQQATXP+ItJvdYvJ9U03TpUsXUOqsw3YAwcDPPIPArWVPl0e4J3OYtZRFKjhA7BgcHow9CPeursLu21SSwW20y5mubcfNGjDa0anoB3OD19zXILgHDjgdsVd06+udMuUudOuXjmTDCRO3tg9amMmtEB7T4cs7HUjcp4e8RWk9tFCXez1O1Mc8ZPLLGR/d7n0FYOu+GtIttCuYZYbWbUITuWbTr1ZGIzySp6nocdsnFZcniy0e6hv73Q7Zb6OMNcNCdyTns4KkeW34kdeKx9OtJfFHiNrDQtOV7i9l220MrrKYydpJLHaOx5OccjGea09ora/wBfmhcupkDUtVtLG50eS9uLewunSea3JwkjL91iKqRKb6dU/dxYGS2D6Afj6/nXpmv/AAov7Tw1LrG+DdCSJILPEscZ74JbJHc43V57p7SWOpJHFLBIDtyUclDnHH155rnqJwjdG9CMZVIqexqrpsi2/l7IZe+/O0jvg5qlKltAgW6F7DIVIxGE2n6+tdIhlEa7BblgRn94Oc89utQsLln/AHyxlCDu+Q7SPQ85I/CvNhiZQd2fUYjKqc4r2d0/T+mcxIImMUVpFF5hH39+e5GD2H/6q6PwxZ3On39pd6lpcV/C+Nsc1wFVsdjg8D61R1mznhUCzdtkhCtHFkZxnkk/X/OKi0c2Gn32n3F3pdzchJh5kDOyrOv90EAE8+h5rup1IzSkj5/EYadKcoy6H1Lb+JdTudKOnzX+n6JZsDtvNHiMvmjoVJP3cAjpXV+EbvSUgtUsb+61WWRCZLqdCuG9+wbPIFefL4qh1+3srWa1s9G+0OsZgifzZY48kfvw2fJj4weCefY12fhSHQfs6zaZ4fnihUGOOOS5JhkwceYyljkdCCQeK7rXhocL0Z2Vv4d2XDXVheS2zzMHlmYLIZB6ZPTHTPvWzdmG2t2853Luhw6LmTP+yB3HWqEepxW2nDzX810O3ZY2zbWJPRRyD/npUHAlJuH1KJXO4oxQBgT90YyR78jpXMuZu7GYHi23t7nw21jCn2i2cbWiuyQkjE8lh3avk/4tfDObwikOpae0lzpM2N0pUL5Tn+HHXHoa+ufEGn2sksFxIcwQ5Hm3MvlxhsdlwC/4frXlPiXTru5uIra5a+1i0vXZnt441IEQBGWbsPTaD26V104RmrMyldO58n02up8faLZ6TrVwNIaQ2O/GyQHdE39wkgZ+tctXNOLg3Flp3VxaSiipGFFFFABS0lFABS0UfhQAlTxM6k4BIKnocevP6Z/Coa1PD9t9o1KJSisMEnIyMYPb2/pVRjztR7g3bUjS6lUnjaQOuSeav2+pXA3rkEHGSAQR1/8A1/hW42hwMFK24QBcD5SSee5qxBoQimXbHtJA52duSCT65wfwrSpg5RumgjXv1MH+073+7b/99NRW5/Z6/wDPGT/vzRWPJLt+JHtWfTXwqvW/4Vf4bVl2FLNBknIIxx+JH9K+cP2iZfO+KF8+wJ+5iG3/AIDXpvwy1iRfAOkoruFCbPvZUEZH6jFeL/Fu5a78dX8rnnCjGc4wOma6HDlpX72G5XkcbRRRXOUFFFFABRRRQAUUUUAFFFOVSSABkk4FAG54M8K6v4y1tNK0C2+0XbLvI3BQiAgFiT2GRX2N4C8O+H/hl4JltJ3dL90/4mF3Ahd5X9F/2R2FcN8LNA0fwNoVtfxSNqT6vCkpu0hKSQFR8yJnkAEnnvir/jbxpbaLZ/Zk1A3Ud0gIS7Hlt5Z7iXoXHoa2VLS72Fe2hzXjqO0vXa5srjU73S7lCsrlQJgcEhmXuvB9+K8U11NPjj8rRtXuJdrZeJ1ZAW9VHsOue9a3jvW4tWu45dOuzcKxOZgTC6/KeHX6Ac9+a5ltO3pOViu5ZEydyAOvXqxBq5zU/dWobGa370ffy467z15Ocf59a1NDaG2hmuGvPIZ18srGxDgccjsR7VjyxtG5VwQQcHPrVixvmtVkTZG8cg2sGQEgHrg9j71jF8r1GerfDafTXuLuLShEb82jCaS7uREkqDn5Q3HJxletZGneLtM0m4v45tGtL9bqPaweMKtu2cfu/X3P/wCuqngLw22v6xFBpemvqcPk/wClRSSxLJH1O6LLAEgc4+vFavxA8F+F9E0TT9X07WtSkOoJIbe0ubVRJG0bBSsmGyvOOoFDm9r2+8u19THIu08NXMmk+KrKO0lffPpazPGVPbAP3h2pnhzS08ljqOp/ZG4Kqkfn5yO/PBrm7KCa4vInjtmkKOM7cFTjsM8GvQEuppbcJMbS3GCQoRF2n0+QmvLzCq0lGFlff+nc97JcIqk3UknoUFhVJTGXjHzZXjbuP9M9qtNHDtBSMiQZBLMdqn0+tTQW8yThxBCRgqZuCc88kk/rU6WjBx5t5axPyy5cuSe3TI3V5spq2rPqad300MbUY2t7FpY3j80D5QJDgY7H3qn4Ug1TWNfh+xf6QLaUSusi7Yo1/vnJ7enWuku5JhCfMvbeZAC2EQFm7DjHJ9vxrI8PXEMfi7/TpLe2huMFnu4XIkHY7QRj/PFejls1KVpL+vmfPZ7TcUpRlv0/r9T6H8I2ml6haXU9xBPq17JJl4tOuXQSsD1lHfsdzE+ldTNc2GmXlo2oLDNNcSKkVpbXe5kB6AqeceprjbKPw9JHALbxXeoykMw0yExZU4zlcNk8ngetVLK98P2uvzz2Dasm1h5cstgRLKc/MHkYZA9AAD0r27O78/Jny2x7U2owCSSOKRFuIYyfsscuH+p7fjWbfalBa20SxbrW/nJdVdxJNjPLc54wB+daNrFYS2Mb2GmB45fmLsFJ/wCBEnn+Vcv4xmkW0M9jbbXgH7yOVWBcj/lmAoyR06HHSsIRTlZIGyLV9be6hEdv5t1dkYV5U/dxN6xr1b6jFYeoaZqmlW8dxc6itjahS7wIhE8jH0C9RyeDxWLda5qV/JFLFfHSptgDeVbCSUL12qCeB71VOoRXdzPBof2p5PKaG61XUbvbbxE8gs5+udo69K7XDkST0Rk3c818U2P9qi7uJnjs7V87XuQHlI9CBwPX2rybWtOjsLpktruK9gAH7+IELkjpz3r2DxZopWCaGPUEv4rdmM91b2vlWxyOVj7n/erylNFvL+WVbCMfZkJKmWRYxjj+8RzyKit7yTS/r8iorUw6Ktaha/ZLgxht6gD5scZxyPzzVWuMsKKKKACiiloASlooxxmgBVXPTrXSeCYBL4gtk2gny3IyeD8pP+P5VzygHYAWOeoUfyruPhrCsviq1H8Bhc4QDLYQ/lz6+ldOEX7+HqjKs7U5PyO7gsUcISrKh5HXPHGT71aj007huVCM5wSea6Sw04kKAjYPQ7sZHXJ/CrkOngOpVUCk4yzfrX1OIhBxeh4sKsr6HCfYG/vyf98iiul+xt/zzX/vsf40V4HO+34nVzT/AKuebeB9WEXhq3ifcPJZhncMHJJ/PnH5Vw3jC5N14hupDnqFwTnGBWfbXckMbRq7BDzgdM8c1BK7SSM7sWYnknvXDKq3BRPU6jKKKKyGFFFFABRRRQAUUU5VLsFUEseAAOTQBJa2811OkNvG0krnAVa9x+G/hFbHTJ7HV9GhbUbiQN9uZA8loApxsOSMHrmr/gXwbB4O8Or4ljt4vEd3JAq3tkI2zbK3VFA+83qfavUvDsek/Z1vbBm0+0uFVvsl+pVY17gN6jnj3rojBRSk/wCv68yd9DP0vxHF4e057OWL+1yq4mEqByEx6gcgDjp2rw/4ra7e6k0iaeWj0JzzbsflibPA9c17143bS9JENs5a1guUOya3AQoCOm/+IE/iBXzZ4ysbG11N/wCznv2KsXnNy6ugGfvKQefoa2fwXXUX2tjinVUQIrM27lgBjGP59/yNRCRlLFGcHsQ1IWUH5c9MHNMriNCSaeWdg00jyMBtBZicD0qczXF6qI4knaJAqAc7VHb6VUq3pcjRX8DRzPC24DzFGSuaVxbnb+CfBsniK1jubLUNJmuomCNYXhdZMc8D1HpimeM7sRa3HaabELFhIY7iGwlYu544OfTGB1rodM09o21Jrq5+16sIlk0yNLZt14+Pu4GCMDnPtWF4N8O6/r3iNr3TdLvZZo3xJOtqXijkOeWPalWbhCUktjeik5xi+p19jp32iwE0keoLIzZVpplHPTBJOf0qWT7TpsYjREZN/wApeJJQSc5wdvDZ7/Su70TTL+3tlbVUsruUHDLCzp82eOCu3P41Y1Pw3q1w0tzDNDErZ/dgoflGSSMfr9K/Pp5lGU2qjX3n3lOrTSUXt/XQ8qgjt7ssZ/tHJ/5Yj7xz0xjrWjeaEumBDOChKiXyp4SWHPBBVuevStO+vriaY20iwRTgD54zzwcZAHU59Ka+j3pt3B0ZJmzh5zM4CH1545rsjiGt3a/S6/PQ6pPucTqVsTGY5bQQrgEBAe465J9/wz61h2OqN4d1+G+srUCZCCkd3Ctwkh9y2cfT+VdvfaLLbljcSQuu3d5VvepIwJ9Rn3ya4nxPa3cdwAlk8UkZGcEsVPqewzX0OWylJ80NV5Hg54qcqd3v+Z7R4I8banrFhLca3esGLYkFrpzBip4VUI+VeO4BPvXVy2M2kaqkyW/2UlMwoXMrqrckvu6knnp3Feb/AAsmsn0Vra51az0ZiwJjv7tkCdCDnrz1A+td/qcuj2ltvk1+a2hMe2Ce1JIkkx94u/zHt0GDX0MbxsmfHS8j1jRNRe80QPBvEiAp+8yvbqQM4P8A9euU1XxFPDfy2l5cXMwKlPL+zGFWPbDn+GqHhiLxNDpSvrN3ZpYuQ8V1FujmljxypjI6n+9WH4s1W7uo/NvL+4fS5ZNoe+iYHIPAjAGW/H29KmFNXb/r+vmJswNe0641HXIoxPdNYsMTxQy7FYD+AAcmp9ahjigtoDe2Vhp0ZBEEpDMFGeD2VuevJ5FcBrV3NJrgi0XWr2SYkiVbiHyx0ztHpVa5n8m3Q6/ZT3Mk7/JFEg3P6ck8devriuhO92yddDuLS907VLa6tNLsjFptunMqylRcSfTGW+tePape6tJeXdjA7SMcrIwXCRJ0APXrnr9K7S38R2elRfZbiG4gYAtFbQ84AH8b9/wqWEPrmmnVpreaCyD7FaCLYzsemB/EO+TxSVpx5L6h8OvQ8avWeJBC0qyHhjgcD8f89qpkEda78+GrKznabUJzOcn91Cc7T6N/njiuLvyI7mdNsbNnAKdB/wDXrhlHleponcpUVJJE8aozjAcZFR1AxaSiigBaDzSikoAlhJBBG7cMYIPTmvRPg9Abnx1p0YR2BSXOByf3ZP8AOvO4Rzkqx9MV6p8AlMnxH0dN7qsizL0zj90eK2oS5akZdmjKsr05LyZ9Aw6aqlCsUgVcbRuzk+3t9a0n05ky7o2eMEt0rehsljzui5U/LmobhQEdFyQO4617FTEOeh5KoJHH/Z/9v/x00Ucf88jRXnai93+kfFVelfs++FdJ8Y/ESLSdegaexe1mcqshQhlXIOR6H8K81qa1uZ7WXzLWaSGTBXdGxU4PBGRXC79D3Vbqd38Y/BmheC9fWz8P+I4dYR8s0SAM1sOMBnX5WJ56Y6cgV59Snk80lO99xWtsFFFFABRRRQA5QWICgkngAV7b8IvBstlM1676XJqrxkfZLtC+2Nl/h7LJ+eORXDfDqKK2uxfrc2gvQdkUNwmQc9+eM17T4a13+2dwltpEuIm2/aIowVz1P1+tb042XN1/rsJ9juvCtgIZIpfD93/Zd3b/AC3Gn3sO7PrsI7e4zV+WbUdPnuHnUzabJIVnjS1HmKSPvJuI3qfXGelW/Dmo2KeVPvBYj54robimBzsauii1HTrtP9FvInUcCKRsGL1Knr+FNy7r+vu/rzHy9jwL4gQQ2zeTo11LfWm8+TZz/K9sxIJZM8nk9PwrwDXo1XUbgtK6zCT5o5ofLcHuWHrX0x8VtEurLz77Rpkv4mlCzWUo2yQ9yUl7ZxXz14112e+1wSmCSF4wAFukVpQR6tj5h6ZpyXuq/wDX4f1+JPWzPW/2bfD+han4W1y71rTtHnnF9BbQz6khaMbh9wc/KSeh9SK2ZvBHhi6tb2z0DRFDWXiiDz/ty+VNFakZctu5EHoT1GO5r51XX9Vj0u602G9lh066ZJJrWJtscjKflJUdxgVPceLPEFzqF3fz6xfSXl3B9muJmmJaWLAGxj3GABiuRqW19Pn5/o/60tpeO9v60/yLvxK/syHx94hj0BYDpYvJBAY1woXP8PtnP/6qp+EtFh8Qah9ha8S1un4gEinbIeeMjkH8Kwq2/DUMd1rFlazRyGJ5UDyW8e6UR5+YqO7AVcpPdiiuh6A3gG+0Gye8177BJZyqYUubi5ceX6lArD5h6HP0rtPCXhXV/D9vFqnhW/m8VW05+ZYr2e0454UBgCwPruBz261xHii38Q2S6gmkR6jP4fkk3Qw6lEHk2r919pztPXpWJ4O8S3SSPa3mp3VtZdWjNw6ofbj0x0+tZYt/umpRurdNDqwsOerFc1n5n0PfXM9vGG1yz1PT5ygwzsZdvpiRiRnnrUdtdXOoWzJY6vNOoBVkSeEOvHOMLn15+tYXhTxrp1lai3ttUihlcZy8xdTz3DdRW3rfjZb6CGHVdD8LaxAqgKY5Sru394ADgZxkV8EsBhp1JRfNDtzRv+N0fX/vkkoxUvO/+f8Amc5qWnzrcOGu7whTyFLylCOw2xqPrgjNbWlBJLJlXS7ALtxvuLE7vX+Isx/IVk29o2o3EzWd/rNqRIS0KYkSLPIjTachRnANWJrG+j2pa+KL6KWM4MU4aJj7Anj8a5qrSahzbeT/AEX6nZ8UeV7/ADMbVNPu7i6uISsUNqf3cTRtDCEJ4IJZQT16noK5vULaw0ZJI7jVJgQuHT7bDcovrnYByfT9a0fEOk38MEcl7KuxwFUz3MUhHJ4JHI79a43Xba9tE8q0tWmkcArLBNkY9WwMZr7fLMw9lRgqaTfe/wCVmtPJ3PEzPAKu3VlPS2yV/wDNfka/w9k0u21qLUbrS5X04RlYJbmJ1hVzgfNhG3Enphh3rvvENmtz4jsLmDQneaRuRYRrblx1GQ8jM2B67fpXm3w+0/WJNaaK6uEhmMZKC8JdXHGQFBxmvTdJtLjWtQI0+2vnu428v/iXwtGoI/jaXPJ9q9ylUdSDk7a9tv6+X5nzFWHJJJX+f9fqen6N/ZlvvuLm1ljnhhL+XfSb2UepAQgY9AT9K4Pxnqtzr+pSXWnGG5kX91Des80zKMEEJDtEanP8TLXpFr4S1CWwjTWboxKqYMhuNrOf9r3qS/utPtj9ik1Jbu7ihO+O1jUIFBHLsO/P40QnFy7sxasfJj6frEesSXdxDe3TpIT58UXyEj2Izj3AxT28TRpqhuEibUrthiW5uAY44juwQiDAOMjH1HFdn8S9XbVNTupdCnW2ggzHIkD7Uf3diMD6CuDvo7GHw5FcapfLfXjynEcEh/dnknp2/wDrVduV2Wn9eglsi2t3b6xqrSQvdanInK+bGqwqRjqcYx7Vbk8RTHUJl1O6MsyDEgtcKkKdBg9O+MAd65CTURqO2G4vBZW2GO2PMjv/APXNU7eZVjkijUo7Die4Yr5Yzxgdz0/OpVSz0HayLWv6oPPlWxsvs0DYYSbSHfp3PY8E49q5achpWIGMnNdlOmgw2y7Li51HVXbIu1z5cfHZD1NYOomOFDbRwCNWwXkc5djnr7fSs6ivrcaZkkkrzn2ptSzlCwEW/YAPvfTn9ajJz2xWTGCjcQOPxNNoopALmlJ4ptLQA4PjoBXT+AvG1/4L1tdU0+zsLu4WJ4lW9R3VQ2MkBWUg4GM5rlaKAPav+GjPFhZt2maAyH+AwzYH/kXP60yT9ofxTIMNpWgbcdPKnx9f9dXjFFWqk1syHTi+h6r/AMLw8R/9A/R/+/c3/wAcoryqin7Wfcn2MOwUUUVmahRRRQAUUUUAFXYtMvJQPLt5WLKHUBTkqT1+lQWkay3MUbkhWYAkda9Z8E3lx4Yuom1PT45tPkIRbwDO3jvjnH9QK0pw5twPNbeG68wQyRkmNsBSMsT6CvcvhnqmnuILd4oYtRGV+V8ROACeB26H6nFdTrfw30nxVaNe+HjE97KoZrR5BG5x3Rh0HtXmp8NCz1N9I1+GOKaMERSwuRJG2CQrt0I46itoL+V/1/X9dSbvqe1x64dJCrDHCylSJLe4Kkk448luoHqKj0W70rUb1JZLZtLlLBnLuGjJHPQHIb3rz957/QNDij1hLbUtLjUJ9oiYF1U9gTycVzWs3VhrMEZ0C+khVc/6NPNslkPYxn14/izzVR0uuo0e1ePtQm8PaL9u02UXUcjbI7qSeNgikfcYHk/XFfLfjC/n1/UZrmeaMGJeIyVHA7KR1+lTa/rOqxWdxa3MNxArkIzGYusmP73bJ9RiuQ86QoE3tsHQA1hKTWjK0EdHVV3hgDyMjFMOOwP41M1zKwYPI7K5BZSxwcdKhGO9Q7dBDkO1uCMdzjNdN4M0abXrxrSK2W5uJE2QBrhYir9ioPLc9hXMAnsTXVLq+ir4e0mxtdMvLLUVkY6hfxXLMblMnaqoeFwMU4+ewG/qq+NvC0trJrVnrVnNat5MF1cBkRW6DYSuGHtzWPpscU+rxMt7El0GLySNbmTkA8+UAcj1HueK6DQda06W5svsWueI47qJgIbIkSBmzwAzHaM+uOK6bxmt34htrEjVtRtb21kANtqJhQoMdFdRll5IGeDg1z1pTS92yS9f8jsw6i3Zq7f9d/68hNQ3tfz3t3ZvfRuiLC+2K28sgcsQoYsv4r9BVQ3kiwuEhvYVbnYLhHjOeuAwzg+maitdBvLWEXIaDUUBIDx28gcgjpzwMe3Wm3FpMHRZ7G6tVYcu9vgMD14x19/avnK1f2rtJpr01/zPtcDRhGCaTT7O/wCun3GgfEd81u0VvDaJkFQ0dtsfGPuhlbkfrVRNSvLjbFdgTBwQPtDPIqnp3bFTabYW6NGXzcKw4XDR8/3ScdR61qWdjpKs5iitp3JJ+S9OOn3eR1z3Ncc3Sp3cY/1953aR6GDNG1ttkUQiQZOY4kAGPb+nXn0q1ZG7uUXzI55I2HAf7pA/Hlvat1oBEFdLiysQDkKrlnAHoVXG7Pel8P6Vq/iG4FpZQGSESAXF6VLxW+7gM3IyfpW1KTrq0YmVSrCEXKWyKuheGYdduxImjwSWcTBJbiZ5IVb/AGVcNw3+6COOhr6A8J28Wn2MIh0q702CM5+zWSAQkepJ+Ynv2+lS+Hfh8dIt4YV1CRVTkpBHkM+AN+59zEn0JxzW5fahp1jC9rLrAtrl+MyS+Y8Z9SOcfjxX1eHpxo0/Zx1PgMXiXiajqWscT4tkjvvFNhZvBZzJIC0ZvJptsbD+LywArH2Lc9MVzT3tjpGp3EWjR22ryTMu/wA63aNVbptUccf7IyTW3q0EeoXjRxXmqX11FxE7xhnBP8QyNoB/Ee1VoNEWMfaNTn1C4voW3hrm5XO8dPljA/XvXZT93Q4Wc346l/tLS2tbqBEdG2vaQRiLHHKlcZHv3r578VMjXf8AZ9sIktrflYYgPlPPDMOSef19q908URa5bXLSX0C2unzOZHdxsefPXec5INeY+KNEaKES+H7YFWRkY21rwqkdC+f8evtW1aN1oKLOBt7p7OcNbwRRsvzhkIyO3U9K2rPVrS8mI1FIQikEtKfMPfjI59vTmrGjKkGk3U9reQ2d+37rbPCXlfPBXPQA+uK0LTRra20e6uLlLKz2qV86UGaSRsZIC9Mds471lyPdP+v69CrrqZGpz2cIc+fB5wbarwKflB6qvYetYEj6fCGIV7iTd9+Qn8setSXllFNPstL97lmGTkEBcdj7Csm6iEczKkgmUfxqDg1nNvew0JITIcohC9MdeaiqQqACWbnAIHrUZOSeMVkxhQaSl7UgAD3xS0lL2oAbRRRQAUUUUAFFFFABRRRQAUUUUAFWjZTiyF3szATgsOcfX0rY8GWFrdamsmpW4nsU/wBYm5l+h+XnH416RdeH/D7WptEvCkc4BjSNPLCnvncWJ7YzW0KSkrti1PF1+8CDg11uh6zrmi2sd1s+0ae7bPLkbIb1HqBxWrP8Pp44p5Y3SYZxCem7jPzelWPA3h0Xl0bSR1M8ikfYbrqR/eHt1x+FVCk0xXPWPhhJcXcA1vw9p63ts7bJtNkuhGUPfaTyw+lereMvAul+ONJBZDEyrgMh2yRtx8ox7+teLaB8P9W8M/6d9ikvrCVv9dCTviUdmXOB+Ar1Pwp4hs2a3tdN1X7Lqa8vZyLvScAH5Qx5H1HSi84PmW/4FK0k0jx7xX8FrzSvMFnqN68o/wBRDcMF8w/3VJOD+FeH65HdWeoy2t9btbXkDlZFb7ykV9/STQ+IrGe21vToJISuGWGbzGXPHGMFT718n/HTwc+mauJNJklvrLGSZTvmix2J7rik7VE2lZrsTrHdnkTTSMu1ncj0LZFMpTz0rqvAXgbUfGs2oLp91p9nDYQfaLm4vp/KjjTOMk4NYN9yjk6K9FT4QeJz4oOizjT7cC1+3f2hLcgWnkZ2iTzPQsQBxnkcVx/ifQNR8M61c6TrMHkXtucOmQQQeQQRwQRyDQK5n2zbJ0fKjaQfmGR+Na+oatNciAzxWMiRDapVMdR1IFS+GPENzpFjq+n2thp90NWt/srtcwCR4h/ejJPyt7/1AqjaaeGmaO5WdXXllWMttHqSOw71UKrjeK0HyN6mnobaIsi+fI/n8EPPbl7dPXcqndj0I/Ku38LXVzHqEc0D6DNaOR5mIiWx2XEpyAPauOsY7/QryKXQ9Vtp2cgAQOw8wHsysBmvRk1aS1gI1+2mGrrG3lxi0MmW4wW8pxwPfPTkV5OOpVanNGKTXm/+Bb8T28DUpU2nWvF9Ela/zv8A5HpNv4pEVsu2eZVfPLRhFIHbOcD6mqzwS3IW5hm1K/Z8hoodQgJIPYLuOPwrz/Tdenv4CLrXYo9oAEQs/Idwey7VZgB+Gan82/mm2xXOthGz5bDeqydickDAH/66+QnlboyaVk+u9v0PqaXLKKnDS50c96iGaO6sru2XGGN1GGyfUYI/+vWFd3NrNPGj6fboR1lWwIYnsRh8H8amu9EjhhkmurjSJW2AtKLyWSVhjoqZUFvXNVLO9s4Dss7TUbkHnFzFDHGD2AMgc498/lXbHDeyjdfg/wBbv8TVyi/h1+RDeXLeSkf9pLKG4KIOAM8AYzVdbm/ss3GmQXk0ibXby7h9oI6ZRRg/j0q7q6XgzdSadawqcFjHKsfJ5/5ZKB+QNcDe6vcRagwt7CeODo5S5uAR64OR+oNejl8HU+D+vuaOLM68IUrTW/8AXZn0d4B18a+32PxJeXRvpAWNvua1iTjjqQdw56H8K9Bi0fw7ojO9tdRR3JGJAJBI7+x3ZJz718v+EtHjmmSa6TVb652g20dqVm8vk/fLkevavqXwFZarZ6Si3j2izYBIKZdV7LhSMGvp0nBXf4f8E+IquLleOnrb9EGp+H5dWhLwl7T5cq0xJY/gOg9qx30i7sZXt/PtBaBCcBSHmb3bk+td/PMo2RvEZWILFcdPf0/WqUmm6ZcxEywQxBiQcYjJI+nWhVZLcxavseQa94an1J1W70q0mSZTtkvLxlTYOp+Yjp1xivOfEFoNQVtJ8MxX1vaLkyXUYkaHA4+VAOp9T71714vu7KxK20Gk6fdxbgHmuMyBffGOT+NeMeLvErC5e38K3l9HenIaYQpBbY74XJII/Cu27nG8lp/Xr+hnbWyPP9Ys7LwYkfkSteX8jZDSLljz0K54rF1SNtahk1LU7557x8LHbxjBC9sbeOPek1/W7mG9mNzeSX0jsu66dclgOwY8gfTrWRHr0dvJJ8n2hBlkQKIlRj345PX1rKU4vQpJ7szZblrfdbGIQwl8uE4cj0J/pVEysBtQlUzkDNFzK007yO5dmOScYqKudydyxffrQaM0lSAUUUUAFLSUooASilpVOOhPoaAG0VOpB7n5hg571agmkLAGUlc9CSfyFAzOop2T/eooENooooAKchw4OAcHODTaX8aaA9T8KaNDb2P9pfZ5DhczLBLvRR13MB0GcdemK6e18T6JHaqqXlop4fdNEZZNw6qfT2P0rzvwLqmp6G/2jT7yGWCVcT2W/wD1q91YY646V3WqaXputaeZtEt5bS5VC8kDBcE+5H/6/rXZSlzR5Vo/6+75kSWt9zWvra38QD7RoWpXF3I3JijZVEZx1I6mrug+EL+9vIv7cu7U7kOy5jj2OD2JbtivOvBUGu6TryyxW1ziXIbbEELL67v6V67Z6nM+oR2GoaS15ZOuJd8m0N05ABySOeBVQlJayjr/AF949OjOn0m/8SeFo0g8RaY2q2ki4TV9LfzDt7B07ADv3o8SaRY62Y7gabNa3Cx5jurc7A2e4x90+x712fgOxbR1fyo3S0c7lM0u0oD2Cn+H8a377w9YXMU32ZPs0smSZYujE+o7iuf2ipzf9f18/wACndo+drp9RuLa7SG0m1C7jTaIoZfJuh/tbhw30rzHUPHl40kmmeJbea8hUeUftPySxD6jk1754g8NQ+H7yWfUbG8jUN+7vbOQfOf723qBXj/xT0OS808X9mia1Fksb2EETwjuJF6N9RW9SKklKO/9f1p9xCk1vseP6j9nN5KbMbYCcoM5wK7/AOEPjq38E2PitnJW+vrARWbeSJF80MDhgeNpFedSKoJ2Elc4yRimHrXBKPNozROx9Eaj8aPDk0OuS3mnTa4dVtLQ/wBm3qBba3ljb5okxyEH3ge5rzf42eL9N8beL4dT0a2e2txZQQFHGMMq4IHsOgPtXn1TWs8lrcxXEJAlicOpZQwBByODwfxqYQ5Xv+QN3GOrRnDZVvTuK6Pwql/MztpEeqC4jGZJLNS/B9RR4jmutfuJ9c1TUtOmvbhRLJtwjucYxsVQARj2rK0nVLzTpCLS9vLVHI3/AGaZoycd+Dya0qqUV7lnfvqgpy11f3F6/wBZ1DUX+y6lcLuEuGkkiAZe2SevFa2n3114YvGfTNR0zVfMwEVgXJJ44B5BqXS/B2py3o1CWTT47fdu36vLsEmf4mXqa0tU021s9ZzNd+H32DHm6duijPHYyptJ56AiuSvTXsl7qcH21X4bHp4VzlVd5NT87p2/U7i1Xxb4kRUfwnYxiMBmmtLby3Hodx6fSnX+na1a3X9m6je6xp99OA4hk+YSDoG9AM8VHolzZyWgf7ZdMpXAVS0v0PyydPfP4VWvbu1vSJL6Z5kX92qPbP5hOfuly7YXr0Ga+ZUYS93ltZ720+7Vn11GFSCs3ePTTX77pG3a+FrrSIZL7WtHu54Il3yyy3qxgjvwTiuJ8WeJItPvoZ9Cihmy2JIxMk+B/wAB/rUt1Hpuo3ZW00YrDkfu7l1fnuQSE2j+XrUknh60jkgi/wBAtZSeFF6IyfYLGef94mulxw0Kt3f0vdP8vyMqtPEuD99K+1tPwu187mW3jMT26O8epRzkHKwwRhBk4wD6VnNpz6zeLc3E9yksBxNDdzfMVHPyhea9NXw7HY6a6/aoZ45ARiW9ncf8BJiOD7jivN/E1smk3X/Etdre9lACG2uJ2kfPVeQpP4cVtl2JoSrfuofr/kcGMoVfq/76V0vl+LTOw8K674e8OyxyyWq27FuZNzksPbd0PvX0h4I8Z6TqGjRS20shiHX5dzD6n19q+U9P1e60e9hhtdBs4J5FBMk++4XO3726TAQ5rtNTi0F9Bj1Dxjrdzq1yibk0+yRYxGD2DKATz719TODmve/Bf8E+Tk439xO3m7v8ke733xDtLa9aMWkztu+SNZVMkg9lHT6GuH8R/GoQSPBpHhyU6l8wDX0yAJ25A6H2NfLPiDX2l1B/7PjjtLVDmFEYk+xJz978qzLTW722n86KTMucln+bn15rKShskSl3PWvF3iLxBqWkSX/i7UpZHcbYrS2nEIT64rgNIuIItE1S/i10adexeWsWnhGka5BPJV+i49/euf1HVLrUrkzX0vmsTzxgfgBVqLU4Le1ZII5PNJzuKoRj05UmtYuMra2S+8ltrYzLu4e4l3yO7H/bbNQVYu7uW6YGYqcdAqBcfkKr1jK19Bq/UKKKKkYUUUUAFFFFABS0UlAC9+KBjPqKWgUAPj4cH0q1bYL7t3O7GMfmQapr97qBVmAnemSAvf6UDRTooooEFL2pKKAClFGMUUAWLWO4LsbYPuCkkpwQB1r0j4f6fDqW1rfVZjNtxJBMcAEehrz6xuvLH2e4DtbE5YRkZ/P8q37SzghkS7iiurWNWB3BSwz7gc/nWtNpSTsG6tc9AvNZ1HRNUhhkSWAcqVf52ceqk8AGvTPAuv6XrLpBqVhLBcB8RXJUMQ3Yn0HbNeV28+m32ktEZra5iY5eCdmDyn1D5+RR6V1fhGysJoUl0G5v7S5i+RreWQMOO2cdOtbtczsnYS0+JH0R4ea6JMGoG3nh4Ikj5H0OetdARImz7OIzAFxszg59jXk2j+Ko7CNYtQtb7zwPlmRQQQOvQ4xXoOgarY6vCWttSt7oAjKocOrehHY1y1otO70LirrQ1Ly2GoafLBLEoMqFdsozj6184/ErwDPpMzXunG4jlbIdbEAsy9l8vpivpYDAABJ+pzWZr2jQaxayI7GC5K7VuYx86+3uKqhV5fclsyJLqtz88tXAF7Oby2YyE7uV8pgP90cVjTIqPhSSMZ56ivpv4ofCfXJcyrpEGsTsCPtVrlSo9WXu3cmvB7vwlq1tceRPpl1vHbp+NOVO0tNQ5kzmCCOtaD6NqKaHHrDWco0t5jbrckfIZAMlc+uKhvbC5sZNl3BLCw6hxg0s1zI1pHaxXFy1qh8wxO3yK56kLnH41DVtw32KqkqQVOCOQRV2GDUdXlVIY7m8kUYCopcgfhVCtHQ7s2WoRyG8urRCcNJbOVcflUyk1F2NKcYymlI1dITUtM1SOO503U3uF4WBg6HP0xnFd7ZNfa9cJb3dlfWVxuCIlwrOhzz95iAK1NJ8QS30CBPiAXhwQ0epg7iAOm8ISD+NOn1hb21Wzj1cX8bgYUaikUZxnGTMgxj3PPavnMTW9rU92NrdXdfmrf1ufXZfTq0I257+Vk163vr6ItT6boOnGSPXZp4pYUyZImiwT3UjkEVDJqukGADw7FLOo+SS5eRYSv0KYP41dutOv41QQpo0VsoD+fFe2bJn/aLZAPuK5a71C409mlGs6auGKlTHA+7r/FEcY9CcVzTwl2nqr7Jyvf7kjrp4iSbbs/TT83+oa6U1SKVNUmvJ1UEbxeeaq+m35e1cXYNpOl3wnXZdhOCs06kMD6Db1q/fa9NqUFw0Gp3kbpnG67hhUnGOFGCfwrh5JHfAcg446CvXwmGag4t2XZM8THYylGanCN/M7HVPF1vLfJLZWs1kqjay2s5QNjvkdT9awbzUH1TUklury5VAdqNI7SOo9qoQ2dzNbTzw280kMABmkVCVjBOBuPbJ9afp1jeahcGLTra4uZlRpCkEZdgqjJbA7AdTXfSw0KTTijx6+NqVk+d6Hq/wq8RRaXcFbbU7mO6YbQ32cSOQPQtkD6Vp/FrW21Bg2qarOsTLkxB9zsM9FUfKK8QjuJ0A8uWRQP7rEYpskjucu7N/vHNdaqJRtbU5mk3cfeNbtO32RHWHovmHLH69qhpKWsgEqaCV4ziMLnIOSoJ4qGlHFNOwG5rkmhyaPpB0qO8TVPLcaj5zAoz7vlKY6DHasKlJJ60lDdwCiiikAUUUUAFFFFABSjk0lLQAClAyQPwpKXHGaAF6MQSRzzirMBBZSx3DOOVz+dVQcHINWYMll2Z3AgD3oGVKKKKBBRRRQAtKrFTxSUDimA5HKtuB5/nXp/hnxJbx6U63Vpbltu3NsME5H8QwcmvMljLqSnJAyR+NS2V9c2TMbaVo92N2D1xVKUoaoNHuem6bqXhq8u/LaK4W6xgLJCAxPofSux0zVDbP5aI7bsbIgDubvhz2ryPS9aby9guBbzHJSYoCdx67m6muksfF3k2MSaxHdJePloriNNqMBnDY6tiuiNXmjZ/19xKjZ6HqsPi6G4Bgt7nVNImzhMxrLG57k98Cut8N6adSube7tdQt5tRjXDyPH5XmAddoBwv1ryLRb+DWNOjgvYrie5DErOsWxpSewqSDWdZ069js006WNQ20ND80nXuR29fxqoXcdOvl/wAMNrXU+n9Gu5lvHj8+ddnLxTjekh9Uk9K6QSKRk/Jzg7j0P9a8D0Lxdf2Mlums6ffNFgFGtlMmDn0HQfyrqdX8SWd3aFLO+u7G73ZCTxlo8+jdwCe4rmlQalbZFcyep6mZIwM+ag7ctVLUdI02/wBi39nHKRnawXBH4ivE9N8Y6np9wkd9pn2mMH5za3AkQ+mFPIr1Xw54sstQhjQNJE5x8sjjKj0NZzjKlZpg4KS7nHeLfhhpOrWk3mXUdxChYpFdEqsee24cjnFeP638DrfTp450lubeyd8G6jIuIlz2yozj6ivrXEU6A7YpEPzDgYzXIeL9Hns7WW88PtcW9wwZpFj+aM9/u9PwrZV3PSVmTypPsfLHiD4MtbWpuND8Q6NqYXcxtzJ5UmMdNuev5V5Tf6Zc2Vz5E8YWQdRnH519JzazrVzdSRa0nhfUIQctDd232acY77l6H61yXi/wj/bP2m40zw9blmIZruyvGuURfUpjP9KLc11ZXX9bXepfLb+v80jitCstMl05fO0q9eaNDiSwu8sx9SrHA+gFSLc3kdvL9ptzNCG3Kl9YgOwA6jBBH4VNp3gK/iY3lrqOhY2My2016I5GI427Tghq2NGv4LO62a7Y2cF+duYrppWABz8wIBAGO1eBiqc6Lcrcy/Fffqj6bA1oVEoJ8rttpZ+elk/xMKy1C+uLaRDqV1oVvIQQCZY7aQdjtOQf0oj1aw025CX+q3WpFc7RYusceT2BIwOa9Fl1AwMktlqumagkhz9jjuW2AemHX5RXCeKdV1KwmM8mj2UERJURmRZTzyccdMd65KeIeJnyyX4r9Vc6ZUZUIc3N87S/KLt8zDuvGmsWha1S8njjQ5RU8n5e/wB5V6/Suc1PWdQ1QYv7l5gG3gNjg+3pRqupz3t08jIkKkECNFACj0rOr3KNCEFzKKTPmMTiJTk1zNo9e+C1rHq/gj4haGt9ptpfahBZrbtf3IgQ7ZWZuT7elejfDmz0jwF4F13T9U8ZadpWq/2hBJ9v0q4Wd5IuCE6ZKnnI7d6+XKStWpPZ/gc2m56B8ejprfFrxDJorWr2MkqSI1qwMbFo1LEEccknPvmuApKWrV7aitbYSiiigAooqe0eGO4VrmIzRDqgfbn8aaV2JkIOCDxxW54u19fEWoQXS6Xp2meVbpAYrCLy0cr/ABsP7xzyayrySCWQG2gMCY5Uyb8/jikt4muGWKCOSW4Y4VEGc/h1p8utk7hfS7RBRUtyrpO6yxmKRThkK7dp9MVFUtWGFFFFABRRS0AJS0lLQAlOB57U2nDt0oAOMe/arNsHedM5LEgeuarDqKswkbkJ4IbrR1AqUUUUAFFFFABRSjvTinGQRjGetMCSCLzJMAtt6lgpJUeuBVq5sHij86B0lh9QRuHHde30qrC8kQMkMm04wwBxn2960La9trq5b+0l8uMjgQjYob1IFVHlejE/Ig0xreS4C3sssUROS0fUHtxXVwWohgmU6jcWnAW2V4/OWXceFLnATvkVhS6PI80babcQXQbBJTgR8jGc1d03VpreVbWeSOAqNiuw3RM3TLf/AFquD5dwaOx0W4k8q40jVJJYZVysQgcFX9xIOBWc8Wo6LqCz6fqF+J4SARKmUZceoOCO1czIsyMvlzCGPeSkobdBI2ecDtmt3Tdf1KzSKLW/NkhdR5buN6qB0wo7cmqT194d+zN/TvER1WUpbz6hZaxgl1hujFHIxPRUBwueuSe9b2n+LWskaLXIbszRgoxYh1XAPGec9K871my0vVLiW4s9R+zyH5v367A/ptA6D/Guauby9tGeCK/laJePlcgH2om3H3lv3/zGnpZns8/i/SGZrhrK3njVvLEmx4WGf4SQB6/rW/pPiLwjbwrqY066srpcgPaXQZR+AIO76ivnr+2buWUSSyNPIWH3+Tj0/nW1pviq2iXZd6fj5t2+FtrewpSq8ys3+v8AmJI+s9I+JekXEG1dRtrpkOI3tw4Rhjsz4O7kDkDkmsx/jLYW9zFF5c8UW4qxkDHbjuCpP+HvXzJb+ONQ0ySRdOaE27ybzHNbqSRnoTj09PWmax4mvNXgjjuNOtY2hG5HgQIUHqCKyaTVlv8Ah+dzaMle7V1/XkfRfir4vaTNayGK30+/Qr/qbp13sh6sCwH5ZzzwK8sh8dWF3q0d1Y6LFpySSKPOttQKMhB+9jGQPXPFedJ4ju4LJNPumhvLTcJNk0WTG3rnr0z+da+jXUUt4ktta2MkjAgMYyn4fl3rCpXnTS7L5r8TtwuHpVpNRf6flf8AL5na+OvFGoXWpNFqVxNqWnmPpcTxX3PqCiDbx2zn3q34C1Wz0m18vT4tSUntaNDycj7wYZx7nj+mLpvglNZlVYLSGBurJ9rMRXtzntz2rTu/ANxo8SSyWVvHsGA8t15kb9PvAdq+dzHF4bE/uak7eWn+Z9Hg8E8K+TlTv1u7/idddW8+tTR7NNu7aQPhLtLKNJQcdymePeuf1zwV4g1W5LWd/qe2NWUSXytID7LgHH5Vl6fqkVqGNw9hauv8NvobXAI9d2atT660xkjNpopt+oludOmtnkyPvbV6ema81UK9Fp0raeV/z0/Ebrxjem9H2V0/zRwfi3wnqmnGSW52tHhi9xLAyhyOqqWQEn6/nVPw74Q/tGzluZxI8RTMX2a5ty+70ZC+4Cti706+udVklk0qafT+C4sbJlUj0R26Z/vV3um6jpfh+w8218G+LV4O8zXh249vTHrX2+BhUVNOtv00/wCHPksbUpOq+ReuvX8zw2/0HUrJn86znCL/ABYBGPqMis5964VwV46EY/H/AOvXuPiu10zxTEjuLu01AAIitZMFGefmdjjv2rkL3wEto7S6tfKyKoG3TLcynP06V1Oi2/dOPmXU86zRXXJL4MsboB7LWdQjGVdZpUhwfUbec/WsTWr3T7qQDTNNWxhHQGVpGP1JrJxXcdzMpKXjFJUDCiiigAq/omq32h6rbalpNzJa31u2+KaM8qai077L9ti/tBZ2tc/OICA5HtnivT4vHHhy20xbGx8B6AxaDY13qJ3S5xgPx0PekrymoKN1+H4jtZc1zzHUL64v7mW4unLzSuZJGJ5Zickn1PNVK6q38Nanr1rq+oaasNxbaXCLm78tgqwozYAXP3voPSuXZdpxkH6VrUjaT1uSmNoopazGB96OKKKaASlpKWkAlPU4Pb8RTaBQAvHerNs43p8qttIO1+jdOOMHH41AcAjDZBHPHepoSC68c4xjOe9D3A1v7fsf+hY0X/vq5/8Aj1Fc/RV+0kTyoKKKKgoKfG/lyK4CsQc4YZBplFAE0cu2TeFXcGDcjIz9KY7bmY4Ayc4HQU0HB4peuMcknpTuBLbMyuoWUJubad33R7mtRLy8+yQJcKtzaQ5VI3T5UBAGcjp+NZqzTCNVxujjydpXIGetTQ6jcRxmNZnWI8FAeCPT+dUnYDobSfT3ikka2AjyT+7cHYP9odOvTFSxPZSxlLeZ41lwvlmQEE47t1AzXO296sO5mSOYOMsvK9+nvTIjbyXJZTJHCfvJGcEDpxnr1qm+oLsams6FqFsiyLN9ptG6SKTgn6Vmwae1zEWRyJAdoV+M8dM+vtW3Z2ck10W8O6s8kiqCy3A8pySTkAZOaytXg1S2mdr+3kRmwfM8vaGA4yDim0mrpCKUe+1m5LxMR1K885Ga6K1PhmTw1M9618dfEypDFAFEDQ45Ys3O6sG4vby4jczszqSCSy5x16ccdarRqsjfM2GPAAXqazVx6Ft7oJujCmSHogLAkc9c+vJ/P2qNfKmUKs5t8LkiQlgzD0wO/v09auaUqeYVnso7yBCd3zbHYE9j1zS6tbaZCxFut5BNnBgmw20/7w6insw1KsdjJLO0JAWYAH95KoXtzn8RxXaeD9Fna4a1ngZlUb8x30a5PfALrXE2cMcsoLxM8atyqOFYj8a9L8DeHvhvrkfk6xrupaJfI3zfadjxOOwBC9a5K9J1U4qSX9eTR34XEfVbVORt99Lfc0zvNO0yfSIoisTeWUJX7bak9ecFg+P1NR6ppetXTvMz2ElmGw0QuxEVBOQCDnFa8PwS0u+tB/wjHi3TZpd+9BIjfMuOnDA1TufB3iTTrJtLGoaeqo4yEMeMgdwcnvwAeOO9eJPI8Rzc9OUZPrfT9bnvUs9pSXvLlf3mQdJ1U3HkaVqui6YWTc+/XAN5/ukmLg/p71qy2fjDSYEutc1C8fSGB3Cwv4LjzVxgbNzgnr6en0rFu/CnivUGa7Twvd3DWp3x3NncQeW5xjcUxz+lcHqVjPbxC6vNE16z1FpTvnRgq7R/sBRhh6k+lduFy2PsrYiknJd03+N3+RxYnMJSqJ0qvuv7/wAUvzNuXxElvcO2+f7ErHy01eaeJpAO22IFTg/7XPtWffeJEkDpqqmOIk+XcWttL5bcdPnYHvjgVN8MNDf4jeK30W+1PUI7ho5Lg3E0zyAKgH8PUtjH4dqp/F7QYPB/iG40KQXl5LGqSLc3ErBWBXgqvP6mvSoRlTell5L/AIY8zE141tZtyfd/8P8Akjk5p8arK2n3UKfvF2Snco9yM5wM/wAhW5rOr+JJ2gjuPEbXsMZCq1k5O0Y/2Qv0yfzrC0kS3Ylghs7acgHDTTFVjHtlgP61pReFr2KB5nOnyW0XLFLxBuOOg7k10xutjjlqYd2iRXDs7sZA5zvXJ79ifbv7daz2Oef6VNeMrTvsiSFcnCKxYD8Sar1Et9BIXmkpaSpAXpSVo6LqjaVcPKtpZXW5Cuy7gWVR7gHoal1zV31qSJzYafZiJSMWVssIb3bHXpUXlzWtp3HbQzRIwA5AwMdBR5jYwDgEYPvTGBBwetSRGNWQurPg5Zc4BHpWqu+pLLNlOkUEqNc3EQl+V0jHyOBz83IzVYxsys6qdgPWtn+3IbSNV0mwit2/iklxKx+mRxVvULJ77wlbazLrVvcXkl21v/ZiKfNjULnzDjjB6VtJU0rXu/Jfq/8AIhOTd2rf1/XU5ekqVkMTYkQhgeQwxTQpdsIpJPYc1g4taMtO4ylrodL8L3t1Gs9wjwW7ZAfYWIOMjI7A+tWrvRbXSbJZ7ho3lySoZ859Aydar2ct2FxfC/hi31Tw74l1O7nlibSraOeOMLgSFnCgEntz2rlpSpkZkXapPC5zgema9D8AyLL4K+IbzEr/AMS+LAHIB85cDFedEHg9j0rioTlKrVTeiat/4Cn+dzSaskJSjmk7UA88V1ECjg8irFqf3o4AIPXNQDrnA4GeangI8xTjC4GQD15oYIq0UUUAFFFFABRRRQAVNGVTBddyHjg4qGlHWgC7bX0trkWrFQx5UjIYehHftVo3ME9tL59hvuGX5ZIflVBwc7R3/wAayi2SCBgj0qxBdyw424YY24bpj0x+f51fMDI41jZyGZsdsD+eamntViAMc0dwpQMShI28jI578/rT768gvf3r26xXBPPkqFjx/u+vvVH360roRtaatpcShH1P7AAAyvJGT82TwCv9a65dIm1NJYIPE8GqkDLQiQopXH958Dj0rzfPORmpbe4eB9ybDnruQMP1qoyS3Qz0GGwsdKvD/bml60+mmF3aKJlVTMF/dyKx4KZJJFYVnbaVqUMwm1SLT5IlBC3UBy7Hsu3OB9acPGOuS2X2Jb6WbTicta3MgdCce/IHHQYrH1G4iuGE32aOzdgzFYkO1iegAJ4GKd7PmX9fkI1ZNJhhlVodQttRiLBj5YZN2MkjcRx9femMmmzN/o8F+0+cmNsOp9g3XHvVzRfFup6TpiR22tsE2NH9naDO0c9D2Bz1pHW81zzbuzZRnAZIEJ+g+v8AOs6lanFXen9fM3p0KlR8sVf5r8i7plxJayJKdIlEIJjBdOmScru28+ua9P8ABEHhy+eGK+02NRjd9nltxOE56kqc/Q/SuS8F6U0Gr29rrvie2tI2UhEETTkEg8bcYzyckHjHevoXw/4Pt7oLc6bqen30e0bXt1aFxwMgjO5ecnt1rqjNcur0MJQaeqFsvBPhO9tt2ku9vITvCmJsJ64TOc/jXM+KfhTFFsubLR21JizFxFFLGyf7W0t8x+noK9Jh0e2gOJ/7WgZc5XllfHcEEn+VaM9rA6M6T6laz7QQFmlAA7Ej5lz36Vl7Rtcqf4FRsnf+v6+Z8vaz4Z1/S4mltvDtxYMnKyHUXjAx3KHoPr+dcVqcHjCKH7TqlzPc2akea0F6sjMvUnhjx05xxxX2YdVkNvJb30sC9sPfxNux2IwM/TFeBfFqzitmnlttVsrePcZtgCEEY6cAg9cAYHOKIe9dN6+QndO54gt9bx38c1gLq2ZPkcm+Cu2cjhh0Hr14xXc6Dp2u/FiKHw9E1lbwaTDJeR3uozGSRYtwVk84D5k3NnBHHrXN+D9H1Txh4pGjaQLJbqVDL5tzmNAFGSxOM49Bjp2rs4/h/wDEO3vreDRdVsZrO4ieJ9U0vUMWsSLzIkkgwQBgEjHpWCShpcpvm1Z5x4r0a48H+K77R7qSxubiyl2O0YLREkZ4yOmDjkcVl31215seRbRcDAEabduB0wP5/rXtfi/wdqvjvU7M3uueDWvNO0sG71OzvGkWVVfarTEA/PyOcc/lXJ618HNf0zQ9a1d7rSpdO0yGKcTwSsy3SSDIMZ28479OaFO6sKzW55y8pTaFSDIJJ2rnv0PtVYnJyeK3PGPhu88Kawunag8TytbxXCtExKlZEDDsPXFYRGOtVzXQrW3EqWGCWZ9saMzYzgDtTASORTlY4A3ELntQgBo2U4I5rpvhn4cg8V+ONH0O6nkhivZykjRrllUKWJH5VjWV6+n/ALyzkKTsSudo4X1z1B/KtPwv4nvtC8Xad4hCreXNpMLgrKT8+ODuI9qAPRPjf8JbLwTpFnq2kT3S2rym2kgv8CVn6h0x1XHFeL16/wDGzUNf/sjRLTxVbaZKbuP7fpk9vKzyWtq5P7gnA3DPdtx968hFJC16hirlvDdACSJHjBOBIoPp7VY0u6vtP3tarsD4yzqDxk+tbEes6peviS9WErypEeB9K6qVKDWrd/Rfm2ZylK+iVv68jKtNE1HUrm2hhjeSe4cRoHPUn1J6V7HoHww0nwfF/aHjrXbCGeNd7afG26ZfQgjrXP3t2lrq3neAp9R1BJLOO3vjfqo/eE5k29gnAHHIribqe7tr9lnnWdyuPLhcyEe2496c+SHvxT+Y43Z6Br/jOLULsW2k3qaZp5Qr5scO3zEzxuGD/nHrXn3ie90x5QNMNxNMwzPcXK4Yt7DtWjd69NFp7W1tFa25mBSRCmXGMcsx9fUegrlvMiVgXzLuGSAcY/Gs6s29xxVjuvht5Z8H/EIujP8A8SpPmHUHzkxx/npXnZOa9D+HDhvC3xEMQZQdIXAB5A86PI+led15uHa9tVS7r/0lG8vhiA4oFHalzxXWZgODyM1NbH99GTtVNwyaiA5yCOvfnFWIG+cEFMhwcY4P/wBb2/SmBUooopAFSRRSTPtiRnbBOFGTgdajra8K66/h3U/t0NvHNOqkRlz9wnv+WamTaTcVdgZtvZ3NwMwQSyDIGVQkZJwOfrxTmsLtZmhNrOJVYoy7DkH0rttL8cWmk6bc2Npa3Lwi28iANJgOd7PmTHYFzwOTgcipLL4hiK0Zpbd2vZJonmbOQ+0YLdsHtj8zWDq1bu0PxFqcVBpOoXE9vDBaTSS3CGSJFXJdRnJH/fJ/KmwaXfT20txFaTNDEGMjheF243Z+m5c/WuztfiAljPctDYtOH1A3KPK+1kixhVXA+U4z0OOajh8exw393crpYkFzGxeOSb5fPfJlkIAwdxOMY6Ko7Ue0ra+5+IanHTafdwTxwy20qyyqrIhU5YN0I9c1JaaTf3csMdvaTO8yu8YC43hAS2PXGDn6V2Fv47t478XxsZFmYxQvCrAoII+VCEjKtvCnjsMd6sS/EC0n1cXNxZzG2sXkk0+CNgpLOCHMh7buCdo6j8aPaVtuQTbWxw9xpd9BapczWkyW7qrLJt+Ug9Oatx+GdYkvxZLp8xujB9pCY6x7d278v8K6C68eC5tNOt5NPCxwB/tCrL8k5P3Ttxxip9f8dWt/f7ba1nWy3wfM7jfhHLuQo4BY7eh42n14FUrXS5e49TiZNOvY41kktJ1QyeUGMZAL/wB3PrV+fwzrEC5lsZB/ozXfbIiBwzfgeo7V12rfEO21XT7u2uLGZEef7TCFmztZfuBvbLMSR6AVC3xG877OlzpUUkK27W8xL/NIHK72yBkEgMP+BUnUr6Wh+Ik31MbUYZ/E11pkWj+HotPaG0itmEAYC4cKSJXLcbnH4cVmRaRqMroBZXJyzKMocZXqPwrrH+IW3w3e6ZBaYLpHBbFjny40GA7EHl8KoHbgmpdJ+JP2X7Es1l8kV2JpdrFi6lcPjJHJP4Cj2le11D8Roq2sPiq1EkP2FbqNIDPtuYFcbFAJA9SARkD0qPSpLkacl3H/AGrbpcyGNYrCLbDI2fuqfWr+nfEqW2aJI7Tyoo5bmcMJCzhnLMmM4AIJUZOeB07UkXj3T7K71F9L06aC3neAQwlxtiVB8zYz98nJ/GsXSnK94L79/wCt/wAPM6IYytF7ml4YtbzUNXlgudOuFsFJQvfIHeNwhYKX6gnt6V7X4Qs9R0ton0u6ntI3/wCXaTEhDZ5APUA8kD0Irw64+I7z6jBdWUV0s0tzLcXIZhtfKbFUDPOFAPXgkjoa9F0PXLXUrhbmS+1I3O0subRSi/KMfNE5BPyZ4OR+NbUPb072grW2vZ39f+D/AJCnWq1mnJt/j+B79pHi61ucpJc+S4JDGcEDI4xk+9S6hcXE4Vob5QJPmiKXACsO+B/j6V51o8puLKJlngvJJXMuI5VL72IPRyPQdQDUflrbQzR2+lzPGERZvOlxK+GZi8eGC7j8vGegHPOTqvbJ6QT07/8ABXn17GF77mp4q0VdVBN5omkXG0gCW5uoQyMO3ynJJr588ZeFHtbmeSKwNnBCUa4NpKs8ah22jyxnsRgjsSK9T1TWLGHVXdtF1gQTTB5JnWElWC8hWD4PPPOa5XWNV0uNpvPu7uKzuQV+xSWXmsnfIZXwTnnp6cVc3iktYL+mtte1+33BotjK+HVvB4M8V2WuHTPE8xgS4S6ZrFcRpsHKr/s9T2xiuin8eXGvT6JqF5D4o0lLeV/Lh0iGNbeVWUoszA/xOXCkHjBNcRrfjy3axW2t7i+muFZZJbj7IYAwznaqmQ4ypxk5zjpzVHUPiNHE4S20oQwJFJF5LSkkq33cnGQBkHbjnsRWE/rO7Sv8ideh6Lf/ABCNlcavqOlaFqW+20xtObU5LaJJWuPNZ13xj5digEZ6/pWB4e8VeLryHUYvGOm3euaBr0ccE6WrKr2+0fKY1HCnGODXN6V8QdOtNNgS4F158XlLJHHYqA+1Arkyebnc3zZYqeDjFUNI8fpa3Uks1koeTUHvJDuAZw3RcgYXHqByPTrRbEJPRX9V+g730IPH39veOPF2qavFoc9vEqmOO2RSwgjgCxlR/u4GQOmT2rnF8Ka08txFHYyPJbxxyyKpBKpIMq30NdifiDb29/bXGnCaGONJfNtnVWSWRyTvJGCACQcYP3AO+aq2vxLuLcTSzadaXOoSRmM3OPLG3OVBUDkLnA56ADOKfNW7LyG7mDL4I16O4it/sYaeVWdY0dScAZx9SBkCmW/g7WJ7Ga4W2IZACsLHEkgxlio77RjP1ro4fildLqYuptMt5UWJEERcjawBy4OM/Nnn2AGap2/xFvkuLS4ubO1nntYbiNCRgbpTyxHQgDgD9ajmxG1l/X9WC77GZeeCtZt9WjsEgEsksBuYmU4WRAMkjPcdMetWdI8K65HqMTtaQlLbUIrV/tBDRCQ4YBx3Qhfxq/L8SLif+zTcabbSy2ckbeczNvdVOSmewY4yMdqsj4h6rqxuraDSYZZLhhJGsQdjHIoARwAedvJHuc0+bEtpKKDXqd/8bLy98Y+H9HV9K03RzpcLBYVyzyuMAxxt/cA5AryxfA+tTStAbW1h2xxSvI8oCqsmdrA+nHNdz4b8JeNr6LTbjxLem00W2nExa+YEAkdWGQzccc11V9d+CtKjltb3xANcuLiIRm0sYsQYwV2ls5UbTj1/rp7PEwtGy+fqv0JTPHL3wRqdtau/ly3Escvk7YCGG7IHH+zk4zVq1+H2v3SK9utlInmMpuPPGEIHQ+nP6iu+1b4heG7JxJbNOskeTDaWy7kVedqF2APAIGcZ4Oa4AfECa18kWEEYgRXBjfJLljks/YnGQMVdX6xbTlXp8xRuLpvgnW723tZ0lt9kqB1jaYptBY5z9MZPtSw+BdUvvtA+1WVveQ3H2Z4S20MQuQwboc9qo2vjeY6813qdmlzpkoWObT4pWhQwgj92rDJXIABI5I471Uj8Yahaams+nN5VpFIZLe1lPmLGMYXJ43FR0J9Kzn7ez5Wv6/ryLRbHgPWZLyW1R7RpEt/PO2cYYA4K/wC8DgY9xSHwBq5RvJa2llRyrxLINyrkAP8A7pzx9Kz9N8W6rp0FxHbypunMrPIy5fMgwxB7Hv8AWpl8aassLxq0I3WsNpuCfMI4jlefUnqe9Tav0sGp2Hg/Sj4fvPEvh/UpA02q2a2EM9t86pKSJBuH93CHPpXMz/D7WoZ7WF/s3m3CyvtEoyojkCNn8wR6g1XvPHOt3V/a3hmiintvM8toogv3xhs+vHHPSqx8Wau2nGze4Dr5qTLKy5kQoAAFPYcAkdzyazp0a0G56Xla/ra3+RTbaSNa7+HmpWUkKXVzaI0t0lsMPuAD/dkP+zniph8NtVFsjXFxbQ3Ek720cDNkvIoYgA9MHa2D7Vlt431ttWuNRaeM3M0YjOYwUUA5GFPGc85qKbxdrc0HlvdMALs3m8KNyylSuQewwTwPU1aWIsrtCNxvh3d2EEd3q11HHYCJ3nkg+doSDhQR6E4wenWtq9+Fz2Vnc3Cal50ifZ2hRI/mYuQGUj8cj6VxGpeLdb1BDDc3rrDsSIxKoCkIcjI7881Lp3izX7WWaSLVZwZmId3+bnGAcnpjt6Y4FChXa1khNdTo/wDhWth/0OOlf9+norznc39+itOSf8/4IOV9xlFFFbDCiiigAope1JQAUUUUAFFFFABWxYeIb6x8OapocBh+w6k8TzholL5jbK7W6jn061j0UAFLSUUATWsP2idY/Miiz/FK2FFdDFqL6AY4Gj0PVIRnI8oSZ+rYBrmKX8qznTVTSWxrTqunrHRnu37PfjG0/wCFnxLeaRo9lb3du8ZuFhKi32ozZXsNzAA59cDrVnRNZ1S5aa9XSltdMnmkneOGyV1iYsTtUk7ivt9BVz9mvU9L0rwD4tutVu4LBFvrKM3csCS+WJGK9G7Z6nsOe1Ufix4ym8M/EvVrWLSraysiyywxKqTLMCv+sO1sKH4bA5GecdKqhyU5qKbVuw6tWc03PW/f9DvtNvtGuW26R4s06zvJOsF7YbPmxzzjj6ZrRvr7xnGYILS98K3krNsXyZJdwO3I6tgLxyemcV5jo/xWs5LuFhFo8LBQWM1uQu70Oev+ea6vSvjRDdmQXOl6BLbQttcx3Vvbk9c7UlxuHTpkc98V01Zp6p3f9djGKt0MST4ieI55W+2WelNExMZkhQvsXoVXjgH1qjr/AInOm2d3LoEslleiNcx2+oIcE8qShQH/AIDW34q+LdrfW2NJ+0aepba6sbWSKUj0KNkf5PFeX69reoaqsy30NrcZHDx7CR7Bicnr71isRGHuyb/r1en3Hf8AVHiI+0gvuu/yjb8TmNU1LWfENw1xqjzXkmzaHYE7QOcDGP8AIrKvLe1WJTb3RllPWPySuPbOauXcE0NuBBbzxnGSyzmTA9ML+X4VjOCG+b73fPWs6dRzTZz16KotR6/13SEZSuNwIyM80gxSsSxJYkn1JptWjBjl+meK1fD0ujQzudftLy5hIGwW0wjIPfOQayccUVM486cRxdnc0tdfTZtQL6JbXNtZlARHcSB2B78gDioLK0W5uVie6ggXODJITge9VKKcEoJJdAbu7mva6dayzIjapBGoDF2dTtBHYf3s+tdRpWpa1pCF9Eu/sNrEyGW7jgEewtgBjn5iPQjrxXAqSvIOO1T3d5c3jh7u4lmcKEBdiflAwB9BitOYmx1+r+KSw23V3Jql2CweVjmNgfQHjGfauZl1i7YnyWWBD/DEoUVnUlEpuQJWFJz1opKKgYUUUUAFLRSUAFFFLQAlKOtJTlGfT8TQAuMgmpYnK4DfUcf5/wAiogOme/TmpIjg5LDpkEEcfnQBH5belFN/KilqOx//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown is the apical four chamber view with color flow Doppler during diastole. There is physiolgic flow (tagged red) into the left ventricle (LV) that extends from the right superior pulmonary veins (RSPV) to the apex of the LV. This color signal is used to position a pulsed wave Doppler sample volume so that quantitatable signals of flow can be obtained from the pulmonary veins and from the mitral leaflet tips.",
"    <div class=\"footnotes\">",
"     RA: right atrium; RV: right ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apical four chamber view with color flow Doppler during systole",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 294px; height: 229px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The apical four chamber view with color flow Doppler was obtained from a normal subject during systole. The systolic flow signal is shown in blue, ie, flow is moving away from the transducer. This signal is used to position a pulsed wave Doppler sample volume in the left ventricular outflow tract (LVOT) so that flow characteristics can be quantitated.",
"    <div class=\"footnotes\">",
"     LV: left ventricle.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42693=[""].join("\n");
var outline_f41_44_42693=null;
var title_f41_44_42694="Sedation-free gastrointestinal endoscopy";
var content_f41_44_42694=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sedation-free gastrointestinal endoscopy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42694/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42694/contributors\">",
"     Jonathan Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42694/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42694/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42694/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42694/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/44/42694/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of gastrointestinal endoscopy has greatly expanded the diagnostic and therapeutic capabilities of gastroenterologists. Adequate patient tolerance is essential for successful completion of a safe examination and compliance with subsequent follow-up. As a result, endoscopists have developed skills in administering a variety of sedative and analgesic agents to facilitate procedures and enhance patient comfort.",
"   </p>",
"   <p>",
"    Most of the attention has been placed on selecting the optimal regimen for producing procedural sedation and monitoring patients adequately during the procedures. More recently, there has been some attempt to determine which patients and which procedures require deeper sedation to achieve optimal conditions. Finally, there has been an effort to make some of the diagnostic procedures more tolerable to avoid the cost and risk of procedural sedation altogether.",
"   </p>",
"   <p>",
"    This topic review will focus on sedation-free endoscopy. Standard methods of procedural sedation and their complications, recommendations for procedural sedation, and the management of patients who are difficult to sedate are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24936?source=see_link\">",
"     \"Overview of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28310?source=see_link\">",
"     \"Complications of procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43049?source=see_link\">",
"     \"Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unsedated endoscopy may be advantageous for several reasons. First, it significantly decreases the risk of hypoxemia and respiratory depression. Second, it reduces the procedure and recovery room time, and the associated costs. Third, it allows patients to leave the endoscopy unit after the procedure without delay and return to work if they so choose, which may produce economic benefit by reducing the indirect costs of endoscopy. Furthermore, a number of studies have demonstrated satisfactory outcomes when focusing on parameters such as successful completion of examinations, patient satisfaction with their comfort level, and their willingness to undergo future examinations without sedation (see below). As a result, in many countries, upper endoscopy, and to a lesser extent, colonoscopy, are commonly performed without routine procedural sedation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. By contrast, sedation-free endoscopy is not widely accepted in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of procedural sedation varies considerably among different countries, reflecting different practice standards and social customs. As an example, in a survey of International Editors for the journal Gastrointestinal Endoscopy, sedation was always or usually administered in 44 percent of procedures in Asia, 56 percent in Europe, and 72 percent in the Americas (Canada, Central and South America) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/5\">",
"     5",
"    </a>",
"    ]. In the United States, only flexible sigmoidoscopy is typically performed without sedation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H254644790\">",
"    <span class=\"h1\">",
"     PATIENT MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is our practice to place an intravenous line for patients undergoing sedation-free endoscopy (with the exception of flexible sigmoidoscopy) in case of vagally mediated syncope. We also typically monitor such patients with oximetry, blood pressure, and telemetry monitoring, irrespective of the lack of data supporting this practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     UPPER ENDOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of reports have demonstrated good patient tolerance with unsedated upper endoscopy using standard (&gt;7 mm diameter) instruments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/6-12\">",
"     6-12",
"    </a>",
"    ]. However, other studies have suggested that while patients may tolerate unsedated procedures and be willing to repeat them without sedation, there is still a significant improvement in patient tolerance when they receive some sedation. As an example, in a randomized, placebo-controlled comparison of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    spray, midazolam plus placebo spray, placebo plus lidocaine spray, and two placebos, tolerance was improved by both midazolam and lidocaine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/6\">",
"     6",
"    </a>",
"    ]. Willingness to repeat the procedure was significantly higher in the two midazolam groups (96 versus 75 and 94 versus 74 percent, respectively). Since there were no adverse consequences in the low-dose midazolam groups, the authors concluded that low dose sedation was preferable.",
"   </p>",
"   <p>",
"    Similar results were observed in another randomized trial comparing upper endoscopy with (1) an 8.5 mm endoscope with no sedation, (2) an 8.5 mm instrument with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    , and (3) an 11.5 mm endoscope and diazepam [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/13\">",
"     13",
"    </a>",
"    ]. Patient tolerance was highest in the smaller instrument with diazepam group. However, this group had more episodes of desaturation than in the unsedated group.",
"   </p>",
"   <p>",
"    The above studies illustrate the difficulty in quantifying the clinical significance in improved procedure tolerance and determining whether marginal differences in patient satisfaction outweigh the cost and safety benefits of avoiding sedation in low-risk individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Ultrathin endoscopes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrathin endoscopes can improve the tolerability of unsedated upper endoscopy. These instruments range in diameter from 3.1 to 6 mm, permitting passage via a transnasal or peroral route and have been used by both gastroenterologists and otolaryngologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. They permit diagnostic evaluation of the same regions of the upper digestive tract that are accessible by standard peroral endoscopes and permit the passage of pediatric biopsy forceps to obtain tissue samples. The small caliber of the scopes has advantages in specialized circumstances, such as in patients with tight esophageal strictures.",
"   </p>",
"   <p>",
"    An increasing number of studies have compared ultrathin upper endoscopy to unsedated or sedated peroral upper endoscopy using standard diameter endoscopes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/16-28\">",
"     16-28",
"    </a>",
"    ]. Most of these studies have demonstrated that the ultrathin scopes were associated with comparable or improved comfort and willingness to have the examination performed again in the same manner. The peroral route may be easier to perform and slightly better tolerated than the transnasal approach, according to the few published comparisons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/16,19\">",
"     16,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, because of their small caliber, the ultrathin endoscopes are somewhat less sensitive than standard endoscopes for detecting lesions (but are equally specific) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/17\">",
"     17",
"    </a>",
"    ]. Other limitations include difficulty estimating the diameter of a luminal stricture and the possibility of missing a stricture because the lumen is so much larger than the endoscope. In addition, there is often difficulty in maneuvering the endoscope due to its lack of rigidity and limited tip control (it can be deflected up and down, but not left or right). Finally, accessories that can be used with the ultrathin endoscope are limited to pediatric biopsy forceps, which provide smaller tissue samples than those obtained with standard or jumbo biopsy forceps.",
"   </p>",
"   <p>",
"    Improvement in the equipment and increased experience with this approach may help to establish its role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234711918\">",
"    <span class=\"h2\">",
"     Recommendation",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is our practice to offer unsedated endoscopy to patients scheduled for elective diagnostic upper endoscopy who are not particularly anxious about the procedure. Our experience is similar to others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/16\">",
"     16",
"    </a>",
"    ] in that we find that acceptance of sedation-free procedures is low and limited to individuals who strongly desire to quickly return to work and those who are fearful of being sedated. We also perform unsedated endoscopy in individuals at high risk for cardiopulmonary complications of sedation. In our experience, both groups tolerate the procedure well.",
"   </p>",
"   <p>",
"    The largest barrier to more widespread use of unsedated procedures in the United States is low patient acceptance. The main reason for this is preprocedure expectations and fears of discomfort and gagging. Until this preconception is altered or until unsedated endoscopy becomes the standard method, there is no other incentive for patients to forego sedation except for increased safety and convenience. At present, there is no financial disincentive for patients to elect the costlier and possibly more pleasant option of sedated procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     COLONOSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A growing body of literature has demonstrated good patient tolerance of colonoscopy either without sedation or with sedation only if needed during the procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/2,29-35\">",
"     2,29-35",
"    </a>",
"    ]. As an example, a German report involving 2500 consecutive patients who received analgesia only if needed found that 95 percent required no sedation to complete the colonoscopy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/33\">",
"     33",
"    </a>",
"    ]. A second series found that 61 percent of 258 individuals having colonoscopy without sedation reported no pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although patient reports on questionnaires of willingness to have repeat procedures without sedation imply adequate levels of comfort, these data do not preclude the possibility that sedation could improve comfort and result in higher compliance with scheduled follow-up examinations. However, a number of observations suggest that pain would not preclude willingness to undergo a follow-up examination in the majority of patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized trial comparing sedation on demand versus routine sedation in 70 patients, pain scores were higher among unsedated patients than among the group receiving routine sedation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/2\">",
"       2",
"      </a>",
"      ]. However, both groups were equally willing to undergo a repeat examination in the same manner.",
"     </li>",
"     <li>",
"      A controlled trial involving 180 patients found no difference in patient procedure ratings between patients receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/60/4042?source=see_link\">",
"       midazolam",
"      </a>",
"      and those receiving no intravenous catheter or medication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The similar findings from studies within and outside of the United States suggest that patient acceptance of sedation upon demand for colonoscopy is not adequately explained by cultural bias. However, the data may be influenced by bias related to the characteristics of patients who agree to participate in such studies, the expertise of the endoscopists, and the relationship of the endoscopist to the patient. It is notable that in one of the reports discussed above [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/2\">",
"     2",
"    </a>",
"    ], only 70 of 250 eligible patients (28 percent) agreed to participate in the study. Men, older patients, and those without pain as a presenting symptom were more willing to be included. It is likely that individuals who are anxious about procedure-related pain may also be particularly unwilling to be enrolled in a trial in which they might not receive sedation.",
"   </p>",
"   <p>",
"    Furthermore, not all studies have found favorable results with a sedation on-demand approach. In a controlled trial involving 259 outpatients, for example, moderate to severe pain was observed significantly more often in the on-demand group (34 versus 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/36\">",
"     36",
"    </a>",
"    ]. Such patients were also more likely to be unwilling to undergo another colonoscopy (22 versus 10 percent).",
"   </p>",
"   <p>",
"    Thus, more work is needed to identify which patients are best suited to tolerate endoscopy without sedation or sedation upon demand. The available data suggest that favorable patient characteristics may include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/2,37,38\">",
"     2,37,38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Older patients",
"     </li>",
"     <li>",
"      Patients who are not anxious",
"     </li>",
"     <li>",
"      Men",
"     </li>",
"     <li>",
"      Absence of abdominal pain history",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data support the possibility that pre-procedure assessment of patient anxiety level and demographics may help endoscopists select individuals for sedation-free procedures. In addition, the relationship between patient anxiety and the amount of discomfort experienced suggests that patient education may improve comfort during procedures and potentially influence the ability to perform procedures without medications. In support of this hypothesis is the observation that pre-procedure preparation with materials such as a videotape may be of some benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/39-41\">",
"     39-41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strategies to reduce anxiety need not be limited to preexamination education and reassurance. The extent to which measures to reduce anxiety during the procedure (music, video headsets, reassurance, etc) could influence procedure tolerance and sedation requirements has not been explored fully.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234711559\">",
"    <span class=\"h2\">",
"     Water immersion",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is increasing interest in using large volume water immersion as an alternative to sedation for colonoscopy. Many, but not all, studies have shown good patient acceptance and higher cecal intubation rates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/42-46\">",
"     42-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial included 125 patients who were assigned to undergo unsedated colonoscopy with either water immersion (63 patients) or standard air insufflation (62 patients) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/42\">",
"       42",
"      </a>",
"      ]. All of the patients were male. Cecal intubation rates were higher in the water immersion group compared with the air insufflation group (97 versus 76 percent). In addition, patients in the water immersion group were more likely to report willingness to repeat the unsedated colonoscopy (90 versus 69 percent).",
"     </li>",
"     <li>",
"      A second trial with 100 patients (99 percent male) also found increased willingness to repeat an unsedated procedure in the water immersion group compared with the air insufflation group (78 versus 54 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/43\">",
"       43",
"      </a>",
"      ]. Cecal intubation rates were 100 percent in both groups.",
"     </li>",
"     <li>",
"      A trial with 230 patients (42 percent male) found that patients who underwent colonoscopy with warm water immersion were just as likely to request sedation during the procedure as patients examined with air insufflation (13 versus 22 percent, p = 0.07) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/44\">",
"       44",
"      </a>",
"      ]. In addition, there was no difference in cecal intubation rates (94 and 96 percent, respectively). However, median pain scores were lower for the water immersion group (28 versus 39 on a 100-point scale). Adenoma detection rates were lower for the water immersion group (25 versus 40 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107424045\">",
"    <span class=\"h2\">",
"     Carbon dioxide insufflation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbon dioxide insufflation, rather than air insufflation, has also been studied as a method to improve patient tolerance of unsedated colonoscopy. Since carbon dioxide is readily absorbed through the intestinal mucosa, excessive colonic distension is avoided. The absorbed carbon dioxide is subsequently eliminated through respiration. In a randomized trial that in part compared carbon dioxide insufflation with air insufflation, patients who underwent the procedure with carbon dioxide insufflation were less likely than those who had air insufflation to request sedation during the procedure (16 versus 26 percent) and reported lower median pain scores (30 versus 50 on a 100 point scale, with higher numbers corresponding to more pain) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     COST IMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased adoption of sedation-free endoscopy could have substantial impact on the cost and efficiency of busy endoscopy units. The cost of the drugs themselves is just a small fraction of the costs associated with using sedation (which include labor and overhead costs for recovery, intravenous fluid, missed work for patients, and the cost of any sedation-associated complications). Large reductions in the overall cost of endoscopy resulting from unsedated procedures could alter the assumptions that form the basis for practice guidelines. As an example, current recommendations for the optimal timing of upper endoscopy in the management of dyspepsia depend upon assumptions made about the cost of upper endoscopy. The American Gastroenterological Association (AGA) guideline for the evaluation of dyspepsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42694/abstract/47\">",
"     47",
"    </a>",
"    ], as well as other AGA guidelines, can be accessed through the AGA web site at",
"    <a class=\"external\" href=\"file://www.gastro.org/practice/medical-position-statements\">",
"     file://www.gastro.org/practice/medical-position-statements",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The future cost effectiveness of colonoscopy screening for colorectal cancer, in particular as it compares to other offered diagnostic strategies, would certainly be favorably affected by a decrease in procedure cost accompanied by the practice of sedation upon demand. However, while sedation-free endoscopy may improve efficiency and make endoscopic screening more feasible, the effects on patient compliance with screening and follow-up procedures are unknown. In addition, while sedation-free endoscopy may improve efficiency with regard to time spent administering sedation and patient recovery time, it is not guaranteed that it will improve efficiency overall. Performing a colonoscopy on an unsedated patient in theory could increase the procedure time since additional maneuvers may be required to prevent discomfort that may not bother a sedated patient and to give patients \"breaks\" during the procedure if it happens to be particularly uncomfortable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H234711680\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unsedated endoscopy may be advantageous for several reasons (see",
"      <a class=\"local\" href=\"#H2\">",
"       'Rationale'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It significantly decreases the risk of hypoxemia and respiratory depression.",
"     </li>",
"     <li>",
"      It reduces the procedure and recovery room time and the associated costs.",
"     </li>",
"     <li>",
"      It allows patients to leave the endoscopy unit after the procedure without delay and return to work if they so choose, which may produce economic benefit by reducing the indirect costs of endoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of reports have demonstrated good patient tolerance with unsedated upper endoscopy using standard (&gt;7 mm diameter) instruments. However, other studies have suggested that while patients may tolerate unsedated procedures and be willing to repeat them without sedation, there is still a significant improvement in patient tolerance when they receive some sedation. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Upper endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is our practice to offer unsedated endoscopy to patients scheduled for elective diagnostic upper endoscopy who are not particularly anxious about the procedure, though we find that acceptance of sedation-free procedures is low and limited to individuals who strongly desire to quickly return to work and those who are fearful of being sedated. (See",
"      <a class=\"local\" href=\"#H234711918\">",
"       'Recommendation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A growing body of literature has demonstrated good patient tolerance of colonoscopy either without sedation or with sedation only if needed during the procedure. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Colonoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is increasing interest in using large volume water immersion as an alternative to sedation for colonoscopy. Many, but not all studies have shown good patient acceptance and higher cecal intubation rates. (See",
"      <a class=\"local\" href=\"#H234711559\">",
"       'Water immersion'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/1\">",
"      Ristikankare MK, Julkunen RJ. Premedication for gastrointestinal endoscopy is a rare practice in Finland: a nationwide survey. Gastrointest Endosc 1998; 47:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/2\">",
"      Rex DK, Imperiale TF, Portish V. Patients willing to try colonoscopy without sedation: associated clinical factors and results of a randomized controlled trial. Gastrointest Endosc 1999; 49:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/3\">",
"      Mulcahy HE, Connor P. Declining use of sedation for routine diagnostic upper GI endoscopy. Gastrointest Endosc 1999; 49:B199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/4\">",
"      Faulx AL, Vela S, Das A, et al. The changing landscape of practice patterns regarding unsedated endoscopy and propofol use: a national Web survey. Gastrointest Endosc 2005; 62:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/5\">",
"      Wang TH, Lin JT. Worldwide use of sedation and analgesia for upper intestinal endoscopy. Sedation for upper GI endoscopy in Taiwan. Gastrointest Endosc 1999; 50:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/6\">",
"      Froehlich F, Schwizer W, Thorens J, et al. Conscious sedation for gastroscopy: patient tolerance and cardiorespiratory parameters. Gastroenterology 1995; 108:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/7\">",
"      al-Atrakchi HA. Upper gastrointestinal endoscopy without sedation: a prospective study of 2000 examinations. Gastrointest Endosc 1989; 35:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/8\">",
"      De Gregorio BT, Poorman JC, Katon RM. Peroral ultrathin endoscopy in adult patients. Gastrointest Endosc 1997; 45:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/9\">",
"      Tan CC, Freeman JG. Throat spray for upper gastrointestinal endoscopy is quite acceptable to patients. Endoscopy 1996; 28:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/10\">",
"      Solomon SA, Kajla VK, Banerjee AK. Can the elderly tolerate endoscopy without sedation? J R Coll Physicians Lond 1994; 28:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/11\">",
"      Dhir V, Swaroop VS, Vazifdar KF, Wagle SD. Topical pharyngeal anesthesia without intravenous sedation during upper gastrointestinal endoscopy. Indian J Gastroenterol 1997; 16:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/12\">",
"      Schutz SM, Lee JG, Schmitt CM, Baillie J. Patient satisfaction with conscious sedation for endoscopy. Gastrointest Endosc 1994; 40:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/13\">",
"      Lieberman DA, Wuerker CK, Katon RM. Cardiopulmonary risk of esophagogastroduodenoscopy. Role of endoscope diameter and systemic sedation. Gastroenterology 1985; 88:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/14\">",
"      Andrus JG, Dolan RW, Anderson TD. Transnasal esophagoscopy: a high-yield diagnostic tool. Laryngoscope 2005; 115:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/15\">",
"      Postma GN, Cohen JT, Belafsky PC, et al. Transnasal esophagoscopy: revisited (over 700 consecutive cases). Laryngoscope 2005; 115:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/16\">",
"      Zaman A, Hahn M, Hapke R, et al. A randomized trial of peroral versus transnasal unsedated endoscopy using an ultrathin videoendoscope. Gastrointest Endosc 1999; 49:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/17\">",
"      Dean R, Dua K, Massey B, et al. A comparative study of unsedated transnasal esophagogastroduodenoscopy and conventional EGD. Gastrointest Endosc 1996; 44:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/18\">",
"      Dumortier J, Napoleon B, Hedelius F, et al. Unsedated transnasal EGD in daily practice: results with 1100 consecutive patients. Gastrointest Endosc 2003; 57:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/19\">",
"      Craig A, Hanlon J, Dent J, Schoeman M. A comparison of transnasal and transoral endoscopy with small-diameter endoscopes in unsedated patients. Gastrointest Endosc 1999; 49:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/20\">",
"      Dumortier J, Ponchon T, Scoazec JY, et al. Prospective evaluation of transnasal esophagogastroduodenoscopy: feasibility and study on performance and tolerance. Gastrointest Endosc 1999; 49:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/21\">",
"      Campo R, Montserrat A, Brullet E. Transnasal gastroscopy compared to conventional gastroscopy: a randomized study of feasibility, safety, and tolerance. Endoscopy 1998; 30:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/22\">",
"      Madhotra R, Mokhashi M, Willner I, et al. Prospective evaluation of a 3.1-mm battery-powered esophagoscope in screening for esophageal varices in cirrhotic patients. Am J Gastroenterol 2003; 98:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/23\">",
"      Birkner B, Fritz N, Schatke W, Hasford J. A prospective randomized comparison of unsedated ultrathin versus standard esophagogastroduodenoscopy in routine outpatient gastroenterology practice: does it work better through the nose? Endoscopy 2003; 35:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/24\">",
"      Preiss C, Charton JP, Schumacher B, Neuhaus H. A randomized trial of unsedated transnasal small-caliber esophagogastroduodenoscopy (EGD) versus peroral small-caliber EGD versus conventional EGD. Endoscopy 2003; 35:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/25\">",
"      Mokhashi MS, Wildi SM, Glenn TF, et al. A prospective, blinded study of diagnostic esophagoscopy with a superthin, stand-alone, battery-powered esophagoscope. Am J Gastroenterol 2003; 98:2383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/26\">",
"      Garcia RT, Cello JP, Nguyen MH, et al. Unsedated ultrathin EGD is well accepted when compared with conventional sedated EGD: a multicenter randomized trial. Gastroenterology 2003; 125:1606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/27\">",
"      Horiuchi A, Nakayama Y. Unsedated ultrathin EGD by using a 5.2-mm-diameter videoscope: evaluation of acceptability and diagnostic accuracy. Gastrointest Endosc 2006; 64:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/28\">",
"      Jobe BA, Hunter JG, Chang EY, et al. Office-based unsedated small-caliber endoscopy is equivalent to conventional sedated endoscopy in screening and surveillance for Barrett's esophagus: a randomized and blinded comparison. Am J Gastroenterol 2006; 101:2693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/29\">",
"      Seow-Choen F, Leong AF, Tsang C. Selective sedation for colonoscopy. Gastrointest Endosc 1994; 40:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/30\">",
"      Herman FN. Avoidance of sedation during total colonoscopy. Dis Colon Rectum 1990; 33:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/31\">",
"      Cataldo PA. Colonoscopy without sedation. Dis Colon Rectum 1996; 39:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/32\">",
"      Ristikankare M, Hartikainen J, Heikkinen M, et al. Is routinely given conscious sedation of benefit during colonoscopy? Gastrointest Endosc 1999; 49:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/33\">",
"      Eckardt VF, Kanzler G, Schmitt T, et al. Complications and adverse effects of colonoscopy with selective sedation. Gastrointest Endosc 1999; 49:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/34\">",
"      Ristikankare M, Julkunen R, Mattila M, et al. Conscious sedation and cardiorespiratory safety during colonoscopy. Gastrointest Endosc 2000; 52:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/35\">",
"      Takahashi Y, Tanaka H, Kinjo M, Sakumoto K. Prospective evaluation of factors predicting difficulty and pain during sedation-free colonoscopy. Dis Colon Rectum 2005; 48:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/36\">",
"      Terruzzi V, Meucci G, Radaelli F, et al. Routine versus \"on demand\" sedation and analgesia for colonoscopy: a prospective randomized controlled trial. Gastrointest Endosc 2001; 54:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/37\">",
"      Mahajan RJ, Johnson JC, Marshall JB. Predictors of patient cooperation during gastrointestinal endoscopy. J Clin Gastroenterol 1997; 24:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/38\">",
"      Cohen J, Haber GB, Lavell L, et al. Predictors of patient satisfaction after colonoscopy: A prospective study of 601 patients (abstract). Gastrointest Endosc 1996; 43:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/39\">",
"      Johnson JE, Morrissey JF, Leventhal H. Psychological preparation for an endoscopic examination. Gastrointest Endosc 1973; 19:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/40\">",
"      Wilson JF, Moore RW, Randolph S, Hanson BJ. Behavioral preparation of patients for gastrointestinal endoscopy: information, relaxation, and coping style. J Human Stress 1982; 8:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/41\">",
"      Levy N, Landmann L, Stermer E, et al. Does a detailed explanation prior to gastroscopy reduce the patient's anxiety? Endoscopy 1989; 21:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/42\">",
"      Leung FW, Aharonian HS, Leung JW, et al. Impact of a novel water method on scheduled unsedated colonoscopy in U.S. veterans. Gastrointest Endosc 2009; 69:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/43\">",
"      Leung J, Mann S, Siao-Salera R, et al. A randomized, controlled trial to confirm the beneficial effects of the water method on U.S. veterans undergoing colonoscopy with the option of on-demand sedation. Gastrointest Endosc 2011; 73:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/44\">",
"      Radaelli F, Paggi S, Amato A, Terruzzi V. Warm water infusion versus air insufflation for unsedated colonoscopy: a randomized, controlled trial. Gastrointest Endosc 2010; 72:701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/45\">",
"      Leung FW, Harker JO, Jackson G, et al. A proof-of-principle, prospective, randomized, controlled trial demonstrating improved outcomes in scheduled unsedated colonoscopy by the water method. Gastrointest Endosc 2010; 72:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/46\">",
"      Amato A, Radaelli F, Paggi S, et al. Carbon dioxide insufflation or warm-water infusion versus standard air insufflation for unsedated colonoscopy: a randomized controlled trial. Dis Colon Rectum 2013; 56:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42694/abstract/47\">",
"      Talley NJ, American Gastroenterological Association. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129:1753.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2569 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42694=[""].join("\n");
var outline_f41_44_42694=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H234711680\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H254644790\">",
"      PATIENT MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      UPPER ENDOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Ultrathin endoscopes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234711918\">",
"      Recommendation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      COLONOSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H234711559\">",
"      Water immersion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H107424045\">",
"      Carbon dioxide insufflation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      COST IMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H234711680\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/2/43049?source=related_link\">",
"      Alternatives and adjuncts to moderate procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/41/28310?source=related_link\">",
"      Complications of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/22/24936?source=related_link\">",
"      Overview of procedural sedation for gastrointestinal endoscopy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_44_42695="Miscellaneous antinuclear antibodies";
var content_f41_44_42695=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Miscellaneous antinuclear antibodies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42695/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42695/contributors\">",
"     Morris Reichlin, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42695/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42695/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42695/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42695/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/44/42695/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 11, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most commercial and many hospital laboratories routinely assay sera for antibodies directed against DNA, histones, snRNP, Sm,",
"    <span class=\"nowrap\">",
"     Ro/SS-A,",
"    </span>",
"    <span class=\"nowrap\">",
"     La/SS-B,",
"    </span>",
"    topoisomerase 1 (Scl-70), and centromere. These antinuclear antibodies are serologic hallmarks of patients with systemic autoimmune disease (",
"    <a class=\"graphic graphic_table graphicRef58564 graphicRef71307 \" href=\"mobipreview.htm?38/63/39934\">",
"     table 1A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of additional autoantibodies also react with well characterized nuclear and perinuclear antigens. Testing for these antibodies is not routinely performed because of the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some do not provide additional clinical information beyond that available from present antibody panels",
"     </li>",
"     <li>",
"      The methodology to detect some of these antibodies has been difficult to adapt for routine testing",
"     </li>",
"     <li>",
"      Some autoantibodies have only recently been described; increased clinical experience may eventually result in greater availability",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These antinuclear antibodies are unlikely to account for many of the false positive antinuclear antibody (ANA) tests found in the normal population since they are rarely detected in healthy individuals. However, some may be specific for rare clinical syndromes. Thus, testing for these antibodies may have diagnostic significance in selected cases. In addition, improved understanding of these antibodies and their epitopes is likely to provide additional insight into the pathogenesis of the autoimmune syndromes.",
"   </p>",
"   <p>",
"    This topic will review the antinuclear antibodies not routinely assayed at present. Overviews of the clinical significance of the commonly assayed antinuclear antibodies and of antinuclear antibodies of investigational or historical interest associated with rheumatoid arthritis are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2234?source=see_link&amp;anchor=H5#H5\">",
"     \"Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis\", section on 'Autoantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NUCLEOSOME (CHROMATIN)-SPECIFIC AUTOANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first autoantibody described in systemic lupus erythematosus (SLE), the \"LE factor,\" was a nucleosome specific autoantibody. These antibodies are now termed nucleosome-restricted or anti-chromatin antibodies because they bind to the complex of DNA and histones, but not to the individual components.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Pathogenic role",
"    </span>",
"    &nbsp;&mdash;&nbsp;An original report suggested that nucleosomes might be critical antigens in the eventual generation of antinuclear antibodies in SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequent observations have provided some support for this hypothesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. As an example, one study involving a murine model of lupus documented the induction of true nucleosome-restricted antibodies early in disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/3\">",
"     3",
"    </a>",
"    ]. The appearance of these antibodies preceded the emergence of antibodies to DNA or histones.",
"   </p>",
"   <p>",
"    Among patients with SLE, the formation of anti-DNA and anti-histone antibodies resulting from an initial reaction against nucleosomes may occur via the following sequential steps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initially, abnormal apoptosis and phagocytosis results in altered nucleosomes and enhanced levels of circulating nucleosomes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      These nucleosome abnormalities facilitate the recognition of nucleosomes by T helper cells.",
"     </li>",
"     <li>",
"      Activated T cells subsequently stimulate production by B cells of nucleosome specific autoantibodies and, importantly, of anti-double stranded (ds) DNA and anti-histone antibodies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Methods of detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Detection of antinucleosome-specific antibodies remains problematic because the nucleosomal material used as substrate also binds anti-dsDNA and anti-histone antibodies. The traditional method of circumventing this problem, absorption techniques, is cumbersome and difficult to perform. An epitope recognized only by nucleosome specific antibodies has not yet been identified.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Incidence and accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the difficulties in detection, there is a paucity of data concerning the incidence and accuracy of antinucleosome-specific autoantibodies. A prevalence of 48 to over 80 percent has been noted in patients with SLE [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. They usually but not always are associated with anti-dsDNA and anti-histone antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/7\">",
"     7",
"    </a>",
"    ]. The specificity of these antibodies remains a source of controversy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Associated clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nucleosome-specific autoantibodies have been linked with lupus nephritis in murine models of SLE. In humans, however, the results are conflicting. Some series have found a weak but significant association with nephritis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] or other clinical manifestations of \"flares\" of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/11\">",
"     11",
"    </a>",
"    ], while others have not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/3,8\">",
"     3,8",
"    </a>",
"    ]. One study of a large cohort of patients with varied connective tissue disorders and control sera from those with hepatitis C virus infection found that IgG anti-nucleosomal antibodies were found exclusively in patients with SLE, systemic sclerosis and MCTD, with prevalences of 72, 46, and 45 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/9\">",
"     9",
"    </a>",
"    ]. In addition, anti-nucleosomal antibodies of the IgG3 subclass were observed only in patients with SLE, and correlated more closely with active disease and particularly with nephritis than did anti-DNA antibodies. In another study that included disease (rheumatoid arthritis) and normal controls, the sensitivity and specificity for SLE were 64 and 99 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical utility of antinucleosome-specific autoantibodies remains undefined since their sensitivity, specificity, and association with particular manifestations of SLE remain undefined. Nevertheless, these antibodies are a source of interest since they may have a role in the pathogenesis of autoantibody production in SLE.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANTI-hnRNP ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spliceosome refers to a complex of nuclear RNA binding proteins which processes pre-mRNA into spliced mature mRNA. Among the subunits of the spliceosome are a group of 30 structurally related proteins known as heterogeneous nuclear ribonuclear proteins, which are called hnRNP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Methods of detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibodies specific for the RNA binding regions of two of the hnRNP proteins, A2 (also called RA33) and A1, produce a finely speckled pattern of staining in the nucleoplasm on indirect immunofluorescence microscopy. Their presence must be confirmed by either immunoblotting or dot blot assays [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Incidence and accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-hnRNP antibodies against the A1 and A2 proteins have been reported with the following frequencies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rheumatoid arthritis &ndash; 50 percent for the A1 protein and 35 percent for the A2 protein",
"     </li>",
"     <li>",
"      SLE &ndash; 22 to 38 percent for A1 and 23 percent for A2",
"     </li>",
"     <li>",
"      Mixed connective tissue disease &ndash; 40 percent for A1 and 38 percent for A2",
"     </li>",
"     <li>",
"      Scleroderma, myositis, Sj&ouml;gren's syndrome &ndash; &lt;5 percent for A2",
"     </li>",
"     <li>",
"      No connective tissue disease &ndash; &lt;7 percent for A1 and A2",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of these antibodies does not appear to correlate with any of the clinical features of RA or SLE, although their presence in patients with SLE is strongly associated with anti-U1 RNP and anti-Sm antibodies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical utility of anti-hnRNP antibodies is currently limited because they crossreact with multiple antigens, and antibodies directed against hnRNP antigens other than A1 and A2 may be found in different autoimmune disorders. As an example, one study found that sera from 22 of 40 patients with scleroderma contained antibodies reactive with a structurally and immunologically distinct component of the spliceosome, named hnRNP I [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/17\">",
"     17",
"    </a>",
"    ]. In addition, in a case report, antibodies to the C1 and C2 core proteins of hnRNP were found in a patient with scleroderma and psoriatic arthritis, but not in patients with scleroderma alone or those with SLE or RA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/18\">",
"     18",
"    </a>",
"    ]. Patients with psoriatic arthritis alone were not evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-hnRNP antibodies have limited utility in the diagnosis of connective tissue diseases since they are found at significant levels in multiple disorders and their presence appears to correlate highly with other specific antibodies (such as anti-Sm antibodies).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     ANTI-PCNA ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of proteins accumulate in the nucleoplasm of cells during the",
"    <span class=\"nowrap\">",
"     G1/S",
"    </span>",
"    phase of the cell cycle which corresponds to the period of DNA synthesis. Approximately 2 to 10 percent of sera from patients with SLE sera contain antibodies which react with one such protein, PCNA (proliferating cell nuclear antigen) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    PCNA has a molecular weight of approximately 33 kD and can be induced in resting cells by several growth factors; the protein binds to at least two nuclear enzymes, uracil-DNA glycosylase and DNA-(cytosine-5) methyltransferase, which are involved in the nucleotide excision, repair, and mismatch repair aspects of DNA synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/20-22\">",
"     20-22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Methods of detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-PCNA antibodies can be detected by indirect immunofluorescence as a finely granular nuclear staining pattern on rapidly dividing cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/23\">",
"     23",
"    </a>",
"    ]. An enzyme-linked immunoassay (ELISA) for the detection of these antibodies has recently been reported. The dominant epitope of PCNA is an area of 14 contiguous amino acids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-PCNA antibodies appear to be specific (&gt;95 percent), but not sensitive (3 to 5 percent), for SLE; they have not been found in sera from patients with RA or other connective tissue diseases, or in normal sera [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/19\">",
"     19",
"    </a>",
"    ]. The incidence of this antibody varies since its production is rapidly inhibited by the administration of corticosteroids and immunosuppressive drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical association",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of anti-PCNA antibodies in patients with SLE is not associated with any particular clinical manifestation other than arthritis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite its high specificity, the anti-PCNA antibody test has limited clinical utility because of its very low sensitivity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ANTI-Hu ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibodies reactive with neuron specific RNA-binding nuclear proteins have been detected in the majority of patients with the paraneoplastic syndromes of sensory neuronopathy, encephalomyelitis, and",
"    <span class=\"nowrap\">",
"     opsoclonus/myoclonus",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/25\">",
"     25",
"    </a>",
"    ]. The proteins, which have molecular weights of 33 to 35 kD, function in the terminal differentiation of the neuron; they are named HuD, HuC, Hel-N1, and Hel-N2. Autoantibodies that react with a cross-reacting epitope on all of these proteins have been referred to as anti-Hu antibodies or more recently as anti-ANNA-1 antibodies (antineuronal nuclear antibody type 1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Methods of detection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anti-Hu antibodies have been classically detected by indirect immunofluorescence on brain tissue sections; they produce a finely speckled staining of the neuronal nuclei, but do not stain glial cell nuclei [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/27\">",
"     27",
"    </a>",
"    ]. An ELISA has recently been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Clinical association",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since undifferentiated tumor cells may express the Hu antigens, anti-Hu antibodies have been found most frequently in patients with small cell carcinoma of the lung. They have been associated with a paraneoplastic neurologic syndrome, listed above, and certain gastrointestinal disorders (such as achalasia or chronic intestinal pseudo-obstruction) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=see_link\">",
"     \"Overview of paraneoplastic syndromes of the nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=see_link\">",
"     \"Paraneoplastic syndromes affecting peripheral nerve and muscle\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/26/2474?source=see_link\">",
"     \"Chronic intestinal pseudo-obstruction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=see_link\">",
"     \"Paraneoplastic and autoimmune encephalitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42023?source=see_link\">",
"     \"Opsoclonus myoclonus ataxia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26983?source=see_link\">",
"     \"Paraneoplastic cerebellar degeneration\"",
"    </a>",
"    .) Patients with sensory neuronopathy and anti-Hu antibodies have also been reported in association with primary Sj&ouml;gren's syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been suggested that anti-Hu antibodies are directed toward an epitope that is shared between the neuronal elements within the enteric nervous system and the underlying malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/31\">",
"     31",
"    </a>",
"    ]. However, two observations suggest that factors other than or in addition to anti-Hu antibodies may underlie the development of a paraneoplastic syndrome:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Removal of the antibodies by plasmapheresis is not clinically beneficial",
"     </li>",
"     <li>",
"      Immunization of animals with HuD does not elicit any neurologic disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS ANTIBODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other autoantibodies reactive with nuclear and perinuclear antigens have been described in association with connective tissue diseases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/34-46\">",
"     34-46",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Anti-fibrillin-I &ndash; linear scleroderma and morphea [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-nucleolus organizer region (NOR 90) &ndash; scleroderma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antinucleolar RNA helicase (Gu) &ndash; scleroderma, SLE, watermelon stomach [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/37\">",
"       37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-DNA helicase (Ku) &ndash; SLE, scleroderma, myositis, RA, or overlap syndromes; many patients have Raynaud phenomenon and esophageal reflux [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/38,47-49\">",
"       38,47-49",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-Mi-2 &ndash; dermatomyositis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/39\">",
"       39",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antinucleosomal high mobility group proteins (HMG) &ndash; juvenile idiopathic arthritis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-major nucleolar phosphoprotein (B23) &ndash; antiphospholipid syndrome [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/41\">",
"       41",
"      </a>",
"      ] and pulmonary hypertension in scleroderma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/50\">",
"       50",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antiannexin XI (56K) &ndash; most connective tissue diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/42\">",
"       42",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-SR proteins &ndash; SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/46\">",
"       46",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-SS-56 &ndash; Sj&ouml;gren's syndrome and SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-poly (ADP-ribose) polymerase and SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-galectin-3 with SLE and",
"      <span class=\"nowrap\">",
"       polymyositis/dermatomyositis",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Anti-Th/To",
"      </span>",
"      (Anti-Th ribonucleoprotein) with scleroderma and idiopathic pulmonary fibrosis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/53,54\">",
"       53,54",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-proteosome in multiple sclerosis and SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antibodies to small nucleolar ribonucleoproteins in patients with systemic sclerosis, primary Raynaud phenomenon, SLE, RA, and inflammatory myopathies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/56\">",
"       56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Anti-topoisomerase II alpha - localized forms of scleroderma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/57\">",
"       57",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-dense fine speckles (DFS) 70 (also known as lens epithelium-derived growth factor [LEDGF]) in atopic dermatitis, Vogt Koyanagi Harada syndrome, and infrequently in rheumatic diseases [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/58\">",
"       58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Anti-telomere antibodies in patients with SLE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42695/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These antibodies are of lesser clinically significance since they are not routinely assayed in clinical laboratories and appear to have more limited specificity and sensitivity than other antinuclear antibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/61/13265?source=see_link\">",
"       \"Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H205784062\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most commercial and many hospital laboratories routinely assay sera for antibodies directed against DNA, histones, snRNP, Sm,",
"      <span class=\"nowrap\">",
"       Ro/SS-A,",
"      </span>",
"      <span class=\"nowrap\">",
"       La/SS-B,",
"      </span>",
"      topoisomerase 1 (Scl-70), and centromere. A number of additional autoantibodies also react with well characterized nuclear and perinuclear antigens. These principally include nucleosome (chromatin)-specific autoantibodies, anti-heterogeneous nuclear ribonuclear proteins (hnRNP) antibodies, anti-proliferating cell nuclear antigen (PCNA) antibodies, and anti-Hu antibodies. Testing for these antibodies is not routinely performed. These antinuclear antibodies are unlikely to account for many of the false positive antinuclear antibody (ANA) tests found in the normal population. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nucleosome (chromatin)-specific autoantibodies have been linked with lupus nephritis in murine models of SLE. However, the results are conflicting in humans. The clinical utility of antinucleosome-specific autoantibodies remains undefined since their sensitivity, specificity, and association with particular manifestations of SLE remain undefined. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Nucleosome (chromatin)-specific autoantibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoantibodies specific for the RNA binding regions of two of the hnRNP proteins, A2 and A1, produce a finely speckled pattern of staining in the nucleoplasm on indirect immunofluorescence microscopy. The presence of these antibodies does not appear to correlate with any of the clinical features of RA or SLE, although their presence in patients with SLE is strongly associated with anti-U1 RNP and anti-Sm antibodies. The clinical utility of anti-hnRNP antibodies is currently limited because they crossreact with multiple antigens. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Anti-hnRNP antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 2 to 10 percent of sera from patients with SLE sera contain antibodies which react with PCNA. Anti-PCNA antibodies in patients with SLE are associated with arthritis but no other clinical manifestation. Despite its high specificity, the anti-PCNA antibody test has limited clinical utility because of its very low sensitivity. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Anti-PCNA antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoantibodies that react with a cross-reacting epitope on neuron specific RNA-binding nuclear proteins have been referred to as anti-Hu antibodies or more recently as anti-ANNA-1 antibodies (antineuronal nuclear antibody type 1). Since undifferentiated tumor cells may express the Hu antigens, anti-Hu antibodies have been found most frequently in patients with small cell carcinoma of the lung and a paraneoplastic neurologic syndrome. It is also observed in certain gastrointestinal disorders. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Anti-Hu antibodies'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/1\">",
"      Hardin JA. The lupus autoantigens and the pathogenesis of systemic lupus erythematosus. Arthritis Rheum 1986; 29:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/2\">",
"      Burlingame RW, Rubin RL, Balderas RS, Theofilopoulos AN. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J Clin Invest 1993; 91:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/3\">",
"      Amoura Z, Piette JC, Bach JF, Koutouzov S. The key role of nucleosomes in lupus. Arthritis Rheum 1999; 42:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/4\">",
"      Burlingame RW, Boey ML, Starkebaum G, Rubin RL. The central role of chromatin in autoimmune responses to histones and DNA in systemic lupus erythematosus. J Clin Invest 1994; 94:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/5\">",
"      Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 1994; 179:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/6\">",
"      Salmon JE, Kimberly RP, Gibofsky A, Fotino M. Defective mononuclear phagocyte function in systemic lupus erythematosus: dissociation of Fc receptor-ligand binding and internalization. J Immunol 1984; 133:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/7\">",
"      Chabre H, Amoura Z, Piette JC, et al. Presence of nucleosome-restricted antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1995; 38:1485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/8\">",
"      Massa M, De Benedetti F, Pignatti P, et al. Anti-double stranded DNA, anti-histone, and anti-nucleosome IgG reactivities in children with systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/9\">",
"      Amoura Z, Koutouzov S, Chabre H, et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 2000; 43:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/10\">",
"      Cervera R, Vi&ntilde;as O, Ramos-Casals M, et al. Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 2003; 62:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/11\">",
"      Ng KP, Manson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum 2006; 55:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/12\">",
"      Cairns AP, McMillan SA, Crockard AD, et al. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 2003; 62:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/13\">",
"      Dreyfuss G, Matunis MJ, Pi&ntilde;ol-Roma S, Burd CG. hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem 1993; 62:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/14\">",
"      Montecucco C, Caporali R, Negri C, et al. Antibodies from patients with rheumatoid arthritis and systemic lupus erythematosus recognize different epitopes of a single heterogeneous nuclear RNP core protein. Possible role of cross-reacting antikeratin antibodies. Arthritis Rheum 1990; 33:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/15\">",
"      Hassfeld W, Steiner G, Studnicka-Benke A, et al. Autoimmune response to the spliceosome. An immunologic link between rheumatoid arthritis, mixed connective tissue disease, and systemic lupus erythematosus. Arthritis Rheum 1995; 38:777.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/16\">",
"      Biamonti G, Ghigna C, Caporali R, Montecucco C. Heterogeneous nuclear ribonucleoproteins (hnRNPs): an emerging family of autoantigens in rheumatic diseases. Clin Exp Rheumatol 1998; 16:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/17\">",
"      Montecucco C, Caporali R, Cobianchi F, Biamonti G. Identification of autoantibodies to the I protein of the heterogeneous nuclear ribonucleoprotein complex in patients with systemic sclerosis. Arthritis Rheum 1996; 39:1669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/18\">",
"      Stanek D, Vencovsk&yacute; J, Kafkov&aacute; J, Raska I. Heterogenous nuclear RNP C1 and C2 core proteins are targets for an autoantibody found in the serum of a patient with systemic sclerosis and psoriatic arthritis. Arthritis Rheum 1997; 40:2172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/19\">",
"      Fritzler MJ, McCarty GA, Ryan JP, Kinsella TD. Clinical features of patients with antibodies directed against proliferating cell nuclear antigen. Arthritis Rheum 1983; 26:140.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/20\">",
"      Takasaki Y, Fishwild D, Tan EM. Characterization of proliferating cell nuclear antigen recognized by autoantibodies in lupus sera. J Exp Med 1984; 159:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/21\">",
"      Muller-Weeks SJ, Caradonna S. Specific association of cyclin-like uracil-DNA glycosylase with the proliferating cell nuclear antigen. Exp Cell Res 1996; 226:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/22\">",
"      Chuang LS, Ian HI, Koh TW, et al. Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. Science 1997; 277:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/23\">",
"      Miyachi K, Fritzler MJ, Tan EM. Autoantibody to a nuclear antigen in proliferating cells. J Immunol 1978; 121:2228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/24\">",
"      Roos G, Landberg G, Huff JP, et al. Analysis of the epitopes of proliferating cell nuclear antigen recognized by monoclonal antibodies. Lab Invest 1993; 68:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/25\">",
"      Furneaux HF, Reich L, Posner JB. Autoantibody synthesis in the central nervous system of patients with paraneoplastic syndromes. Neurology 1990; 40:1085.",
"     </a>",
"    </li>",
"    <li>",
"     Furneaux, HM. Neuronal nuclear autoantibodies, type 1 (Hu) In: Autoantibodies, Peter, JB, Schoenfeld, Y (Eds), Elsevier Science, Amsterdam, 1996, p. 551.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/27\">",
"      Graus F, Elkon KB, Cordon-Cardo C, Posner JB. Sensory neuronopathy and small cell lung cancer. Antineuronal antibody that also reacts with the tumor. Am J Med 1986; 80:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/28\">",
"      Dropcho EJ, King PH. Autoantibodies against the Hel-N1 RNA-binding protein among patients with lung carcinoma: an association with type I anti-neuronal nuclear antibodies. Ann Neurol 1994; 36:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/29\">",
"      Alamowitch S, Graus F, Uchuya M, et al. Limbic encephalitis and small cell lung cancer. Clinical and immunological features. Brain 1997; 120 ( Pt 6):923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/30\">",
"      Darnell RB, DeAngelis LM. Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 1993; 341:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/31\">",
"      Lennon VA, Sas DF, Busk MF, et al. Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology 1991; 100:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/32\">",
"      Griffin, JW, Cornblath, DR, Alexander, E. Sensory ganglionitis associated with connective tissue disorders (abstract). Neurology 1988; 38:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/33\">",
"      Sillevis Smitt PA, Manley GT, Posner JB. Immunization with the paraneoplastic encephalomyelitis antigen HuD does not cause neurologic disease in mice. Neurology 1995; 45:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/34\">",
"      Hirakata M, Okano Y, Pati U, et al. Identification of autoantibodies to RNA polymerase II. Occurrence in systemic sclerosis and association with autoantibodies to RNA polymerases I and III. J Clin Invest 1993; 91:2665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/35\">",
"      Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992; 35:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/36\">",
"      Dick T, Mierau R, Sternfeld R, et al. Clinical relevance and HLA association of autoantibodies against the nucleolus organizer region (NOR-90). J Rheumatol 1995; 22:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/37\">",
"      Arnett FC, Reveille JD, Valdez BC. Autoantibodies to a nucleolar RNA helicase protein in patients with connective tissue diseases. Arthritis Rheum 1997; 40:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/38\">",
"      Cooley HM, Melny BJ, Gleeson R, et al. Clinical and serological associations of anti-Ku antibody. J Rheumatol 1999; 26:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/39\">",
"      Love LA, Leff RL, Fraser DD, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991; 70:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/40\">",
"      Jung F, Neuer G, Bautz FA. Antibodies against a peptide sequence located in the linker region of the HMG-1/2 box domains in sera from patients with juvenile rheumatoid arthritis. Arthritis Rheum 1997; 40:1803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/41\">",
"      Li XZ, McNeilage LJ, Whittingham S. Autoantibodies to the major nucleolar phosphoprotein B23 define a novel subset of patients with anticardiolipin antibodies. Arthritis Rheum 1989; 32:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/42\">",
"      Misaki Y, Van Venrooij WJ, Pruijn GJ. Prevalence and characteristics of anti-56K/annexin XI autoantibodies in systemic autoimmune diseases. J Rheumatol 1995; 22:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/43\">",
"      von M&uuml;hlen CA, Chan EK, Angl&eacute;s-Cano E, et al. Advances in autoantibodies in SLE. Lupus 1998; 7:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/44\">",
"      Arnett FC, Tan FK, Uziel Y, et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. Arthritis Rheum 1999; 42:2656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/45\">",
"      Hayem G, Chazerain P, Combe B, et al. Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis. J Rheumatol 1999; 26:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/46\">",
"      Neugebauer KM, Merrill JT, Wener MH, et al. SR proteins are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes. Arthritis Rheum 2000; 43:1768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/47\">",
"      Hirakata M, Suwa A, Kuwana M, et al. Association between autoantibodies to the Ku protein and DPB1*. Arthritis Rheum 2005; 52:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/48\">",
"      Schild-Poulter C, Su A, Shih A, et al. Association of autoantibodies with Ku and DNA repair proteins in connective tissue diseases. Rheumatology (Oxford) 2008; 47:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/49\">",
"      Rozman B, Cucnik S, Sodin-Semrl S, et al. Prevalence and clinical associations of anti-Ku antibodies in patients with systemic sclerosis: a European EUSTAR-initiated multi-centre case-control study. Ann Rheum Dis 2008; 67:1282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/50\">",
"      Ulanet DB, Wigley FM, Gelber AC, Rosen A. Autoantibodies against B23, a nucleolar phosphoprotein, occur in scleroderma and are associated with pulmonary hypertension. Arthritis Rheum 2003; 49:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/51\">",
"      Billaut-Mulot O, Cocude C, Kolesnitchenko V, et al. SS-56, a novel cellular target of autoantibody responses in Sj&ouml;gren syndrome and systemic lupus erythematosus. J Clin Invest 2001; 108:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/52\">",
"      Lim Y, Lee DY, Lee S, et al. Identification of autoantibodies associated with systemic lupus erythematosus. Biochem Biophys Res Commun 2002; 295:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/53\">",
"      Kuwana M, Kimura K, Hirakata M, et al. Differences in autoantibody response to Th/To between systemic sclerosis and other autoimmune diseases. Ann Rheum Dis 2002; 61:842.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/54\">",
"      Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, et al. Anti-th/to-positivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006; 33:1600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/55\">",
"      Mayo I, Arribas J, Villoslada P, et al. The proteasome is a major autoantigen in multiple sclerosis. Brain 2002; 125:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/56\">",
"      Van Eenennaam H, Vogelzangs JH, Bisschops L, et al. Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations. Clin Exp Immunol 2002; 130:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/57\">",
"      Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma. Arthritis Rheum 2004; 50:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/58\">",
"      Ganapathy V, Casiano CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): what exactly are the autoantibodies trying to tell us? Arthritis Rheum 2004; 50:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42695/abstract/59\">",
"      Salonen EM, Miettinen A, Walle TK, et al. Anti-telomere antibodies in systemic lupus erythematosus (SLE): a comparison with five antinuclear antibody assays in 430 patients with SLE and other rheumatic diseases. Ann Rheum Dis 2004; 63:1250.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1823 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-183.1.191.153-340D2F8564-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42695=[""].join("\n");
var outline_f41_44_42695=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H205784062\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NUCLEOSOME (CHROMATIN)-SPECIFIC AUTOANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Pathogenic role",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Methods of detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Incidence and accuracy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Associated clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANTI-hnRNP ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Methods of detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Incidence and accuracy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      ANTI-PCNA ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Methods of detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Accuracy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical association",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ANTI-Hu ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Methods of detection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Clinical association",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      MISCELLANEOUS ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H205784062\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1823\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1823|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/31/30205\" title=\"table 1A\">",
"      ANA disease associations I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/7/28797\" title=\"table 1B\">",
"      ANA disease associations II",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/26/2474?source=related_link\">",
"      Chronic intestinal pseudo-obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2234?source=related_link\">",
"      Investigational biologic markers in the diagnosis and assessment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/2/42023?source=related_link\">",
"      Opsoclonus myoclonus ataxia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/0/40968?source=related_link\">",
"      Overview of paraneoplastic syndromes of the nervous system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/56/906?source=related_link\">",
"      Paraneoplastic and autoimmune encephalitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/22/26983?source=related_link\">",
"      Paraneoplastic cerebellar degeneration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/27/37304?source=related_link\">",
"      Paraneoplastic syndromes affecting peripheral nerve and muscle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/61/13265?source=related_link\">",
"      Patient information: Antinuclear antibodies (ANA) (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_44_42696="Overview of male sexual dysfunction";
var content_f41_44_42696=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of male sexual dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42696/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42696/contributors\">",
"     Glenn R Cunningham, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42696/contributors\">",
"     Raymond C Rosen, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42696/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42696/contributors\">",
"     Peter J Snyder, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42696/contributors\">",
"     Michael P O'Leary, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42696/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42696/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/44/42696/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male sexual dysfunction has long been known to be common. Of late, knowledge of normal male sexual function and the causes of sexual dysfunction have become better understood, and more effective treatments are available.",
"    <br/>",
"   </p>",
"   <p>",
"    This topic review will provide an overview of normal and abnormal sexual function in men. Male sexual dysfunction includes erectile dysfunction, diminished libido, and abnormal ejaculation. The evaluation and treatment of men with sexual dysfunction and sexual dysfunction associated with SSRIs are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=see_link\">",
"     \"Evaluation of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link\">",
"     \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"    </a>",
"    .)",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2095227\">",
"    <span class=\"h1\">",
"     PHYSIOLOGY OF MALE SEXUAL FUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal male sexual function requires interactions among vascular, neurologic, hormonal, and psychological systems. The initial obligatory event required for male sexual activity, the acquisition and maintenance of penile erection, is primarily a vascular phenomenon, triggered by neurologic signals and facilitated only in the presence of an appropriate hormonal milieu and psychological mindset.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2095279\">",
"    <span class=\"h2\">",
"     Neural influences",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychogenic erections are triggered by neural impulses originating in discrete loci of the central and peripheral nervous systems [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/1\">",
"       1",
"      </a>",
"      ]. Sexual images may originate in response to erotic visual or auditory stimuli or be generated via fantasy. The centrally perceived sensual input is relayed by neural signals to a spinal cord neural center located at T-11 to L-2 (the thoracolumbar erection center). From there, neural impulses flow to the pelvic vascular bed, redirecting blood into the corpora cavernosae.",
"     </li>",
"     <li>",
"      Reflex erections are created by tactile stimulus to the penis or genital area which activates a reflex arc with sacral roots originating at S-2 to S-4 (the sacral erection center). Psychogenic erections are more common during man&rsquo;s early sexually active years, whereas reflex erectile activity dominates during his mature years.",
"     </li>",
"     <li>",
"      Nonsexual, nocturnal erections, occurring three to four times nightly, start in early adolescence. Nocturnal erectile activity may go unnoticed by sleeping men, although most men will be aware of an erection when they arise in the morning. These early morning erections often fade after urination, creating the incorrect impression that they are a reflex response to a full bladder.",
"      <br/>",
"      <br/>",
"      Nocturnal erections occur only during rapid eye movement (REM) sleep (",
"      <a class=\"graphic graphic_figure graphicRef56491 \" href=\"mobipreview.htm?24/23/24958\">",
"       figure 1",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/2\">",
"       2",
"      </a>",
"      ]. Men who sleep fitfully and depressed men rarely experience REM sleep and do not have nocturnal or early morning erections. Nocturnal erections persist throughout life, although, for as yet unexplained reasons, nocturnal erectile activity is not as tightly coupled to REM sleep in older men.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2095400\">",
"    <span class=\"h2\">",
"     Role of blood flow and nitric oxide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal erections require blood to flow from the hypogastric arterial system into specialized erectile chambers, the paired corpora cavernosae flanking the penile urethra, and the corpus spongiosum at the glans penis. As blood flow accelerates, the pressure within the intracavernosal spaces increases dramatically, preventing penile venous outflow from emissary veins. This combination of increased intracavernosal blood flow and reduced venous outflow allows a man to acquire and maintain a firm erection.",
"   </p>",
"   <p>",
"    High levels of intrapenile nitric oxide act as a local neurotransmitter to facilitate the relaxation of intracavernosal trabeculae, thereby maximizing blood flow and penile engorgement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/3\">",
"     3",
"    </a>",
"    ]. Nitric oxide is formed under the influence of the enzyme nitric oxide synthase, which, in conjunction with NADPH and oxygen, transforms the substrate amino acid arginine to citrulline and nitric oxide.",
"   </p>",
"   <p>",
"    The absolute prerequisites for penile erectile activity are an adequate arterial inflow to provide a constant source of intracavernosal oxygen and sufficient nitric oxide synthase to generate nitric oxide. Nitric oxide acts by promoting the generation of cyclic GMP.",
"   </p>",
"   <p>",
"    Detumescence (loss of erection) occurs when nitric oxide-induced vasodilation disappears because of metabolism of cyclic GMP, which is primarily mediated by intracavernosal type 5 cyclic GMP phosphodiesterase [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/4\">",
"     4",
"    </a>",
"    ]. Detumescence also is in part regulated by norepinephrine pathways.",
"   </p>",
"   <p>",
"    The role of nitric oxide may have important therapeutic implications for patients with erectile dysfunction (ED). Low intracavernosal nitric oxide synthase levels are found in cigarette smokers and patients with diabetes and testosterone deficiency, which may explain why these factors are associated with a high frequency of ED. On the other hand,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    , as well as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/40/21127?source=see_link\">",
"     vardenafil",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?19/4/19528?source=see_link\">",
"     tadalafil",
"    </a>",
"    , are all phosphodiesterase (PDE-5) inhibitors. All three PDE-5 inhibitors enhance intracavernosal cyclic GMP levels to improve the erectile response to sexual stimulation in many men with ED. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=see_link\">",
"     \"Treatment of male sexual dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interference with oxygen delivery or nitric oxide synthesis can prevent intracavernosal blood pressure from rising to a level sufficient to impede venous outflow, leading to an inability to acquire or sustain a rigid erection. Examples include decreased blood flow and inadequate intracavernosal oxygen levels when atherosclerosis involves the hypogastric artery or other feeder vessels [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/5\">",
"     5",
"    </a>",
"    ], and diabetes mellitus, which is associated with suboptimal nitric oxide synthase activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2095523\">",
"    <span class=\"h2\">",
"     Hormonal influences",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone plays an integral role in normal male sexual function. The onset of adolescent nocturnal erections coincides with the pulsatile release of gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) activation of Leydig cell testosterone secretion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Testosterone deficiency results in impotence in experimental animals and men, and sexual potency returns when testosterone levels are normalized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Testosterone acts through psychogenic channels to enhance libido.",
"     </li>",
"     <li>",
"      Testosterone is necessary for maintenance of intrapenile nitric oxide synthase levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63447781\">",
"    <span class=\"h2\">",
"     Normal sexual activity with age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sexual activity is affected by age, health status, and gender. In a population-based survey, men were more likely than women to be sexually active and report a good quality sex life [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/10\">",
"     10",
"    </a>",
"    ]. Gender differences increased with age and were most noticeable in the 75 to 85 year old group: 39 percent of men versus 17 percent of women were sexually active.",
"   </p>",
"   <p>",
"    Men and women in good health were more likely to be sexually active compared to those in fair or poor health. Men lost more years of sexually active life as a result of poor health than women.",
"   </p>",
"   <p>",
"    Although men may remain sexually active, there are a number of age-associated changes in sexual function in men including delay in erection, diminished intensity and duration of orgasm, and decreased force of seminal emission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/11\">",
"     11",
"    </a>",
"    ].",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63447488\">",
"    <span class=\"h1\">",
"     SEXUAL DYSFUNCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Male sexual dysfunction includes erectile dysfunction, diminished libido, and abnormal ejaculation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H63447840\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 1994 survey, the Massachusetts Male Aging Study (MMAS), revealed that male sexual dysfunction, presenting as erectile dysfunction, diminished libido, or abnormal ejaculation, first emerges as a common problem for men in their early 40s and increases with advancing age. At age 40, as an example, 40 percent acknowledged some level of impaired sexual function and another 10 percent recognized a waning sexual prowess or interest with each succeeding decade (",
"    <a class=\"graphic graphic_figure graphicRef81051 \" href=\"mobipreview.htm?32/46/33517\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/12\">",
"     12",
"    </a>",
"    ]. A nine-year longitudinal follow-up study of this same cohort confirmed the age-associated declines in most domains of sexual function: sexual intercourse, erection frequency, sexual desire, satisfaction with sex, and orgasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The high prevalence of sexual problems was confirmed by data derived from the National Health and Social Life Survey [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/14\">",
"     14",
"    </a>",
"    ]. Even in a cohort of younger men ages 18 to 59, 31 percent suffered from sexual dysfunction. In this population-representative national survey, comparably",
"    <strong>",
"     -",
"    </strong>",
"    aged women reported a somewhat higher degree of sexual dysfunction (41 percent). The factors responsible for maintaining normal sexual function in the female are less well characterized than in the male. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=see_link\">",
"     \"Sexual dysfunction in women: Epidemiology, risk factors, and evaluation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The age-associated increase in the prevalence of sexual dysfunction noted in the MMAS was strongly confirmed by a larger cross-sectional analysis of data from a prospective cohort study of 31,742 men ages 53 to 90 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2095582\">",
"    <span class=\"h2\">",
"     Decreased libido",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of reduced libido is estimated to be 5 to 15 percent in men. It increases with age and it frequently accompanies other sexual disorders. Men with ED may experience loss of libido as a secondary consequence of ED. This usually is ascertained from a detailed sexual history, including the chronology of the disorder. However, most patients who complain of erectile dysfunction (ED) do not complain of reduced libido or sexual desire.",
"   </p>",
"   <p>",
"    The causes of low libido include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications (SSRIs, anti-androgens, 5-alpha reductase inhibitors, opioid analgesics)",
"     </li>",
"     <li>",
"      Alcoholism",
"     </li>",
"     <li>",
"      Depression",
"     </li>",
"     <li>",
"      Fatigue",
"     </li>",
"     <li>",
"      Hypoactive sexual disorder",
"     </li>",
"     <li>",
"      Recreational drugs",
"     </li>",
"     <li>",
"      Relationship problems",
"     </li>",
"     <li>",
"      Other sexual dysfunction (fear of humiliation)",
"     </li>",
"     <li>",
"      Sexual aversion disorder",
"     </li>",
"     <li>",
"      Systemic illness",
"     </li>",
"     <li>",
"      Testosterone deficiency",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Most of these conditions are potentially treatable, so it is important to take a good medical history, perform a careful examination, and obtain relevant laboratory studies to determine if any of them are present. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12824?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical features and diagnosis of male hypogonadism\", section on 'Laboratory tests'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2095590\">",
"    <span class=\"h2\">",
"     Erectile dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erectile dysfunction (ED) is defined as the consistent or recurrent inability to acquire or sustain an erection of sufficient rigidity and duration for sexual intercourse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2095601\">",
"    <span class=\"h3\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of sexual activity decreases with age in both men and women, and sexual problems become more common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H63447781\">",
"     'Normal sexual activity with age'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In men, the most common sexual problem is erectile dysfunction (ED). A number of cross-sectional and longitudinal studies suggest a high prevalence of ED in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/12-15,18\">",
"     12-15,18",
"    </a>",
"    ]. A multinational study of 27,839 men in eight countries (USA, UK, Germany, France, Italy, Spain, Mexico, and Brazil) was conducted with the same survey instrument [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/19\">",
"     19",
"    </a>",
"    ]. The ages ranged from 20 to 75 years, and the overall prevalence of ED was 16 percent. It was 8 percent in men 20 to 30 years of age and 37 percent in men 70 to 75 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2095608\">",
"    <span class=\"h3\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study, exercise was associated with a lower risk of ED, while obesity, smoking, watching television, and the presence of comorbid conditions were associated with a higher risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/15\">",
"     15",
"    </a>",
"    ]. The lowest prevalence was noted in men without chronic medical problems who engaged in healthy behaviors. In obese men with erectile dysfunction, weight loss and increased physical activity are associated with an improvement in erectile function in about one-third of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Frequency of sexual activity appears to predict the development of ED. This was illustrated in a five-year longitudinal cohort study of 989 men ages 55 to 75 years, who did not have ED at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/21\">",
"     21",
"    </a>",
"    ]. After adjusting for comorbidities and other major risk factors, men who reported intercourse less than once per week developed ED at twice the rate as men who reported intercourse once per week (79 versus",
"    <span class=\"nowrap\">",
"     33/1000",
"    </span>",
"    RR 2.2).",
"   </p>",
"   <p>",
"    In a prospective, cohort study of 570 men followed for approximately 25 years, the presence of risk factors for coronary heart disease (smoking, obesity, dyslipidemia) in midlife (mean age 46 years) were associated with incident ED (mean age 72 years at the time of follow-up) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to age, the best predictors of erectile dysfunction are diabetes mellitus, hypertension, obesity, dyslipidemia, cardiovascular disease, smoking, and medication use [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/12-14,22-27\">",
"     12-14,22-27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38341?source=see_link\">",
"     \"Erectile dysfunction in diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H189242047\">",
"     'Drugs'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other diseases associated with erectile dysfunction include systemic sclerosis (scleroderma), Peyronie's disease, and prostate cancer treatment (eg, brachytherapy, prostatectomy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=see_link\">",
"     \"Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17273?source=see_link\">",
"     \"Peyronie's disease: Diagnosis and medical management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189242040\">",
"    <span class=\"h3\">",
"     Association with cardiovascular disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erectile dysfunction and cardiovascular disease share many risk factors, and their pathophysiology is mediated through endothelial dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Cardiovascular disease and its risk factors increase the risk for later ED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/22,28,29\">",
"     22,28,29",
"    </a>",
"    ]; on the other hand, erectile dysfunction may be an early warning sign of future cardiovascular events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/24,30\">",
"     24,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This was illustrated in a study of 9457 men aged 55 years or older who were randomized to the placebo group of the Prostate Cancer Prevention Trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/30\">",
"     30",
"    </a>",
"    ]. After five years of follow-up, the following results were seen:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      3816 men (47 percent) had ED at study entry.",
"     </li>",
"     <li>",
"      Of the 4247 men who did not have ED at study entry, 2420 (57 percent) developed the problem during the five-year follow-up (incident ED). In the group with incident ED, the adjusted hazard ratio for subsequent cardiovascular events was 1.25 (95% CI 1.02-1.53).",
"     </li>",
"     <li>",
"      For men with either incident or prevalent (at study entry) ED, the adjusted hazard ratio was 1.45 (95% CI 1.25-1.69).",
"     </li>",
"     <li>",
"      For subsequent cardiovascular events, the unadjusted risk of an incident cardiovascular event was 0.024 and 0.015 per person-year among men with and without ED at study entry. This association was in the range of risk seen with current smoking or a family history of myocardial infarction.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, men with ED without an obvious cause (eg, pelvic trauma) and who have no symptoms of coronary or other vascular disease should be screened for cardiovascular disease and its associated risk factors prior to initiating therapy for their sexual dysfunction, since there are potential cardiac risks associated with sexual activity in patients with heart disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8442?source=see_link\">",
"     \"Sexual activity in patients with heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=see_link\">",
"     \"Screening for coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189242047\">",
"    <span class=\"h3\">",
"     Drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eight of the 12 most commonly prescribed medications list erectile dysfunction (ED) as a side effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/32,33\">",
"     32,33",
"    </a>",
"    ], and it is estimated that 25 percent of cases of ED are due to medications. Examples of medications that disrupt normal male sexual function include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antidepressants - Most antidepressants are associated with ED, but in particular, the selective serotonin reuptake inhibitors (SSRIs) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=see_link\">",
"       \"Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/22/17767?source=see_link\">",
"       Spironolactone",
"      </a>",
"     </li>",
"     <li>",
"      Sympathetic blockers such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/53/19289?source=see_link\">",
"       clonidine",
"      </a>",
"      , guanethidine, or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/15/28918?source=see_link\">",
"       methyldopa",
"      </a>",
"     </li>",
"     <li>",
"      Thiazide diuretics [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/34/33312?source=see_link\">",
"       Ketoconazole",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/54/2921?source=see_link\">",
"       Cimetidine",
"      </a>",
"      , but apparently not",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/45/728?source=see_link\">",
"       famotidine",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of antihypertensive drugs on ED was assessed in the Treatment of Mild Hypertension Study (TOMHS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/35\">",
"     35",
"    </a>",
"    ]. In this trial, patients with mild hypertension were randomly assigned to therapy with lifestyle modifications plus placebo or one of five antihypertensive drugs, each from a different class:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/11/37047?source=see_link\">",
"     acebutolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/296?source=see_link\">",
"     amlodipine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/14/26854?source=see_link\">",
"     chlorthalidone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/19/8505?source=see_link\">",
"     enalapril",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    . The incidence of ED at two years was higher with chlorthalidone (a thiazide diuretic) than placebo (17.1 versus 8.1 percent); no other drug was different from placebo. Similar findings were noted in an older study in which sexual dysfunction was more common with a thiazide diuretic than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/49/8986?source=see_link\">",
"     propranolol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It had been thought that beta blockers are an important cause of ED, but a systematic review of randomized, controlled trials found only a small increased risk of sexual dysfunction with beta blocker therapy (5 per 1000 patients treated) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=see_link\">",
"     \"Major side effects of beta blockers\"",
"    </a>",
"    .) Alpha-adrenergic blockers, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/59/8119?source=see_link\">",
"     doxazosin",
"    </a>",
"    , have been observed to improve sexual function and libido [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Common over-the-counter products contain chemicals like nicotine and alcohol that have a disruptive effect on male sexual function. Although some recreational drugs, such as cocaine and heroin, can initially stimulate libido and sexual arousal, they ultimately exert a negative impact on the ability to acquire and sustain erectile function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Judicious substitution of an equally effective but less sexually noxious prescription antihypertensive drug, H2 antagonist, or antidepressant, as well as recreational drug abstinence, may be sufficient to restore sexual function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189242054\">",
"    <span class=\"h3\">",
"     Psychosocial factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression, stress, or the drugs used to treat depression can result in ED.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189242061\">",
"    <span class=\"h3\">",
"     Neurological",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurologic causes of erectile dysfunction include stroke, spinal cord or back injury, multiple sclerosis, or dementia. In addition, pelvic trauma, prostate surgery, or priapism may cause ED.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H264155997\">",
"    <span class=\"h3\">",
"     Bicycling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Less obvious, but of increasing importance, has been the possible (but controversial) association of ED with bicycling. Anything that places prolonged pressure on the pudendal and cavernosal nerves or compromises blood flow to the cavernosal artery can result in penile numbness and impotence. The penile numbness has been attributed to the pressure on the perineal nerves, whereas the ED is thought to be due to a decrease in oxygen pressure in the pudendal arteries (which may be more of a problem with certain bicycle seats) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/39\">",
"     39",
"    </a>",
"    ]. This is thought to be a potential problem for serious cyclists.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2096023\">",
"    <span class=\"h3\">",
"     Endocrine disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Testosterone deficiency affects peripheral mechanisms that are responsible for penile erections. Testosterone deficient men are still capable of exhibiting some erectile activity during nocturnal penile tumescence studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. However, the penile swelling in this setting usually is not of sufficient rigidity to permit vaginal penetration. This defect is corrected after normalization of testosterone levels, probably due to restoration of intrapenile nitric oxide synthase levels.",
"   </p>",
"   <p>",
"    The testosterone level associated with ED is uncertain. In a study of 1162 men, serum testosterone levels &lt;225",
"    <span class=\"nowrap\">",
"     ng/dL",
"    </span>",
"    were associated with an increased frequency of sexual dysfunction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/42\">",
"     42",
"    </a>",
"    ]. The effects of testosterone on libido are more consistent than on erectile function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/43\">",
"     43",
"    </a>",
"    ]. Testosterone replacement can restore nocturnal erections in hypogonadal men but the effects are greater when testosterone plus a PDE-5 inhibitor are administered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other disruptions in hormone secretion, including hyperprolactinemia, hyperthyroidism, and hypothyroidism are commonly associated with ED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/45\">",
"     45",
"    </a>",
"    ]. Restoration of the normal hormonal state usually results in the return of erectile function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recognition that one-third of men with type 2 diabetes mellitus have subnormal testosterone concentrations suggests that this hormone deficiency, and not just diabetic",
"    <span class=\"nowrap\">",
"     vasculopathy/neuropathy,",
"    </span>",
"    may play a role in the ED so commonly seen in men with diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <br/>",
"    <strong>",
"    </strong>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H189241025\">",
"    <span class=\"h2\">",
"     Ejaculatory disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ejaculatory disorders are a heterogeneous group of disorders that include premature, delayed, and retrograde ejaculation, and anorgasmia. Painful orgasm may also be included in this category; this topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17273?source=see_link\">",
"     \"Peyronie's disease: Diagnosis and medical management\"",
"    </a>",
"    .)",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2096103\">",
"    <span class=\"h3\">",
"     Premature ejaculation (PE)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature ejaculation (PE) is also referred to as rapid or early ejaculation and is defined according to three essential criteria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/48\">",
"     48",
"    </a>",
"    ]: (1) brief ejaculatory latency; (2) loss of control; and (3) psychological distress in the patient",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    partner.",
"   </p>",
"   <p>",
"    Ejaculatory latency of about a minute or less may qualify a man for the diagnosis, which should include consistent inability to delay or control ejaculation, and marked distress about the condition. All three components should be present to qualify for the diagnosis. Subtypes of the disorder are symptom-based, including lifelong versus acquired, global versus situational PE, and the co-occurrence of other sexual problems, particularly ED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/49,50\">",
"     49,50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 30 percent of men with PE have concurrent ED, which typically results in early ejaculation without full erection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. A wide range of severity is seen, with patients ejaculating on or prior to penetration in the most severe cases. Patients sometimes present for infertility concerns. Normative data on average latency of ejaculation in different age and ethnic groups is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The etiology of the disorder is uncertain or obscure in most cases. Negative conditioning and penile hypersensitivity may be etiological factors in PE, although neither mechanism has received adequate experimental support to date [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/49,53\">",
"     49,53",
"    </a>",
"    ]. Similarly, a genetic basis for the disorder has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/54,55\">",
"     54,55",
"    </a>",
"    ] but is lacking adequate scientific support. PE is a highly prevalent disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]; however, accurate population-based data are not available. Although usually associated with less bother than ED, the disorder may be highly distressing in some instances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/56\">",
"     56",
"    </a>",
"    ]. It is frequently associated with sexual problems in the partner, particularly anorgasmia or a sexual pain disorder (eg, vaginismus). In such cases, couples or sex therapy approaches may be of particular value. These may be combined with pharmacotherapy or behavioral therapy for treatment of PE in the man [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. Cultural factors are important in determining the degree of distress associated with the disorder.",
"    <br/>",
"    <br/>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2096118\">",
"    <span class=\"h3\">",
"     Delayed ejaculation, anejaculation, and male anorgasmia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ejaculatory dysfunction (EjD) includes a spectrum of disorders in men ranging from delayed ejaculation to a complete inability to ejaculate, anejaculation, and retrograde ejaculation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/53,57\">",
"     53,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple etiological factors have been identified, including organic and psychogenic factors. Any medical disease, drug, or surgical procedure that interferes with either central (including spinal or supraspinal) control of ejaculation or the autonomic innervation to the seminal tract, including the sympathetic innervation to the seminal vesicles, the prostatic urethra, and bladder neck, or sensory innervation to the anatomical structures involved in the ejaculation process, can result in delayed ejaculation, anejaculation, and anorgasmia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Retrograde ejaculation commonly occurs following surgery for benign prostatic hyperplasia, whereas anejaculation is always associated with radical prostatectomy or cystoprostatectomy. Orgasm is typically not impaired with these latter procedures.",
"   </p>",
"   <p>",
"    Lower urinary tract symptoms in aging men are often associated with ejaculatory disorders [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Commonly used drugs such as certain alpha blockers (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/28/39365?source=see_link\">",
"     tamsulosin",
"    </a>",
"    ) and antidepressants, particularly serotonin-uptake inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    ), have been associated with loss of orgasm or ejaculation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Little is known about the physiology of the male orgasm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/53\">",
"     53",
"    </a>",
"    ]. Precise prevalence data for these disorders are not available, although later studies suggest that EjD may be almost as prevalent as erectile dysfunction (ED) in aging men [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/59\">",
"     59",
"    </a>",
"    ]. Loss of ejaculation is often age-related and may be associated with other sexual dysfunction in the male, particularly ED [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/53,57\">",
"     53,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/24/386?source=see_link\">",
"       \"Patient information: Sex problems in men (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/20/16706?source=see_link\">",
"       \"Patient information: Sex as you get older (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=see_link\">",
"       \"Patient information: Sexual problems in men (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2096111\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sexual dysfunction is common in men and increases with age. There are several kinds of male sexual dysfunction: decreased libido, erectile dysfunction, and ejaculatory disorders. Ejaculatory disorders include premature ejaculation, delayed ejaculation, and anejaculation. Painful orgasm is also included in this category, and is reviewed separately (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17273?source=see_link\">",
"       \"Peyronie's disease: Diagnosis and medical management\"",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Estimated prevalence of male sexual dysfunction",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced libido is estimated to affect approximately 5 to 15 percent of men [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/14\">",
"       14",
"      </a>",
"      ]. It increases with age and it frequently accompanies other sexual disorders. (See",
"      <a class=\"local\" href=\"#H2095582\">",
"       'Decreased libido'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erectile dysfunction was reported by 18 percent of men ages 50 to 59 in one study [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/14\">",
"       14",
"      </a>",
"      ], and by 37 percent of those age 70 to 75 years in a second report [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/19\">",
"       19",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H2095590\">",
"       'Erectile dysfunction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Premature ejaculation is considered to be the most common of the ejaculatory disorders, with an estimated overall prevalence of 20 to 30 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42696/abstract/50\">",
"       50",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H189241025\">",
"       'Ejaculatory disorders'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <strong>",
"     Erectile dysfunction: risk factors and association with cardiovascular disease",
"    </strong>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A number of medications, most commonly the selective serotonin reuptake inhibitors, are associated with erectile dysfunction. (See",
"      <a class=\"local\" href=\"#H189242047\">",
"       'Drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other important risk factors for erectile dysfunction include obesity, smoking, inactivity, and the presence of comorbid conditions. (See",
"      <a class=\"local\" href=\"#H2095608\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Erectile dysfunction and cardiovascular disease share many risk factors and their pathophysiology is mediated through endothelial dysfunction. Cardiovascular disease and its risk factors increase the risk for later ED; on the other hand, erectile dysfunction may be an early warning sign of future cardiovascular events. (See",
"      <a class=\"local\" href=\"#H189242040\">",
"       'Association with cardiovascular disease'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Therefore, men with ED without an obvious cause (eg, pelvic trauma) and who have no symptoms of coronary or other vascular disease should be screened for cardiovascular disease and its associated risk factors prior to initiating therapy for their sexual dysfunction, since there are potential cardiac risks associated with sexual activity in patients with heart disease.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/1\">",
"      Krane RJ, Goldstein I, Saenz de Tejada I. Impotence. N Engl J Med 1989; 321:1648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/2\">",
"      Karacan I, Williams RL, Thornby JI, Salis PJ. Sleep-related penile tumescence as a function of age. Am J Psychiatry 1975; 132:932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/3\">",
"      Sommer F, Schwarzer U, Klotz T, et al. Erectile dysfunction in cyclists. Is there any difference in penile blood flow during cycling in an upright versus a reclining position? Eur Urol 2001; 39:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/4\">",
"      Jeremy JY, Ballard SA, Naylor AM, et al. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997; 79:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/5\">",
"      Virag R, Bouilly P, Frydman D. Is impotence an arterial disorder? A study of arterial risk factors in 440 impotent men. Lancet 1985; 1:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/6\">",
"      Saenz de Tejada I, Goldstein I, Azadzoi K, et al. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989; 320:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/7\">",
"      Santen RJ, Bardin CW. Episodic luteinizing hormone secretion in man. Pulse analysis, clinical interpretation, physiologic mechanisms. J Clin Invest 1973; 52:2617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/8\">",
"      Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983; 12:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/9\">",
"      Mills TM, Wiedmeier VT, Stopper VS. Androgen maintenance of erectile function in the rat penis. Biol Reprod 1992; 46:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/10\">",
"      Lindau ST, Gavrilova N. Sex, health, and years of sexually active life gained due to good health: evidence from two US population based cross sectional surveys of ageing. BMJ 2010; 340:c810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/11\">",
"      Kandeel FR, Koussa VK, Swerdloff RS. Male sexual function and its disorders: physiology, pathophysiology, clinical investigation, and treatment. Endocr Rev 2001; 22:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/12\">",
"      Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/13\">",
"      Araujo AB, Mohr BA, McKinlay JB. Changes in sexual function in middle-aged and older men: longitudinal data from the Massachusetts Male Aging Study. J Am Geriatr Soc 2004; 52:1502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/14\">",
"      Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 281:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/15\">",
"      Bacon CG, Mittleman MA, Kawachi I, et al. Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med 2003; 139:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/16\">",
"      Lindau ST, Schumm LP, Laumann EO, et al. A study of sexuality and health among older adults in the United States. N Engl J Med 2007; 357:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/17\">",
"      McVary KT. Clinical practice. Erectile dysfunction. N Engl J Med 2007; 357:2472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/18\">",
"      Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med 2007; 120:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/19\">",
"      Rosen RC, Fisher WA, Eardley I, et al. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004; 20:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/20\">",
"      Esposito K, Giugliano F, Di Palo C, et al. Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial. JAMA 2004; 291:2978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/21\">",
"      Koskim&auml;ki J, Shiri R, Tammela T, et al. Regular intercourse protects against erectile dysfunction: Tampere Aging Male Urologic Study. Am J Med 2008; 121:592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/22\">",
"      Fung MM, Bettencourt R, Barrett-Connor E. Heart disease risk factors predict erectile dysfunction 25 years later: the Rancho Bernardo Study. J Am Coll Cardiol 2004; 43:1405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/23\">",
"      Sullivan ME, Keoghane SR, Miller MA. Vascular risk factors and erectile dysfunction. BJU Int 2001; 87:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/24\">",
"      Chiurlia E, D'Amico R, Ratti C, et al. Subclinical coronary artery atherosclerosis in patients with erectile dysfunction. J Am Coll Cardiol 2005; 46:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/25\">",
"      Mannino DM, Klevens RM, Flanders WD. Cigarette smoking: an independent risk factor for impotence? Am J Epidemiol 1994; 140:1003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/26\">",
"      Saigal CS, Wessells H, Pace J, et al. Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 2006; 166:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/27\">",
"      Grover SA, Lowensteyn I, Kaouache M, et al. The prevalence of erectile dysfunction in the primary care setting: importance of risk factors for diabetes and vascular disease. Arch Intern Med 2006; 166:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/28\">",
"      Baumh&auml;kel M, B&ouml;hm M. Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients. Int J Clin Pract 2007; 61:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/29\">",
"      Min JK, Williams KA, Okwuosa TM, et al. Prediction of coronary heart disease by erectile dysfunction in men referred for nuclear stress testing. Arch Intern Med 2006; 166:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/30\">",
"      Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005; 294:2996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/31\">",
"      Shamloul R, Ghanem H. Erectile dysfunction. Lancet 2013; 381:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/32\">",
"      Wein AJ, Van Arsdalen KN. Drug-induced male sexual dysfunction. Urol Clin North Am 1988; 15:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/33\">",
"      Slag MF, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients. JAMA 1983; 249:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/34\">",
"      Comparison of propranolol and hydrochlorothiazide for the initial treatment of hypertension. II. Results of long-term therapy. Veterans Administration Cooperative Study Group on Antihypertensive Agents. JAMA 1982; 248:2004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/35\">",
"      Grimm RH Jr, Grandits GA, Prineas RJ, et al. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997; 29:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/36\">",
"      Ko DT, Hebert PR, Coffey CS, et al. Beta-blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. JAMA 2002; 288:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/37\">",
"      Kirby RS, O'Leary MP, Carson C. Efficacy of extended-release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int 2005; 95:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/38\">",
"      Cocores JA, Miller NS, Pottash AC, Gold MS. Sexual dysfunction in abusers of cocaine and alcohol. Am J Drug Alcohol Abuse 1988; 14:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/39\">",
"      Schwarzer U, Sommer F, Klotz T, et al. Cycling and penile oxygen pressure: the type of saddle matters. Eur Urol 2002; 41:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/40\">",
"      Kwan M, Greenleaf WJ, Mann J, et al. The nature of androgen action on male sexuality: a combined laboratory-self-report study on hypogonadal men. J Clin Endocrinol Metab 1983; 57:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/41\">",
"      Wu FC, Tajar A, Pye SR, et al. Hypothalamic-pituitary-testicular axis disruptions in older men are differentially linked to age and modifiable risk factors: the European Male Aging Study. J Clin Endocrinol Metab 2008; 93:2737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/42\">",
"      Marberger M, Roehrborn CG, Marks LS, et al. Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. J Clin Endocrinol Metab 2006; 91:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/43\">",
"      Isidori AM, Giannetta E, Gianfrilli D, et al. Effects of testosterone on sexual function in men: results of a meta-analysis. Clin Endocrinol (Oxf) 2005; 63:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/44\">",
"      Rochira V, Balestrieri A, Madeo B, et al. Sildenafil improves sleep-related erections in hypogonadal men: evidence from a randomized, placebo-controlled, crossover study of a synergic role for both testosterone and sildenafil on penile erections. J Androl 2006; 27:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/45\">",
"      Spark RF, White RA, Connolly PB. Impotence is not always psychogenic. Newer insights into hypothalamic-pituitary-gonadal dysfunction. JAMA 1980; 243:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/46\">",
"      De Rosa M, Zarrilli S, Vitale G, et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J Clin Endocrinol Metab 2004; 89:621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/47\">",
"      Dhindsa S, Prabhakar S, Sethi M, et al. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab 2004; 89:5462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/48\">",
"      Althof SE, Abdo CH, Dean J, et al. International Society for Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation. J Sex Med 2010; 7:2947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/49\">",
"      Rowland D, McMahon CG, Abdo C, et al. Disorders of orgasm and ejaculation in men. J Sex Med 2010; 7:1668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/50\">",
"      Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010; 57:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/51\">",
"      Patrick DL, Althof SE, Pryor JL, et al. Premature ejaculation: an observational study of men and their partners. J Sex Med 2005; 2:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/52\">",
"      Rosen RC, McMahon CG, Niederberger C, et al. Correlates to the clinical diagnosis of premature ejaculation: results from a large observational study of men and their partners. J Urol 2007; 177:1059.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/53\">",
"      McMahon CG, Abdo C, Incrocci L, et al. Disorders of orgasm and ejaculation in men. J Sex Med 2004; 1:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/54\">",
"      Waldinger MD, Rietschel M, N&ouml;then MM, et al. Familial occurrence of primary premature ejaculation. Psychiatr Genet 1998; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/55\">",
"      Waldinger MD. The neurobiological approach to premature ejaculation. J Urol 2002; 168:2359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/56\">",
"      Rowland DL, Patrick DL, Rothman M, Gagnon DD. The psychological burden of premature ejaculation. J Urol 2007; 177:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/57\">",
"      Hatzimouratidis K, Hatzichristou D. Sexual dysfunctions: classifications and definitions. J Sex Med 2007; 4:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/58\">",
"      Coolen LM, Allard J, Truitt WA, McKenna KE. Central regulation of ejaculation. Physiol Behav 2004; 83:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/59\">",
"      Blanker MH, Bosch JL, Groeneveld FP, et al. Erectile and ejaculatory dysfunction in a community-based sample of men 50 to 78 years old: prevalence, concern, and relation to sexual activity. Urology 2001; 57:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/60\">",
"      Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol 2005; 47:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42696/abstract/61\">",
"      Rosen R, Altwein J, Boyle P, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003; 44:637.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6840 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-89.32.226.102-E9F4F161E5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42696=[""].join("\n");
var outline_f41_44_42696=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2096111\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2095227\">",
"      PHYSIOLOGY OF MALE SEXUAL FUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2095279\">",
"      Neural influences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2095400\">",
"      Role of blood flow and nitric oxide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2095523\">",
"      Hormonal influences",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63447781\">",
"      Normal sexual activity with age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H63447488\">",
"      SEXUAL DYSFUNCTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H63447840\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2095582\">",
"      Decreased libido",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2095590\">",
"      Erectile dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2095601\">",
"      - Prevalence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2095608\">",
"      - Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H189242040\">",
"      - Association with cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H189242047\">",
"      - Drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H189242054\">",
"      - Psychosocial factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H189242061\">",
"      - Neurological",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H264155997\">",
"      - Bicycling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2096023\">",
"      - Endocrine disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H189241025\">",
"      Ejaculatory disorders",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2096103\">",
"      - Premature ejaculation (PE)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2096118\">",
"      - Delayed ejaculation, anejaculation, and male anorgasmia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2096111\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/6840\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/6840|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/23/24958\" title=\"figure 1\">",
"      Tumescence and REM sleep",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/46/33517\" title=\"figure 2\">",
"      Impotence in men by age",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/33/12824?source=related_link\">",
"      Clinical features and diagnosis of male hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/28/38341?source=related_link\">",
"      Erectile dysfunction in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32533?source=related_link\">",
"      Evaluation of male sexual dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/39/3704?source=related_link\">",
"      Major side effects of beta blockers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/20/13642?source=related_link\">",
"      Overview of the treatment and prognosis of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/20/16706?source=related_link\">",
"      Patient information: Sex as you get older (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?0/24/386?source=related_link\">",
"      Patient information: Sex problems in men (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?28/33/29205?source=related_link\">",
"      Patient information: Sexual problems in men (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/55/17273?source=related_link\">",
"      Peyronie's disease: Diagnosis and medical management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/50/26409?source=related_link\">",
"      Screening for coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/15/8442?source=related_link\">",
"      Sexual activity in patients with heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2039?source=related_link\">",
"      Sexual dysfunction associated with selective serotonin reuptake inhibitor (SSRI) antidepressants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/42/25258?source=related_link\">",
"      Sexual dysfunction in women: Epidemiology, risk factors, and evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/36/30282?source=related_link\">",
"      Treatment of male sexual dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_44_42697="Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn";
var content_f41_44_42697=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of intraventricular hemorrhage in the newborn",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42697/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42697/contributors\">",
"     Lisa M Adcock, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42697/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42697/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42697/contributors\">",
"     Douglas R Nordli, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/44/42697/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/44/42697/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/44/42697/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraventricular hemorrhage (IVH; also known as subependymal or germinal matrix-IVH) is an important cause of brain injury in premature infants. Although the incidence has declined since the 1980s, IVH remains a significant problem, since improved survival of extremely premature infants has resulted in a greater number of survivors with this condition [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical presentation, and diagnosis of IVH are discussed in this topic review. The management, complications, and outcome of IVH in the newborn are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31465?source=see_link\">",
"     \"Management and complications of intraventricular hemorrhage in the newborn\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450996784\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450996791\">",
"    <span class=\"h2\">",
"     Preterm infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preterm infants, the site of origin of bleeding is generally the subependymal germinal matrix, which is located between the caudate nucleus and thalamus at the level of the foramen of Monro [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/3\">",
"     3",
"    </a>",
"    ]. Neuropathologic studies suggest that the hemorrhage is primarily within the capillary network, which freely communicates with the venous system, although bleeding can also occur from the arterial circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/4\">",
"     4",
"    </a>",
"    ]. Vessels in this region occupy border zones between cerebral arteries and the collecting zone of the deep cerebral veins, and have increased permeability when subjected to hypoxia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    increased venous pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22723266\">",
"     'Germinal matrix fragility'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450996798\">",
"    <span class=\"h3\">",
"     Severity and grading of IVH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severity of hemorrhage is based on whether the bleeding is confined to the germinal matrix region or if it extends into the adjacent ventricular system or white matter (intraparenchymal). The following grading system is used to define the extent of bleeding (",
"    <a class=\"graphic graphic_table graphicRef69537 \" href=\"mobipreview.htm?8/16/8459\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade I &ndash; Bleeding is confined to the germinal matrix (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50918 \" href=\"mobipreview.htm?19/34/20002\">",
"       image 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef70815 \" href=\"mobipreview.htm?29/7/29810\">",
"       image 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Grade II &ndash; IVH occupies 50 percent or less of the lateral ventricle volume",
"     </li>",
"     <li>",
"      Grade III &ndash; IVH occupies more than 50 percent of the lateral ventricle volume (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87340 \" href=\"mobipreview.htm?0/28/456\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Grade IV &ndash; Hemorrhagic infarction in periventricular white matter ipsilateral to large IVH (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef87222 \" href=\"mobipreview.htm?4/39/4730\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Grade I corresponds to mild, grade II moderate, and grades III and IV severe IVH. Each grade of IVH may be unilateral, or bilateral with either symmetric, or asymmetric grades of IVH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450996997\">",
"    <span class=\"h2\">",
"     Term infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, the initial site of bleeding in term infants is variable based on limited data as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one neuropathologic study of 32 term infants, the majority of IVH arose from the choroid plexus [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another study of term infants, ultrasonographic imaging showed subependymal germinal matrix and choroid plexus hemorrhages occurred at similar rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Thalamic hemorrhage may also contribute to IVH in term infants, as described in a series of 19 cases, in which two-thirds had associated thalamic hemorrhage detected by computed tomography [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/8\">",
"       8",
"      </a>",
"      ]. This is likely a venous hemorrhagic infarction caused by thrombosis in the internal cerebral vein(s), or more extensive venous thrombosis, rather than a primary hemorrhage.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that the origin of intracranial bleeding in term infants differs from that seen in preterm infants with subependymal IVH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVH generally occurs in preterm infants, and the incidence increases with decreasing gestational age and birth weight.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVH occurs most frequently in infants born before 32 weeks gestation or less than 1500 g birth weight. Since the late 1990s, the reported rate of IVH in the United States is about 20 percent in very low birth weight (VLBW) infants (birth weight &lt;1500 g) and 45 percent in extremely low birth weight (ELBW) infants (birth weight &lt;750 g) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/9-12\">",
"     9-12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, the incidence of IVH increases with decreasing gestational age as illustrated by a population-based study of 2896 premature infants (&lt;32 weeks gestation), in which IVH rates decreased 3.5 percent with each added week of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of severe IVH also increases with decreasing gestational age and birth weight as noted by the following studies (see",
"    <a class=\"local\" href=\"#H450996798\">",
"     'Severity and grading of IVH'",
"    </a>",
"    above):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study from the National Institute of Child Health and Human Development (NICHD) neonatal research network of 9575 infants with gestational age between 22 and 28 weeks and birth weight 401 to 1500 g, the overall incidence of IVH was 36 percent for all grades of IVH, which increased with decreasing gestational age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/12\">",
"       12",
"      </a>",
"      ]. The prevalence of severe IVH (defined as grades III and IV) also increased with decreasing gestation with rates of 38, 36, 26, 21, 14, 11, and 7 percent of survivors for infants with gestational ages 22, 23, 24, 25, 26, 27, and 28, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a population-based prospective study of all preterm infants with gestational age below 27 weeks born in Sweden from 2004 to 2007, the incidence of IVH increased from 5.2 percent of survivors born at 26 weeks gestation to 19 and 20 percent of survivors born between 22 and 23 weeks gestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although older literature has suggested that VLBW infants who were small for gestational age (SGA) were less likely to have IVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/15\">",
"     15",
"    </a>",
"    ], subsequent data have shown no difference in the incidence of IVH between SGA and appropriate size for gestational age premature infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22723714\">",
"    <span class=\"h2\">",
"     Term infants",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe IVH occurs infrequently in term infants, although minor hemorrhages are not uncommon. In a study of 505 healthy asymptomatic term infants who underwent head ultrasonography within 72 hours of life, the incidence of IVH was 4 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/18\">",
"     18",
"    </a>",
"    ]. In the term infant, IVH may be associated with trauma (eg, abdominal compression), alloimmune thrombocytopenia, rupture of a vascular malformation, sinovenous thrombosis (particularly in infants with thalamic involvement), and a diagnosis of hemophilia and other coagulation abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In some cases, it is unclear whether the coagulation abnormality is causal or is a result of IVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of IVH in",
"    <strong>",
"     premature",
"    </strong>",
"    infants is due to [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Germinal matrix fragility from the lack of structural support of rete of immature blood vessels due to immaturity.",
"     </li>",
"     <li>",
"      Disturbances of cerebral blood flow, particularly ischemia-reperfusion, increased arterial flow, or increased venous pressure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22723266\">",
"    <span class=\"h2\">",
"     Germinal matrix fragility",
"    </span>",
"    &nbsp;&mdash;&nbsp;In preterm infants, IVH generally originates within the germinal matrix, the highly cellular and richly vascularized layer in the subependymal, subventricular zone that gives rise to neurons and glia during fetal development [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/23\">",
"     23",
"    </a>",
"    ]. As the fetus matures, the germinal matrix begins to involute starting at 28 weeks as its cellularity and vascularity decrease, and by term it is generally absent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the germinal matrix, the capillary network consists of numerous thin-walled, large blood vessels that lack structural support, which contributes to the increased risk of hemorrhage in this area of the brain compared to other regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/3,22,25-27\">",
"     3,22,25-27",
"    </a>",
"    ]. The microvasculature of the germinal matrix is particularly fragile because of the abundance of angiogenic blood vessels that have a paucity of pericytes; and have immature basal lamina, and deficiency of tight junctions and glial fibrillary acidic protein (GFAP) in the astrocyte endfeet (which are components of a competent blood-brain barrier) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/22\">",
"     22",
"    </a>",
"    ]. Glial fibers normally develop with increasing maturation as demonstrated in a study showing minimal immunocytochemical staining of GFAP at 27 weeks gestation, which became more prominent with increasing gestational age, especially after 31 weeks gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/28\">",
"     28",
"    </a>",
"    ]. The deficient structural support makes the germinal matrix vulnerable to injury primarily due to hemodynamic instability in preterm infants, related to altered cerebral blood flow caused by a variety of",
"    <span class=\"nowrap\">",
"     perinatal/neonatal",
"    </span>",
"    events or disorders (eg,",
"    <span class=\"nowrap\">",
"     hypoxia/ischemia).",
"    </span>",
"   </p>",
"   <p>",
"    This fragile capillary network drains into a well-developed deep venous system that forms the terminal vein, which changes direction in a U-turn fashion as it empties into the internal cerebral vein. It is postulated that the venous system is prone to venous congestion and stasis, resulting in increased cerebral venous pressure, which contributes to germinal matrix IVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cerebral blood flow instability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fluctuations of cerebral blood flow (CBF) in preterm infants are associated with IVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/29-32\">",
"     29-32",
"    </a>",
"    ]. Preterm infants are particularly vulnerable to alterations in CBF because they have impaired autoregulation of CBF compared to term infants. This impairment results in a pressure-passive circulation, in which the infant cannot sustain constant CBF with changes in systemic blood pressure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/33\">",
"     33",
"    </a>",
"    ]. As a result, increases or decreases in blood pressure are reflected by similar changes in CBF, leading to injury of the fragile blood vessels of the germinal matrix.",
"   </p>",
"   <p>",
"    The association of impaired autoregulation and IVH were demonstrated in studies of preterm infants that monitored mean arterial blood pressure (MAP), and CBF using near-infrared spectroscopy (NIRS).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 32 preterm infants (gestational age between 23 and 31 weeks) who were receiving mechanical ventilation, 8 of 17 patients with impaired autoregulation (based on concordant changes in CBF and MAP) developed severe germinal matrix-intraventricular hemorrhage, periventricular leukomalacia (PVL), or both. In contrast, only 2 of 15 infants with apparently intact autoregulation developed severe lesions.",
"     </li>",
"     <li>",
"      In another study of 88 preterm infants &lt;32 weeks, the risk of IVH was associated with greater cerebral pressure passivity (based on MAP and NIRS measurements) but not with MAP variations alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational studies that did not monitor CBF have shown that changes in blood pressure are associated with IVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The assumption is affected infants were more likely to have impaired autoregulation. Causes of abrupt elevation of MAP that may contribute to IVH include noxious stimuli, rapid volume expansion with fluid boluses, tracheal suctioning, and seizures. (See",
"    <a class=\"local\" href=\"#H22724341\">",
"     'Risk factors'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Other factors that have been implicated with fluctuations of CBF and IVH include hypercarbia, hypoglycemia, and asphyxia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22724341\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVH risk factors include prenatal conditions, complications of labor and delivery, and postnatal conditions. They can often be related to underlying pathogenetic processes, such as fluctuations in cerebral blood flow (CBF) during rapid fluid boluses, or increases in cerebral venous pressure (CVP) with fetal head compression during labor and delivery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prenatal factors &ndash; Maternal chorioamnionitis, lack of antenatal steroid therapy, and prenatal asphyxia",
"     </li>",
"     <li>",
"      Neonatal and postnatal factors &ndash; Prematurity, coagulation abnormalities, respiratory distress, hypotension, hypoxia, and hypercapnia",
"     </li>",
"     <li>",
"      Labor and delivery factors &ndash; Mode of delivery, breech presentation, and intrapartum asphyxia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363809198\">",
"    <span class=\"h2\">",
"     Prenatal factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363809482\">",
"    <span class=\"h3\">",
"     Chorioamnionitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal intrauterine infection",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    amniotic sac inflammation are associated with increased risk of IVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/36-42\">",
"     36-42",
"    </a>",
"    ]. The severity of IVH also increases with chorioamnionitis as illustrated by a large multicenter Canadian prospective study of 3094 preterm infants (gestational age less than 33 weeks) born between 2005 and 2006 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/37\">",
"     37",
"    </a>",
"    ]. Patients with chorioamnionitis (15 percent of the cohort) were more likely to have severe IVH (defined as grades III and IV) compared to those without chorioamnionitis (22 versus 11 percent). In a multivariate logistic regression, which included adjustments for gestational age, birthweight, treatment with antenatal corticosteroids, and presence of maternal hypertension, infants with chorioamnionitis had a 1.6-fold increased risk of severe IVH compared to those without chorioamnionitis.",
"   </p>",
"   <p>",
"    Indirect evidence linking maternal intrauterine infection to IVH is provided in a meta-analysis that showed prenatal antibiotic use for prolonged rupture of membranes reduced the incidence of all grades of IVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/43\">",
"     43",
"    </a>",
"    ]. In addition, a low neonatal neutrophil count (less than 1000",
"    <span class=\"nowrap\">",
"     neutrophils/microL)",
"    </span>",
"    within 2.5 hours of birth was associated with IVH and its severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/44\">",
"     44",
"    </a>",
"    ]. For infants born at 28 through 36 weeks of gestation, the lower limits of normal for neutrophil counts at birth and at six to eight hours after birth were",
"    <span class=\"nowrap\">",
"     1000/microL",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     1500/microL.",
"    </span>",
"    This degree of neutropenia is associated with infection or preeclampsia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6410?source=see_link&amp;anchor=H686757902#H686757902\">",
"     \"Clinical features and diagnosis of sepsis in term and late preterm infants\", section on 'Total neutrophil count'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A contributory role for maternal inflammation is supported by several studies that have shown the association between IVH and increased cytokine production and release (used as a biomarker for inflammation)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    histologic evidence of inflammation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/39,41,42,45,46\">",
"     39,41,42,45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363810455\">",
"    <span class=\"h3\">",
"     Maternal drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antenatal steroid therapy has been shown to decrease the risk of IVH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/13,47-49\">",
"     13,47-49",
"    </a>",
"    ], even in pregnancies complicated by chorioamnionitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether the use of maternal",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    is associated with IVH. In one series of 108 infants (gestational age &le;34 weeks), the incidence of IVH was greater in preterm infants whose mothers used aspirin in the last week of pregnancy compared to controls [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/50\">",
"     50",
"    </a>",
"    ]. However, in a systematic review of trials of antiplatelet agents (primarily low-dose aspirin) to prevent preeclampsia, the rate of IVH was not different between treatment and control groups (RR 0.88, 95% CI 0.63-1.22) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363809863\">",
"    <span class=\"h2\">",
"     Neonatal and postnatal factors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450996411\">",
"    <span class=\"h3\">",
"     Prematurity",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, prematurity is the most important neonatal risk factor for IVH because of preterm infants&rsquo; germinal matrix fragility and inability to autoregulate CBF. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pathogenesis'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450996418\">",
"    <span class=\"h3\">",
"     Other risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other neonatal and postnatal factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Respiratory distress with episodes of hypocapnia, hypercapnia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypoxia. These factors are associated with fluctuations in CBF and elevated CVP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increases in arterial blood pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/34\">",
"       34",
"      </a>",
"      ], which may be caused by noxious stimuli (eg, manual ventilation) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/53\">",
"       53",
"      </a>",
"      ] and rapid fluid boluses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/54\">",
"       54",
"      </a>",
"      ], are associated with increased CBF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mechanical ventilation, likely by contributing to fluctuations in CBF and increased CVP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/55,56\">",
"       55,56",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inter-hospital transport [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bicarbonate therapy may be associated with an increased risk of IVH, potentially due to hyperosmolarity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/58\">",
"       58",
"      </a>",
"      ]. In one report, the increased risk of IVH appeared to be related to the rapidity of infusion of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?40/56/41862?source=see_link\">",
"       sodium bicarbonate",
"      </a>",
"      , which may alter CBF [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data are conflicting on whether or not hypothermia, pneumothorax, and coagulation and platelet defects are associated with IVH:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hypothermia following birth has been linked to increased risk of IVH in some studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/60\">",
"       60",
"      </a>",
"      ] but not others [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/61\">",
"       61",
"      </a>",
"      ]; differing definitions of hypothermia, variations in size of study groups, and differing study design may explain conflicting results.",
"     </li>",
"     <li>",
"      Several reports have shown an association between pneumothorax and IVH, postulated to be related to increased CVP [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/56,62,63\">",
"       56,62,63",
"      </a>",
"      ]. In contrast, in a study of 675 premature infants (&le;28 weeks), there was no increase in IVH occurrence in the 62 neonates with pneumothorax compared with those without this complication [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Coagulation and platelet abnormalities &ndash; Thrombocytopenia and coagulation defects are common in premature infants, especially those with other risk factors for IVH. Although several observational studies have shown an association between these two conditions and IVH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/65-68\">",
"       65-68",
"      </a>",
"      ], it remains uncertain whether coagulopathy and thrombocytopenia have a causal role in the pathogenesis of IVH. In particular, the failure of procoagulant therapy to reduce IVH raises questions about a causal relationship [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/69,70\">",
"       69,70",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363810447\">",
"    <span class=\"h4\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data suggest that genetic factors contribute to IVH. A study of premature twin pairs reported IVH occurred in 9 of 63 monozygotic twins (26 percent) and 39 of 185 dizygotic twins (21 percent), and logistic regression analysis suggested that there were familial factors that contributed to IVH susceptibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proposed genetic factors include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemostatic genes &ndash; There are conflicting reports on whether mutations of hemostasis genes predispose preterm infants to IVH, but these are likely to be of lesser importance than other risk factors described above.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In a prospective study, DNA testing for factor V Leiden, prothrombin G20210A, and mutations of factor VII and XIII were performed in a cohort of 1008 VLBW infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/72\">",
"       72",
"      </a>",
"      ]. There was no difference in the rate of IVH in the 178 infants with a mutation of one of the hemostatic genes compared to 830 infants without a mutation. As an example, the rates of IVH in the 74 infants with mutations of factor V Leiden compared to those without were 19 versus 17.5 percent.",
"     </li>",
"     <li>",
"      In contrast, two smaller case-control studies reported an increased risk of IVH in preterm infants with factor V Leiden mutations [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/73,74\">",
"       73,74",
"      </a>",
"      ]. In the first study, 5 of 22 infants with grades II to IV IVH compared to 1 of 29 control infants without IVH had a factor V Leiden mutation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/73\">",
"       73",
"      </a>",
"      ]. In the second study of 130 preterm infants with birth weight &lt;2500 g, those with grade I IVH were more likely to have a mutation of factor V Leiden compared to control infants without IVH (frequency of mutated allele, 10 versus 4.8 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Collagen gene &ndash; In several case reports, a mutation in the collagen gene Col4a1 has been associated with severe prenatal intracranial hemorrhage, but there are no reported studies with large cohorts [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/75,76\">",
"       75,76",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Inflammatory genes &ndash; Although data are conflicting, polymorphisms in the proinflammatory cytokine IL-6 have been proposed as genetic modifiers for the risk of IVH [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/46,77\">",
"       46,77",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363810257\">",
"    <span class=\"h2\">",
"     Labor and delivery",
"    </span>",
"    &nbsp;&mdash;&nbsp;It remains uncertain whether labor and route of birth affect the risk of IVH. During labor and vaginal delivery, compression of the fetal head by the uterus increases CVP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/78\">",
"     78",
"    </a>",
"    ], which theoretically could promote IVH. However, data are inconsistent on whether or not vaginal delivery increases the risk of IVH when compared with caesarean delivery.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two single-center retrospective studies reported an increased risk of IVH in preterm infants delivered vaginally than those delivered by caesarean birth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/79,80\">",
"       79,80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Other single center observational studies report no difference in the risk of IVH between the two modes of delivery [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/81-83\">",
"       81-83",
"      </a>",
"      ]. A similar finding that the mode of delivery did not affect the incidence of IVH was reported in a review of the Israeli National VLBW Infant Database of all very low birth weight (VLBW) infants born between 1995 and 2004 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/84\">",
"       84",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Systematic review of randomized controlled trials found that data were insufficient to determine whether or not caesarean delivery reduces the risk of IVH in preterm infants [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/85,86\">",
"       85,86",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22723807\">",
"    <span class=\"h2\">",
"     Prenatal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal IVH appears to be rare. In a report from Italy, six cases of intracranial hemorrhage were detected among 6641 prenatal ultrasound examinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/87\">",
"     87",
"    </a>",
"    ]. In a review of the literature, 35 additional case reports were identified. These 41 cases were divided into three groups: isolated IVH (n = 20), parenchymal hemorrhage alone (n = 13), and subdural or subarachnoid hemorrhage (n = 8). Overall outcome was poor.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363810578\">",
"    <span class=\"h2\">",
"     Postnatal IVH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22723479\">",
"    <span class=\"h3\">",
"     Manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;IVH has three different presentations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Silent presentation &ndash; A clinically silent IVH without symptoms occurs in 25 to 50 percent of cases, with detection of the hemorrhage by routine ultrasonographic screening [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/88\">",
"       88",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Ultrasound screening'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Saltatory or stuttering course is the most common presentation and evolves over hours to several days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/89\">",
"       89",
"      </a>",
"      ]. It is characterized by nonspecific findings, including an altered level of consciousness, hypotonia, decreased spontaneous and elicited movements, and subtle changes in eye position and movement. Respiratory function sometimes is disturbed.",
"     </li>",
"     <li>",
"      Catastrophic deterioration is the least common presentation and evolves over minutes to hours [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/89\">",
"       89",
"      </a>",
"      ]. Signs include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Stupor or coma",
"     </li>",
"     <li>",
"      Irregular respirations, hypoventilation, or apnea",
"     </li>",
"     <li>",
"      Decerebrate posturing",
"     </li>",
"     <li>",
"      Generalized tonic seizures",
"     </li>",
"     <li>",
"      Flaccid weakness",
"     </li>",
"     <li>",
"      Cranial nerve abnormalities, including pupils fixed to light",
"     </li>",
"     <li>",
"      Other features of the catastrophic presentation include a bulging anterior fontanelle, hypotension, bradycardia, a falling hematocrit, metabolic acidosis, and inappropriate antidiuretic hormone secretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H450996469\">",
"    <span class=\"h3\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all IVH in premature infants takes place within the first five postnatal days, with 50, 25, 15, and 10 percent of cases occurring on the first, second, third, fourth, and fifth days of life, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/90\">",
"     90",
"    </a>",
"    ]. In one series in which serial ultrasound examinations were performed beginning shortly after birth in infants with birth weight &lt;1750 g, IVH was detected before one hour of age in 20 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/91\">",
"     91",
"    </a>",
"    ]. IVH progressed over three to five days in approximately 20 to 40 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/90\">",
"     90",
"    </a>",
"    ]. Late IVH is associated with low cerebral blood flow, which may be due to low superior vena caval flow seen in infants with large ductal shunts or hypotension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/92-94\">",
"     92-94",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H363810853\">",
"    <span class=\"h2\">",
"     Coexisting lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In neuropathologic studies, IVH rarely is an isolated lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/95\">",
"     95",
"    </a>",
"    ]. The majority of infants who die more than one week after IVH also have periventricular leukomalacia (PVL) or necrosis in the pons and the subiculum of the hippocampus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33913?source=see_link\">",
"     \"Periventricular leukomalacia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial ultrasonography is generally used to diagnosis IVH. It is the preferred imaging modality because of its high sensitivity for detecting acute hemorrhage, portability, and lack of ionizing radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/90\">",
"     90",
"    </a>",
"    ]. Coronal and parasagittal views are obtained routinely to identify blood in the germinal matrix, ventricles, or cerebral parenchyma, and any other echogenic abnormalities. Ultrasonography is able to accurately grade the severity of IVH based upon the location and extent of the IVH (",
"    <a class=\"graphic graphic_table graphicRef69537 \" href=\"mobipreview.htm?8/16/8459\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/3\">",
"     3",
"    </a>",
"    ]. Grade I (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef50918 \" href=\"mobipreview.htm?19/34/20002\">",
"     image 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef70815 \" href=\"mobipreview.htm?29/7/29810\">",
"     image 2",
"    </a>",
"    ), grade II, and grades III (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87340 \" href=\"mobipreview.htm?0/28/456\">",
"     image 3",
"    </a>",
"    ) and IV (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef87222 \" href=\"mobipreview.htm?4/39/4730\">",
"     image 4",
"    </a>",
"    ) correspond to mild, moderate, and severe IVH, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Ultrasound screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because up to one-half of IVH cases are clinically silent, routine ultrasound screening should be performed in premature infants. (See",
"    <a class=\"local\" href=\"#H22723479\">",
"     'Manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In our center, we follow the following recommendations published by the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/96\">",
"     96",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine ultrasound screening should be performed on all infants with a gestational age less than 30 weeks.",
"     </li>",
"     <li>",
"      Screening should be performed at 7 to 14 days of age and repeated at 36 to 40 weeks postmenstrual age (estimated gestational age based upon completed weeks from the mother's last menstrual period).",
"     </li>",
"     <li>",
"      Ultrasound screening should also be considered in infants with abnormal clinical signs, high severity of illness, or other major risk factors.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This strategy is designed to detect clinically unsuspected IVH that may influence monitoring and management, as well as periventricular leukomalacia (PVL)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ventriculomegaly, which provides prognostic information about neurodevelopmental outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33913?source=see_link&amp;anchor=H16#H16\">",
"     \"Periventricular leukomalacia\", section on 'Ultrasound'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    IVH also occurs in preterm infants with birth gestation 30 to 34 weeks; for example, a study described IVH incidences between 3.3 and 6.3 percent in a group of 463 infants in this gestational range [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/97\">",
"     97",
"    </a>",
"    ]. However, there is currently no specific guideline for cranial ultrasound screening in these older preterm infants. As a result, clinical suspicion for IVH should be high for any preterm infants with a gestational age &ge;30 weeks who exhibit any subtle changes in neurologic or respiratory status, or who have conditions associated with IVH, and a cranial ultrasound should be performed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19665628\">",
"    <span class=\"h2\">",
"     Other radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography (CT) or magnetic resonance imaging (MRI) scans offer no significant advantage as a routine screening tool to detect IVH or document ventricular size in comparison with cranial ultrasound. In addition, the need to transport infants to the scanner, exposure to ionizing radiation (CT), and the requirement for nonmetallic monitoring and support equipment and a long examination time (MRI) limit their usefulness in the neonatal setting. These modalities are helpful, however, to document additional complicating lesions, including subdural or posterior fossa hemorrhages, peripheral areas of infarction, or other parenchymal abnormalities. CT scanning is generally avoided now in newborns except for emergencies (eg, neurosurgical emergency) when ultrasound or MRI is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lumbar puncture",
"    </span>",
"    &nbsp;&mdash;&nbsp;If cranial ultrasonography is not available, lumbar puncture can assist in the diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/44/42697/abstract/3\">",
"     3",
"    </a>",
"    ]. In IVH, the cerebrospinal fluid (CSF) typically contains numerous red blood cells and a high protein concentration. The CSF becomes xanthochromic several hours after the hemorrhage, and the glucose concentration may be reduced. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25625?source=see_link\">",
"     \"Lumbar puncture: Indications, contraindications, technique, and complications in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a parent might have about a given condition. These articles are best for parents who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for parents who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to the parents of your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    Basics topics (see",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/4/7233?source=see_link\">",
"     \"Patient information: Intraventricular hemorrhage in newborns (The Basics)\"",
"    </a>",
"    )",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraventricular hemorrhage (IVH; also known as",
"    <span class=\"nowrap\">",
"     subependymal/intraventricular",
"    </span>",
"    hemorrhage) is an important cause of brain injury in premature infants.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      IVH occurs most frequently in infants born &lt;32 weeks gestation or with a birth weight &lt;1500 g. The risk of IVH increases with decreasing gestational age. Additional risk factors include chorioamnionitis, lack of prenatal glucocorticoid therapy, prolonged neonatal resuscitation, and respiratory distress syndrome. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22724341\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In preterm infants, IVH generally originates from the germinal matrix, because of its structural fragility, which makes it vulnerable to disturbances in cerebral blood flow (CBF). Preterm infants are particularly vulnerable to alterations in CBF because of impaired cerebrovascular autoregulation, so that they are unable to sustain constant CBF with changes in systemic blood. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The presentation of IVH can be clinically silent, saltatory, or catastrophic. A clinically silent syndrome occurs in 25 to 50 percent of cases but can be detected by routine ultrasonographic screening. Most IVH occurs within the first five postnatal days. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of IVH is made by cranial ultrasonography. The grading of the severity of IVH is based upon the location and extent of the IVH (",
"      <a class=\"graphic graphic_table graphicRef69537 \" href=\"mobipreview.htm?8/16/8459\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because approximately one-half of IVH is clinically silent, we recommend ultrasound screening in premature infants (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). All infants with gestational age &lt;30 weeks or &lt;1500 g birth weight should be initially screened with ultrasound at 7 to 14 days with a repeat ultrasound at 36 to 40 weeks postmenstrual age. Clinical suspicion for IVH should be high for any preterm infants with a gestational age &ge;30 weeks who exhibit any subtle changes in neurologic or respiratory status, or who have conditions associated with IVH, and a cranial ultrasound should be performed. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/1\">",
"      Owens R. Intraventricular hemorrhage in the premature neonate. Neonatal Netw 2005; 24:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/2\">",
"      Kenet G, Kuperman AA, Strauss T, Brenner B. Neonatal IVH--mechanisms and management. Thromb Res 2011; 127 Suppl 3:S120.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Intracranial hemorrhage: Germinal matrix-intraventricular hemorrhage. In: Neurology of the Newborn, 4th ed, WB Saunders, Philadelphia 2001. p.428.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/4\">",
"      Ghazi-Birry HS, Brown WR, Moody DM, et al. Human germinal matrix: venous origin of hemorrhage and vascular characteristics. AJNR Am J Neuroradiol 1997; 18:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/5\">",
"      Takashima S, Tanaka K. Microangiography and vascular permeability of the subependymal matrix in the premature infant. Can J Neurol Sci 1978; 5:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/6\">",
"      Lacey DJ, Terplan K. Intraventricular hemorrhage in full-term neonates. Dev Med Child Neurol 1982; 24:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/7\">",
"      Heibel M, Heber R, Bechinger D, Kornhuber HH. Early diagnosis of perinatal cerebral lesions in apparently normal full-term newborns by ultrasound of the brain. Neuroradiology 1993; 35:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/8\">",
"      Roland EH, Flodmark O, Hill A. Thalamic hemorrhage with intraventricular hemorrhage in the full-term newborn. Pediatrics 1990; 85:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/9\">",
"      Jain NJ, Kruse LK, Demissie K, Khandelwal M. Impact of mode of delivery on neonatal complications: trends between 1997 and 2005. J Matern Fetal Neonatal Med 2009; 22:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/10\">",
"      Philip AG, Allan WC, Tito AM, Wheeler LR. Intraventricular hemorrhage in preterm infants: declining incidence in the 1980s. Pediatrics 1989; 84:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/11\">",
"      Wilson-Costello D, Friedman H, Minich N, et al. Improved survival rates with increased neurodevelopmental disability for extremely low birth weight infants in the 1990s. Pediatrics 2005; 115:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/12\">",
"      Stoll BJ, Hansen NI, Bell EF, et al. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics 2010; 126:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/13\">",
"      Bajwa NM, Berner M, Worley S, et al. Population based age stratified morbidities of premature infants in Switzerland. Swiss Med Wkly 2011; 141:w13212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/14\">",
"      EXPRESS Group, Fellman V, Hellstr&ouml;m-Westas L, et al. One-year survival of extremely preterm infants after active perinatal care in Sweden. JAMA 2009; 301:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/15\">",
"      Amato M, Konrad D, H&uuml;ppi P, Donati F. Impact of prematurity and intrauterine growth retardation on neonatal hemorrhagic and ischemic brain damage. Eur Neurol 1993; 33:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/16\">",
"      Bartels DB, Kreienbrock L, Dammann O, et al. Population based study on the outcome of small for gestational age newborns. Arch Dis Child Fetal Neonatal Ed 2005; 90:F53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/17\">",
"      Giapros V, Drougia A, Krallis N, et al. Morbidity and mortality patterns in small-for-gestational age infants born preterm. J Matern Fetal Neonatal Med 2012; 25:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/18\">",
"      Hayden CK Jr, Shattuck KE, Richardson CJ, et al. Subependymal germinal matrix hemorrhage in full-term neonates. Pediatrics 1985; 75:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/19\">",
"      Wu YW, Hamrick SE, Miller SP, et al. Intraventricular hemorrhage in term neonates caused by sinovenous thrombosis. Ann Neurol 2003; 54:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/20\">",
"      Tarantino MD, Gupta SL, Brusky RM. The incidence and outcome of intracranial haemorrhage in newborns with haemophilia: analysis of the Nationwide Inpatient Sample database. Haemophilia 2007; 13:380.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Intracranial hemorrhage: subdural, primary subarachnoid, cerebellar, intraventricular (term infant), and miscellaneous. In: Neurology of the Newborn, 5th ed, Saunders, Philadelphia 2008. p.483.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/22\">",
"      Ballabh P. Intraventricular hemorrhage in premature infants: mechanism of disease. Pediatr Res 2010; 67:1.",
"     </a>",
"    </li>",
"    <li>",
"     Sidman RL, Rakic P. Development of the human central nervous system. In: Histology and histopathology of the nervous system, Haymaker W, Adams RD (Eds), CC Thomas, Springfield, IL 1982. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/24\">",
"      Perlman JM. The relationship between systemic hemodynamic perturbations and periventricular-intraventricular hemorrhage--a historical perspective. Semin Pediatr Neurol 2009; 16:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/25\">",
"      Gould SJ, Howard S. Glial differentiation in the germinal layer of fetal and preterm infant brain: an immunocytochemical study. Pediatr Pathol 1988; 8:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/26\">",
"      Grunnet ML. Morphometry of blood vessels in the cortex and germinal plate of premature neonates. Pediatr Neurol 1989; 5:12.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Neuronal proliferation, migration, organization, and myelination. In: Neurology of the Newborn, 5th ed, Saunders, Philadelphia 2008. p.51.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/28\">",
"      Gould SJ, Howard S. An immunohistochemical study of the germinal layer in the late gestation human fetal brain. Neuropathol Appl Neurobiol 1987; 13:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/29\">",
"      Tsuji M, Saul JP, du Plessis A, et al. Cerebral intravascular oxygenation correlates with mean arterial pressure in critically ill premature infants. Pediatrics 2000; 106:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/30\">",
"      O'Leary H, Gregas MC, Limperopoulos C, et al. Elevated cerebral pressure passivity is associated with prematurity-related intracranial hemorrhage. Pediatrics 2009; 124:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/31\">",
"      Perlman JM, McMenamin JB, Volpe JJ. Fluctuating cerebral blood-flow velocity in respiratory-distress syndrome. Relation to the development of intraventricular hemorrhage. N Engl J Med 1983; 309:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/32\">",
"      Perlman JM, Goodman S, Kreusser KL, Volpe JJ. Reduction in intraventricular hemorrhage by elimination of fluctuating cerebral blood-flow velocity in preterm infants with respiratory distress syndrome. N Engl J Med 1985; 312:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/33\">",
"      Soul JS, Hammer PE, Tsuji M, et al. Fluctuating pressure-passivity is common in the cerebral circulation of sick premature infants. Pediatr Res 2007; 61:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/34\">",
"      Bada HS, Korones SB, Perry EH, et al. Mean arterial blood pressure changes in premature infants and those at risk for intraventricular hemorrhage. J Pediatr 1990; 117:607.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/35\">",
"      Fanaroff AA, Fanaroff JM. Short- and long-term consequences of hypotension in ELBW infants. Semin Perinatol 2006; 30:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/36\">",
"      Been JV, Degraeuwe PL, Kramer BW, Zimmermann LJ. Antenatal steroids and neonatal outcome after chorioamnionitis: a meta-analysis. BJOG 2011; 118:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/37\">",
"      Soraisham AS, Singhal N, McMillan DD, et al. A multicenter study on the clinical outcome of chorioamnionitis in preterm infants. Am J Obstet Gynecol 2009; 200:372.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/38\">",
"      Kasper DC, Mechtler TP, B&ouml;hm J, et al. In utero exposure to Ureaplasma spp. is associated with increased rate of bronchopulmonary dysplasia and intraventricular hemorrhage in preterm infants. J Perinat Med 2011; 39:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/39\">",
"      Dammann O, Leviton A. Maternal intrauterine infection, cytokines, and brain damage in the preterm newborn. Pediatr Res 1997; 42:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/40\">",
"      Verma U, Tejani N, Klein S, et al. Obstetric antecedents of intraventricular hemorrhage and periventricular leukomalacia in the low-birth-weight neonate. Am J Obstet Gynecol 1997; 176:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/41\">",
"      Zanardo V, Vedovato S, Suppiej A, et al. Histological inflammatory responses in the placenta and early neonatal brain injury. Pediatr Dev Pathol 2008; 11:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/42\">",
"      Furukawa S, Sameshima H, Ikenoue T. Circulatory disturbances during the first postnatal 24 hours in extremely premature infants 25 weeks or less of gestation with histological fetal inflammation. J Obstet Gynaecol Res 2008; 34:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/43\">",
"      Hutzal CE, Boyle EM, Kenyon SL, et al. Use of antibiotics for the treatment of preterm parturition and prevention of neonatal morbidity: a metaanalysis. Am J Obstet Gynecol 2008; 199:620.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/44\">",
"      Palta M, Sadek-Badawi M, Carlton DP. Association of BPD and IVH with early neutrophil and white counts in VLBW neonates with gestational age &lt;32 weeks. J Perinatol 2008; 28:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/45\">",
"      Kassal R, Anwar M, Kashlan F, et al. Umbilical vein interleukin-6 levels in very low birth weight infants developing intraventricular hemorrhage. Brain Dev 2005; 27:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/46\">",
"      Harding DR, Dhamrait S, Whitelaw A, et al. Does interleukin-6 genotype influence cerebral injury or developmental progress after preterm birth? Pediatrics 2004; 114:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/47\">",
"      Lee BH, Stoll BJ, McDonald SA, et al. Adverse neonatal outcomes associated with antenatal dexamethasone versus antenatal betamethasone. Pediatrics 2006; 117:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/48\">",
"      Elimian A, Garry D, Figueroa R, et al. Antenatal betamethasone compared with dexamethasone (betacode trial): a randomized controlled trial. Obstet Gynecol 2007; 110:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/49\">",
"      Shankaran S, Bauer CR, Bain R, et al. Prenatal and perinatal risk and protective factors for neonatal intracranial hemorrhage. National Institute of Child Health and Human Development Neonatal Research Network. Arch Pediatr Adolesc Med 1996; 150:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/50\">",
"      Rumack CM, Guggenheim MA, Rumack BH, et al. Neonatal intracranial hemorrhage and maternal use of aspirin. Obstet Gynecol 1981; 58:52S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/51\">",
"      Duley L, Henderson-Smart DJ, Knight M, King JF. Antiplatelet agents for preventing pre-eclampsia and its complications. Cochrane Database Syst Rev 2004; :CD004659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/52\">",
"      Fabres J, Carlo WA, Phillips V, et al. Both extremes of arterial carbon dioxide pressure and the magnitude of fluctuations in arterial carbon dioxide pressure are associated with severe intraventricular hemorrhage in preterm infants. Pediatrics 2007; 119:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/53\">",
"      Funato M, Tamai H, Noma K, et al. Clinical events in association with timing of intraventricular hemorrhage in preterm infants. J Pediatr 1992; 121:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/54\">",
"      Goldberg RN, Chung D, Goldman SL, Bancalari E. The association of rapid volume expansion and intraventricular hemorrhage in the preterm infant. J Pediatr 1980; 96:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/55\">",
"      Aly H, Hammad TA, Essers J, Wung JT. Is mechanical ventilation associated with intraventricular hemorrhage in preterm infants? Brain Dev 2012; 34:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/56\">",
"      Wallin LA, Rosenfeld CR, Laptook AR, et al. Neonatal intracranial hemorrhage: II. Risk factor analysis in an inborn population. Early Hum Dev 1990; 23:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/57\">",
"      Mohamed MA, Aly H. Transport of premature infants is associated with increased risk for intraventricular haemorrhage. Arch Dis Child Fetal Neonatal Ed 2010; 95:F403.",
"     </a>",
"    </li>",
"    <li>",
"     Goddard-Finegold J. Pharmacologic prevention of intraventricular hemorrhage. In: Current Topics in Neonatology, Hansen TN, McIntosh N (Eds), WB Saunders, Philadelphia 1997. p.170.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/59\">",
"      Papile LA, Burstein J, Burstein R, et al. Relationship of intravenous sodium bicarbonate infusions and cerebral intraventricular hemorrhage. J Pediatr 1978; 93:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/60\">",
"      Miller SS, Lee HC, Gould JB. Hypothermia in very low birth weight infants: distribution, risk factors and outcomes. J Perinatol 2011; 31 Suppl 1:S49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/61\">",
"      Audeh S, Smolkin T, Bental Y, et al. Does admission hypothermia predispose to intraventricular hemorrhage in very-low-birth-weight infants? Neonatology 2011; 100:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/62\">",
"      Hill A, Perlman JM, Volpe JJ. Relationship of pneumothorax to occurrence of intraventricular hemorrhage in the premature newborn. Pediatrics 1982; 69:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/63\">",
"      Mehrabani D, Gowen CW Jr, Kopelman AE. Association of pneumothorax and hypotension with intraventricular haemorrhage. Arch Dis Child 1991; 66:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/64\">",
"      Bhatia R, Davis PG, Doyle LW, et al. Identification of pneumothorax in very preterm infants. J Pediatr 2011; 159:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/65\">",
"      von Lindern JS, van den Bruele T, Lopriore E, Walther FJ. Thrombocytopenia in neonates and the risk of intraventricular hemorrhage: a retrospective cohort study. BMC Pediatr 2011; 11:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/66\">",
"      Setzer ES, Webb IB, Wassenaar JW, et al. Platelet dysfunction and coagulopathy in intraventricular hemorrhage in the premature infant. J Pediatr 1982; 100:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/67\">",
"      Salonvaara M, Riikonen P, Kekom&auml;ki R, et al. Intraventricular haemorrhage in very-low-birthweight preterm infants: association with low prothrombin activity at birth. Acta Paediatr 2005; 94:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/68\">",
"      Lupton BA, Hill A, Whitfield MF, et al. Reduced platelet count as a risk factor for intraventricular hemorrhage. Am J Dis Child 1988; 142:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/69\">",
"      Shirahata A, Nakamura T, Shimono M, et al. Blood coagulation findings and the efficacy of factor XIII concentrate in premature infants with intracranial hemorrhages. Thromb Res 1990; 57:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/70\">",
"      Bassan H. Intracranial hemorrhage in the preterm infant: understanding it, preventing it. Clin Perinatol 2009; 36:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/71\">",
"      Bhandari V, Bizzarro MJ, Shetty A, et al. Familial and genetic susceptibility to major neonatal morbidities in preterm twins. Pediatrics 2006; 117:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/72\">",
"      H&auml;rtel C, K&ouml;nig I, K&ouml;ster S, et al. Genetic polymorphisms of hemostasis genes and primary outcome of very low birth weight infants. Pediatrics 2006; 118:683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/73\">",
"      Pet&auml;j&auml; J, Hiltunen L, Fellman V. Increased risk of intraventricular hemorrhage in preterm infants with thrombophilia. Pediatr Res 2001; 49:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/74\">",
"      Koml&oacute;si K, Havasi V, Bene J, et al. Increased prevalence of factor V Leiden mutation in premature but not in full-term infants with grade I intracranial haemorrhage. Biol Neonate 2005; 87:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/75\">",
"      Gould DB, Phalan FC, Breedveld GJ, et al. Mutations in Col4a1 cause perinatal cerebral hemorrhage and porencephaly. Science 2005; 308:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/76\">",
"      de Vries LS, Koopman C, Groenendaal F, et al. COL4A1 mutation in two preterm siblings with antenatal onset of parenchymal hemorrhage. Ann Neurol 2009; 65:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/77\">",
"      G&ouml;pel W, H&auml;rtel C, Ahrens P, et al. Interleukin-6-174-genotype, sepsis and cerebral injury in very low birth weight infants. Genes Immun 2006; 7:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/78\">",
"      Svenningsen L, Lindemann R, Eidal K. Measurements of fetal head compression pressure during bearing down and their relationship to the condition of the newborn. Acta Obstet Gynecol Scand 1988; 67:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/79\">",
"      Deulofeut R, Sola A, Lee B, et al. The impact of vaginal delivery in premature infants weighing less than 1,251 grams. Obstet Gynecol 2005; 105:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/80\">",
"      Dani C, Poggi C, Bertini G, et al. Method of delivery and intraventricular haemorrhage in extremely preterm infants. J Matern Fetal Neonatal Med 2010; 23:1419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/81\">",
"      Paul DA, Sciscione A, Leef KH, Stefano JL. Caesarean delivery and outcome in very low birthweight infants. Aust N Z J Obstet Gynaecol 2002; 42:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/82\">",
"      Haque KN, Hayes AM, Ahmed Z, et al. Caesarean or vaginal delivery for preterm very-low-birth weight (&lt; or =1,250 g) infant: experience from a district general hospital in UK. Arch Gynecol Obstet 2008; 277:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/83\">",
"      Durie DE, Sciscione AC, Hoffman MK, et al. Mode of delivery and outcomes in very low-birth-weight infants in the vertex presentation. Am J Perinatol 2011; 28:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/84\">",
"      Riskin A, Riskin-Mashiah S, Bader D, et al. Delivery mode and severe intraventricular hemorrhage in single, very low birth weight, vertex infants. Obstet Gynecol 2008; 112:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/85\">",
"      Alfirevic Z, Milan SJ, Livio S. Caesarean section versus vaginal delivery for preterm birth in singletons. Cochrane Database Syst Rev 2012; 6:CD000078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/86\">",
"      Alfirevic Z, Milan SJ, Livio S. Caesarean section versus vaginal delivery for preterm birth in singletons. Cochrane Database Syst Rev 2012; 6:CD000078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/87\">",
"      Vergani P, Strobelt N, Locatelli A, et al. Clinical significance of fetal intracranial hemorrhage. Am J Obstet Gynecol 1996; 175:536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/88\">",
"      Lazzara A, Ahmann P, Dykes F, et al. Clinical predictability of intraventricular hemorrhage in preterm infants. Pediatrics 1980; 65:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/89\">",
"      Tarby TJ, Volpe JJ. Intraventricular hemorrhage in the premature infant. Pediatr Clin North Am 1982; 29:1077.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Intracranial hemorrhage: Germinal matrix-intraventricular hemorrhage. In: Neurology of the Newborn, 5th ed, Saunders, Philadelphia 2008. p.517.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/91\">",
"      Shaver DC, Bada HS, Korones SB, et al. Early and late intraventricular hemorrhage: the role of obstetric factors. Obstet Gynecol 1992; 80:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/92\">",
"      Kluckow M, Evans N. Low superior vena cava flow and intraventricular haemorrhage in preterm infants. Arch Dis Child Fetal Neonatal Ed 2000; 82:F188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/93\">",
"      Evans N, Kluckow M. Early ductal shunting and intraventricular haemorrhage in ventilated preterm infants. Arch Dis Child Fetal Neonatal Ed 1996; 75:F183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/94\">",
"      Ment LR, Ehrenkranz RA, Duncan CC, Lange RC. Delayed hemorrhagic infarction. A cause of late neonatal germinal matrix and intraventricular hemorrhage. Arch Neurol 1984; 41:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/95\">",
"      Armstrong DL, Sauls CD, Goddard-Finegold J. Neuropathologic findings in short-term survivors of intraventricular hemorrhage. Am J Dis Child 1987; 141:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/96\">",
"      Ment LR, Bada HS, Barnes P, et al. Practice parameter: neuroimaging of the neonate: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2002; 58:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/44/42697/abstract/97\">",
"      Bhat V, Karam M, Saslow J, et al. Utility of performing routine head ultrasounds in preterm infants with gestational age 30-34 weeks. J Matern Fetal Neonatal Med 2012; 25:116.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5051 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-1A66C01F0E-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42697=[""].join("\n");
var outline_f41_44_42697=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H450996784\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450996791\">",
"      Preterm infants",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H450996798\">",
"      - Severity and grading of IVH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H450996997\">",
"      Term infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prematurity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22723714\">",
"      Term infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22723266\">",
"      Germinal matrix fragility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cerebral blood flow instability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22724341\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H363809198\">",
"      Prenatal factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H363809482\">",
"      - Chorioamnionitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H363810455\">",
"      - Maternal drug therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H363809863\">",
"      Neonatal and postnatal factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H450996411\">",
"      - Prematurity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H450996418\">",
"      - Other risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H363810447\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H363810257\">",
"      Labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22723807\">",
"      Prenatal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H363810578\">",
"      Postnatal IVH",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22723479\">",
"      - Manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H450996469\">",
"      - Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H363810853\">",
"      Coexisting lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Ultrasound screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19665628\">",
"      Other radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lumbar puncture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5051\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5051|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?19/34/20002\" title=\"diagnostic image 1\">",
"      Bilateral grade I IVH sagittal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/7/29810\" title=\"diagnostic image 2\">",
"      Bilateral grade I IVH coronal",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?0/28/456\" title=\"diagnostic image 3\">",
"      Grade III IVH in preterm infant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?4/39/4730\" title=\"diagnostic image 4\">",
"      Grade IV IVH in preterm infant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5051|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/16/8459\" title=\"table 1\">",
"      Grading IVH by cranial imaging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/16/6410?source=related_link\">",
"      Clinical features and diagnosis of sepsis in term and late preterm infants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/1/25625?source=related_link\">",
"      Lumbar puncture: Indications, contraindications, technique, and complications in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/46/31465?source=related_link\">",
"      Management and complications of intraventricular hemorrhage in the newborn",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/4/7233?source=related_link\">",
"      Patient information: Intraventricular hemorrhage in newborns (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/7/33913?source=related_link\">",
"      Periventricular leukomalacia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_44_42698="Acute inferior MI tutorial";
var content_f41_44_42698=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57189&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1259px;\">",
"  <div class=\"figure\" style=\"width: 545px\">",
"   <div class=\"ttl\">",
"    Acute inferior transmural myocardial infarction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 525px; height: 220px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ST segment elevation in leads II, III, and aVF is characteristic of an acute inferior infarct. Reciprocal ST segment depression is present in this case in leads V1 to V4, and aVL.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 594px\">",
"   <div class=\"ttl\">",
"    Normal ECG",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 594px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal electrocardiogram showing normal sinus rhythm at a rate of 75 beats/min, a PR interval of 0.14 sec, a QRS interval of 0.10 sec, and a QRS axis of approximately 75&deg;.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ary Goldberger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42698=[""].join("\n");
var outline_f41_44_42698=null;
var title_f41_44_42699="Suggestion therapy for habit cough";
var content_f41_44_42699=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58800&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major elements of a 15-minute suggestion-therapy session for habit-cough syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       &bull; Expressing confidence, communicated verbally and behaviorally, that the therapist will be able to show the patient how to stop the cough",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Explaining the cough as a vicious cycle of an initial irritant, now gone, that had set up a pattern of coughing that caused irritation and additional symptoms",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Encouraging the suppression of cough to break the cycle (the therapist closely observes the patient for initiation of the muscular movement that precedes coughing and immediately exhorts the patient to hold the cough back, emphasizing that each second the cough is delayed makes further inhibition of cough easier)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Offering an alternative behavior to coughing in the form of inhaling a generated mist or sipping bodytemperature water with encouragement to inhale the mist or sip the water every time the patient begins to feel the urge to cough",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Repeating expressions of confidence that the patient is developing the ability to resist the urge to cough",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; When some ability to suppress cough is observed (usually after &sim;10 min), asking in a rhetorical manner if the patient is beginning to feel that he or she can resist the urge to cough (eg, \"You are beginning to feel that you can resist the urge to cough, aren't you?\")",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Discontinuing the session when the patient can repeatedly answer positively to the question, \"Do you feel that you can now resist the urge to cough on your own?\" (this question is only asked after the patient has gone 5 minutes without coughing)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Lokshin B, Lindgren S, Weinberger M, Koviach J. Outcome of habit cough in children treated with a brief session of suggestion therapy. Annals of Asthma, Allergy, and Immunology 1991; 67:579. Copyright &copy;1991 American College of Allergy, Asthma and Immunology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42699=[""].join("\n");
var outline_f41_44_42699=null;
var title_f41_44_42700="Conditions leading to lymphoma";
var content_f41_44_42700=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F77563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F77563&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with the development of lymphoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Inherited immunodeficiency states",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Klinefelter's syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chediak-Higashi syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ataxia telangiectasia syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Wiscott-Aldrich syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Common variable immunodeficiency disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       X-linked lymphoproliferative disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Autoimmune lymphoproliferative syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bloom Syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Acquired immunodeficiency states",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Iatrogenic immunosuppression (eg, treatment of autoimmune disease or malignancy, organ transplantation)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       HIV-1 infection",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acquired agammaglobulinemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Multicentric Castleman's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Autoimmune disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Autoimmune hemolytic anemia",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Rheumatoid arthritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Systemic lupus erythematosus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sj&ouml;gren's syndrome (sicca complex)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hashimoto's thyroiditis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Inflammatory disorders",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Acquired angioedema (acquired C1 esterase inhibitor deficiency)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Celiac disease, dermatitis herpetiformis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inflammatory bowel disease treated with azathioprine/6-MP",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Chemicals and drugs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Phenytoin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Dioxin, phenoxy-herbicides (Agent Orange), agricultural pesticides",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Ionizing radiation",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chemotherapy, radiation therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tumor necrosis factor antagonists",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hair dyes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infectious agents (other than HIV)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Epstein-Barr virus",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Human T-cell leukemia/lymphoma virus (HTLV)-I",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Human herpesvirus type 8 (HHV-8, primary effusion lymphoma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Helicobacter pylori",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Campylobacter jejuni (Mediterranean lymphoma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chlamydia psittaci (ocular adnexal lymphoma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Borrelia afzelii (Cutaneous B-cell lymphoma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hepatitis C virus (mixed cryoglobulinemia, splenic marginal zone lymphoma)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mycobacterium tuberculosis, EBV (pyothorax-assoc. lymphoma)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Freedman, AS, Nadler, LM. Malignancies of lymphoid cells. In: Harrision's Principles of Internal Medicine, 14th edition, Fauci, AS, Braunwald, E, Isselbacher, KJ, et al (Eds), McGraw-Hill, New York 1998. Copyright &copy; 1998 McGraw-Hill.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42700=[""].join("\n");
var outline_f41_44_42700=null;
var title_f41_44_42701="Iron stores thalassemia major";
var content_f41_44_42701=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Correlation between hepatic iron concentration and total body iron stores in thalassemia major patients without cirrhosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 424px; height: 296px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The correlation is shown for 25 patients with liver biopsy samples that had a dry weight of 1.0 mg or more. The regression line (middle blue line) and 95 percent confidence limits (upper red and lower green lines) are shown.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Angelucci E, Brittenham GM, McLaren CE, et al. Hepatic iron concentration and total body iron stores in thalassemia major. N Engl J Med 2000; 343:327.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42701=[""].join("\n");
var outline_f41_44_42701=null;
var title_f41_44_42702="TT granulation tissue";
var content_f41_44_42702=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tympanostomy tube surrounded by granulation tissue",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 253px; height: 249px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Long-term tympanostomy tube occluded and surrounded by granulation tissue.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G, Rosenfeld RM. Care of the child with tympanostomy tubes. A visual guide for the pediatrician. Pediatrics 1994; 93:924. Copyright &copy; 1994 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42702=[""].join("\n");
var outline_f41_44_42702=null;
var title_f41_44_42703="Primary ileal NET somatostatin receptor scintigraphy";
var content_f41_44_42703=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F62072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F62072&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary ileal neuroendocrine tumor with disseminated liver metastases on somatostatin receptor scintigraphy fused with SPECT/CT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 309px; height: 356px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     SPECT: single photon emission computed tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_44_42703=[""].join("\n");
var outline_f41_44_42703=null;
